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A B S T R A C T
Background
Tuberculosis (TB) is the world’s leading infectious cause of death. Extrapulmonary TB accounts for 15% of TB cases, but the proportion
is increasing, and over half a million people were newly diagnosed with rifampicin-resistant TB in 2016. Xpert® MTB/RIF (Xpert) is a
World Health Organization (WHO)-recommended, rapid, automated, nucleic acid amplification assay that is used widely for simultaneous
detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens. This Cochrane Review assessed the
accuracy of Xpert in extrapulmonary specimens.
Objectives
To determine the diagnostic accuracy of Xpert a) for extrapulmonary TB by site of disease in people presumed to have extrapulmonary TB;
and b) for rifampicin resistance in people presumed to have extrapulmonary TB.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin
American Caribbean Health Sciences Literature (LILACS), Scopus, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform,
the International Standard Randomized Controlled Trial Number (ISRCTN) Registry, and ProQuest up to 7 August 2017 without language
restriction.
Selection criteria
We included diagnostic accuracy studies of Xpert in people presumed to have extrapulmonary TB. We included TB meningitis and pleural,
lymph node, bone or joint, genitourinary, peritoneal, pericardial, and disseminated TB. We used culture as the reference standard.
For pleural TB, we also included a composite reference standard, which defined a positive result as the presence of granulomatous
inflammation or a positive culture result. For rifampicin resistance, we used culture-based drug susceptibility testing or MTBDRplus as the
reference standard.
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Data collection and analysis
Two review authors independently extracted data, assessed risk of bias and applicability using the QUADAS-2 tool. We determined pooled
predicted sensitivity and specificity for TB, grouped by type of extrapulmonary specimen, and for rifampicin resistance. For TB detection,
we used a bivariate random-eNects model. Recognizing that use of culture may lead to misclassification of cases of extrapulmonary TB as
‘not TB' owing to the paucibacillary nature of the disease, we adjusted accuracy estimates by applying a latent class meta-analysis model.
For rifampicin resistance detection, we performed univariate meta-analyses for sensitivity and specificity separately to include studies in
which no rifampicin resistance was detected. We used theoretical populations with an assumed prevalence to provide illustrative numbers
of patients with false positive and false negative results.
Main results
We included 66 unique studies that evaluated 16,213 specimens for detection of extrapulmonary TB and rifampicin resistance. We
identified only one study that evaluated the newest test version, Xpert MTB/RIF Ultra (Ultra), for TB meningitis. FiQy studies (76%) took
place in low- or middle-income countries. Risk of bias was low for patient selection, index test, and flow and timing domains and was
high or unclear for the reference standard domain (most of these studies decontaminated sterile specimens before culture inoculation).
Regarding applicability, in the patient selection domain, we scored high or unclear concern for most studies because either patients were
evaluated exclusively as inpatients at tertiary care centres, or we were not sure about the clinical settings.
Pooled Xpert sensitivity (defined by culture) varied across diNerent types of specimens (31% in pleural tissue to 97% in bone or joint
fluid); Xpert sensitivity was > 80% in urine and bone or joint fluid and tissue. Pooled Xpert specificity (defined by culture) varied less than
sensitivity (82% in bone or joint tissue to 99% in pleural fluid and urine). Xpert specificity was ≥ 98% in cerebrospinal fluid, pleural fluid,
urine, and peritoneal fluid.
Xpert testing in cerebrospinal fluid
Xpert pooled sensitivity and specificity (95% credible interval (CrI)) against culture were 71.1% (60.9% to 80.4%) and 98.0% (97.0% to
98.8%), respectively (29 studies, 3774 specimens; moderate-certainty evidence).
For a population of 1000 people where 100 have TB meningitis on culture, 89 would be Xpert-positive: of these, 18 (20%) would not have
TB (false-positives); and 911 would be Xpert-negative: of these, 29 (3%) would have TB (false-negatives).
For TB meningitis, ultra sensitivity and specificity against culture (95% confidence interval (CI)) were 90% (55% to 100%) and 90% (83%
to 95%), respectively (one study, 129 participants).
Xpert testing in pleural fluid
Xpert pooled sensitivity and specificity (95% CrI) against culture were 50.9% (39.7% to 62.8%) and 99.2% (98.2% to 99.7%), respectively
(27 studies, 4006 specimens; low-certainty evidence).
For a population of 1000 people where 150 have pleural TB on culture, 83 would be Xpert-positive: of these, seven (8%) would not have TB
(false-positives); and 917 would be Xpert-negative: of these, 74 (8%) would have TB (false-negatives).
Xpert testing in urine
Xpert pooled sensitivity and specificity (95% CrI) against culture were 82.7% (69.6% to 91.1%) and 98.7% (94.8% to 99.7%), respectively
(13 studies, 1199 specimens; moderate-certainty evidence).
For a population of 1000 people where 70 have genitourinary TB on culture, 70 would be Xpert-positive: of these, 12 (17%) would not have
TB (false-positives); and 930 would be Xpert-negative: of these, 12 (1%) would have TB (false-negatives).
Xpert testing for rifampicin resistance
Xpert pooled sensitivity (20 studies, 148 specimens) and specificity (39 studies, 1088 specimens) were 95.0% (89.7% to 97.9%) and 98.7%
(97.8% to 99.4%), respectively (high-certainty evidence).
For a population of 1000 people where 120 have rifampicin-resistant TB, 125 would be positive for rifampicin-resistant TB: of these, 11 (9%)
would not have rifampicin resistance (false-positives); and 875 would be negative for rifampicin-resistant TB: of these, 6 (1%) would have
rifampicin resistance (false-negatives).
For lymph node TB, the accuracy of culture, the reference standard used, presented a greater concern for bias than in other forms of
extrapulmonary TB.
Authors' conclusions
In people presumed to have extrapulmonary TB, Xpert may be helpful in confirming the diagnosis. Xpert sensitivity varies across diNerent
extrapulmonary specimens, while for most specimens, specificity is high, the test rarely yielding a positive result for people without TB
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(defined by culture). Xpert is accurate for detection of rifampicin resistance. For people with presumed TB meningitis, treatment should
be based on clinical judgement, and not withheld solely on an Xpert result, as is common practice when culture results are negative.
2 April 2019
Up to date
All studies incorporated from most recent search
Updated review: all eligible published studies found in the last search (7 Aug, 2017) were included
P L A I N   L A N G U A G E   S U M M A R Y
Xpert® MTB/RIF test for diagnosing extrapulmonary tuberculosis and rifampicin resistance
Why is improving the diagnosis of extrapulmonary tuberculosis important?
Tuberculosis (TB) is the world’s leading infectious cause of death. It mainly aNects the lungs (pulmonary TB) but may occur in other body
parts than the lungs (extrapulmonary TB). In most people, TB can be cured if the disease is diagnosed and properly treated. One problem
involved in treating TB is that the bacteria become resistant to antibiotics. Not recognizing TB early (false-negative result) may result in
delayed diagnosis and treatment and increased illness and death. An incorrect TB diagnosis (false-positive result) may result in increased
anxiety and unnecessary treatment.
What is the aim of this review?
To find out how accurate Xpert® MTB/RIF (Xpert) is for diagnosing extrapulmonary TB and drug resistance. We included eight forms
of extrapulmonary TB: tuberculous meningitis and pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, and
disseminated TB.
What was studied in this review?
Xpert is a relatively new, automated, rapid test that detects TB and rifampicin resistance at the same time. Rifampicin is an important drug
for treating people with TB. Another Cochrane Review showed that Xpert is accurate for diagnosing pulmonary TB. The current review
assessed Xpert accuracy for detecting eight forms of extrapulmonary TB, as well as the diNerent specimens that may be collected for
diagnosis, for instance, cerebrospinal fluid, pleural fluid, and urine. Xpert results were measured against culture results (benchmark).
What are the main results reported in this review?
We included 66 studies that evaluated 16,213 specimens for extrapulmonary TB and rifampicin resistance. Only one study evaluated the
newest test version, Xpert Ultra (Ultra), for tuberculous meningitis.
In urine and bone or joint fluid and tissue, Xpert was sensitive (more than 80%), that is, registered positive in people who actually had TB.
In cerebrospinal fluid, pleural fluid, urine, and peritoneal fluid, Xpert was highly specific (98% or more), that is, did not register positive
in people who were actually negative.
For a population of 1000 people:
• where 100 have TB meningitis on culture, 89 would be Xpert-positive: of these, 18 (20%) would not have TB; and 911 would be Xpert-
negative: of these, 29 (3%) would have TB.
• where 150 have pleural TB on culture, 83 would be Xpert-positive: of these, seven (8%) would not have TB ; and 917 would be Xpert-
negative: of these, 74 (8%) would have TB.
• where 70 have genitourinary TB on culture, 70 would be Xpert-positive: of these, 12 (17%) would not have TB; and 930 would be Xpert-
negative: of these, 12 (1%) would have TB.
• where 120 have rifampicin-resistant TB, 125 would be positive for rifampicin-resistant TB: of these, 11 (9%) would not have rifampicin
resistance; and 875 would be negative for rifampicin-resistant TB: of these, 6 (1%) would have rifampicin resistance.
How confident are we in the review's results?
The diagnosis of extrapulmonary TB was made by assessing patients with culture, generally considered to be the best reference standard.
However, it appears that culture did not work well as a reference test for lymph node TB.
Who do the review's results apply to?
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
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People presumed to have extrapulmonary TB. Most studies included only inpatients at tertiary care centres or did not report the clinical
setting. Therefore, we could not say how the test would work in primary care.
What are the implications of this review?
Xpert may be helpful in diagnosing extrapulmonary TB. The ability of Xpert to detect TB varies when diNerent specimens are used, while
Xpert rarely yields a positive result for people without TB (defined by culture). Xpert is accurate for diagnosing rifampicin resistance. In
patients thought to have TB meningitis, which is considered a medical emergency, providers should use clinical judgement and should
not rely solely on an Xpert result when deciding to withhold treatment, as is common practice when culture results are negative.
How up-to-date is this review?
The review authors searched for studies published up to 7 August 2017.
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
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Summary of findings 1.   Xpert® MTB/RIF in cerebrospinal fluid
Participants: patients presumed to have TB meningitis
Prior testing: patients who received Xpert testing may first have undergone a health examination (history and physical examination) and possibly a chest radiograph
Role: replacement test for usual practice
Settings: primarily tertiary care centres (the index test was often run in reference laboratories)
Index (new) test: Xpert
Studies: cross-sectional studies
Limitations: participants were evaluated exclusively as inpatients at a tertiary care centre, or, if the clinical setting was not reported, Xpert was performed at a reference
laboratory rather than at primary care facilities and local hospitals
Pooled sensitivity (95% CrI): 71.1% (60.9 to 80.4); pooled specificity (95% CrI): 98.0% (97.0 to 98.8)
1000 people tested for TB using Xpert® MTB/RIF (95% CrI)Test result
Prevalence of 1% Prevalence of 5% Prevalence of 10%
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
True-positives (patients with TB meningitis) 7 (6 to 8) 36 (30 to 40) 71 (61 to 80)
False-negatives (patients incorrectly classified as not having
TB meningitis)
3 (2 to 4) 14 (10 to 20) 29 (20 to 39)
433 (29) ⊕⊕⊕⊝
Moderatea,b
True-negatives (patients without TB meningitis) 970 (960 to 978) 931 (922 to 939) 882 (873 to 889)
False-positives (patients incorrectly classified as having TB
meningitis)
20 (12 to 30) 19 (11 to 28) 18 (11 to 27)
3341 (29) ⊕⊕⊕⊕
High
Abbreviations: Crl: credible interval; TB: tuberculosis.
The median prevalence in the included studies was 10%. We also included other plausible prevalence estimates for the target condition.
Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity. The results presented in this table should not be interpreted in
isolation from results of the individual included studies contributing to each summary test accuracy measure. These are reported in the main body of the text of the review.
aAs assessed by QUADAS-2, for the reference standard domain only four studies (14%) had unclear risk of bias because specimens underwent decontamination. We did not
downgrade.
bThe wide CrI around true-positives and false-negatives may lead to diNerent decisions depending on which credible limits are assumed. We downgraded one level.
GRADE certainty of the evidence
High: we are very confident that the true eNect lies close to that of the estimate of the eNect.
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Moderate: we are moderately confident in the eNect estimate: the true eNect is likely to be close to the estimate of the eNect, but there is a possibility that it is substantially
diNerent.
Low: our confidence in the eNect estimate is limited: the true eNect may be substantially diNerent from the estimate of the eNect.
Very low: we have very little confidence in the eNect estimate: the true eNect is likely to be substantially diNerent from the estimate of eNect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 2.   Xpert® MTB/RIF in pleural fluid
Participants: patients presumed to have pleural TB
Prior testing: patients who received Xpert testing may first have undergone a health examination (history and physical examination) and possibly a chest radiograph
Role: replacement test for standard practice, which may include more invasive tests, such as pleural biopsy
Settings: primarily tertiary care centres (the index test was often run in reference laboratories)
Index (new) test: Xpert
Reference standard: solid or liquid culture
Studies: cross-sectional studies
Limitations: in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, Xpert was performed at a reference laboratory
Pooled sensitivity (95% CrI): 50.9% (39.7 to 62.8); pooled specificity (95% CrI): 99.2% (98.2 to 99.7)
1000 people tested for TB using Xpert®MTB/RIF (95% CrI)Test result
Prevalence of 10% Prevalence of 15% Prevalence of 25%
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
True-positives (patients with pleural TB) 25 (20 to 31) 76 (60 to 94) 127 (99 to 157)
False-negatives (patients incorrectly classified as not having
pleural TB)
25 (19 to 30) 74 (56 to 90) 123 (93 to 151)
606 (27) ⊕⊕⊝⊝
Lowa,b
True-negatives (patients without pleural TB) 942 (933 to 947) 843 (835 to 847) 744 (736 to 748)
False-positives (patients incorrectly classified as having
pleural TB)
8 (3 to 17) 7 (3 to 15) 6 (2 to 14)
3399 (27) ⊕⊕⊕⊕ 
High
Abbreviations: CrI: credible interval; TB: tuberculosis.
The median prevalence in the included studies was 15%. We also included other plausible prevalence estimates for the target condition.
aAs assessed by QUADAS-2, for the reference standard domain, ten studies (37%) had unclear risk of bias because specimens underwent decontamination. We did not downgrade.
bFor individual studies, sensitivity estimates ranged from 10% to 100%. We could not explain heterogeneity by study quality or other factors. We downgraded two levels for
inconsistency.
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GRADE certainty of the evidence
High: we are very confident that the true eNect lies close to that of the estimate of the eNect.
Moderate: we are moderately confident in the eNect estimate: the true eNect is likely to be close to the estimate of the eNect, but there is a possibility that it is substantially
diNerent.
Low: our confidence in the eNect estimate is limited: the true eNect may be substantially diNerent from the estimate of the eNect.
Very low: we have very little confidence in the eNect estimate: the true eNect is likely to be substantially diNerent from the estimate of eNect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 3.   Xpert® MTB/RIF in urine
Participants: patients presumed to have genitourinary TB
Prior testing: patients who received Xpert testing may first have undergone a health examination (history and physical examination) and possibly a chest radiograph
Role: replacement test for standard practice, which may include more invasive tests, such as biopsy of affected organs
Settings: primarily tertiary care centres (the index test was often run in reference laboratories)
Index (new) test: Xpert
Reference standard: solid or liquid culture
Studies: cross-sectional studies
Limitations: in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, Xpert was performed at a reference laboratory
Sensitivity: 82.7% (69.6 to 91.1); specificity: 98.7% (94.8 to 99.7)
1000 people tested for TB using Xpert®MTB/RIF 
(95% Crl)
Test result
Prevalence of 2% Prevalence of 7% Prevalence of 15%
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
True-positives (patients with genitourinary TB) 17 (14 to 18) 58 (49 to 64) 124 (104 to 137)
False-negatives (patients incorrectly classified as not having
genitourinary TB)
3 (2 to 6) 12 (6 to 21) 26 (13 to 46)
73 (13) ⊕⊕⊕⊝ 
Moderatea,b
True-negatives (patients without genitourinary TB) 967 (929 to 977) 918 (882 to 927) 839 (806 to 847)
False-positives (patients incorrectly classified as having geni-
tourinary TB)
13 (3 to 51) 12 (3 to 48) 11 (3 to 44)
1126 (13) ⊕⊕⊕⊝
Moderatec
Abbreviations: Crl: credible interval; TB: tuberculosis.
The median prevalence in the included studies was 7%. We included what we considered to be plausible prevalence estimates for the target condition.
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aAs assessed by QUADAS-2, for the reference standard domain only four studies (31%) had unclear risk of bias because specimens underwent decontamination.
bFor individual studies, sensitivity estimates ranged from 0% to 100%. We thought that the small number of culture-positives in studies could explain some, but probably not
all, of the variation in sensitivity results. We downgraded one level.
cThe wide CrI around true-negatives and false-positives may lead to diNerent decisions depending on which credible limits are assumed. We downgraded one level.
GRADE certainty of the evidence
High: we are very confident that the true eNect lies close to that of the estimate of the eNect.
Moderate: we are moderately confident in the eNect estimate: the true eNect is likely to be close to the estimate of the eNect, but there is a possibility that it is substantially
diNerent.
Low: our confidence in the eNect estimate is limited: the true eNect may be substantially diNerent from the estimate of the eNect.
Very low: we have very little confidence in the eNect estimate: the true eNect is likely to be substantially diNerent from the estimate of eNect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 4.   Xpert® MTB/RIF for rifampicin resistance
Participants: patients with TB detected by Xpert® MTB/RIF
Role: replacement test for standard practice, which includes culture-based drug susceptibility testing or MTBDRplus
Settings: primarily tertiary care centres (the index test was often run in central (reference laboratories), where drug susceptibility testing for the reference standard could
be performed)
Index (new) test: Xpert® MTB/RIF
Reference standard: culture-based drug susceptibility testing using solid or liquid media or MTBDRplus
Studies: cross-sectional studies
Pooled sensitivity (95% CrI): 95.0% (89.7 to 97.9); pooled specificity (95% CrI): 98.7% (97.8 to 99.4)
1000 people tested for rifampicin resistance using
Xpert®MTB/RIF (95% Crl)
Test result
Prevalence of 5% Prevalence of 12%
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
True-positives (patients correctly classified as rifampicin resistant) 48 (45 to 49) 114 (108 to 117)
False-negatives (patients incorrectly classified as rifampicin susceptible) 2 (1 to 5) 6 (3 to 12)
148 (20) ⊕⊕⊕⊕
High
True-negatives (patients correctly classified as rifampicin susceptible) 938 (929 to 944) 869 (861 to 875)
False-positives (patients incorrectly classified as rifampicin resistant) 12 (6 to 21) 11 (5 to 19)
1088 (39) ⊕⊕⊕⊕ 
High
Abbreviations: Crl: credible interval; TB: tuberculosis.
The median prevalence in the included studies was 12%.
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GRADE certainty of the evidence
High: we are very confident that the true eNect lies close to that of the estimate of the eNect.
Moderate: we are moderately confident in the eNect estimate: the true eNect is likely to be close to the estimate of the eNect, but there is a possibility that it is substantially
diNerent.
Low: our confidence in the eNect estimate is limited: the true eNect may be substantially diNerent from the estimate of the eNect.
Very low: we have very little confidence in the eNect estimate: the true eNect is likely to be substantially diNerent from the estimate of eNect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
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B A C K G R O U N D
Tuberculosis (TB) is caused by infection with Mycobacterium
tuberculosis (M. tuberculosis) bacteria. TB causes tremendous
suNering worldwide and has surpassed HIV/AIDS as the world’s
leading infectious cause of death. The World Health Organization
(WHO) estimates that globally in 2016, 1.3 million HIV-negative
people and 374,000 HIV-positive people died from TB and 10.4
million people became ill with TB (WHO 2017a). Drug-resistant
TB is an enormous threat. In 2016, an estimated 600,000 people
were newly diagnosed with rifampicin-resistant TB, 490,000 of
whom had multidrug-resistant TB (MDR-TB) (WHO 2017a). MDR-TB
is caused by infection with M. tuberculosis bacteria that are resistant
to at least rifampicin and isoniazid. Rifampicin is the most eNective
first-line anti-TB drug. When people receive proper treatment, TB is
treatable and curable.
TB predominantly aNects the lungs (pulmonary TB).
Extrapulmonary TB, which refers to TB in parts of the body other
than the lungs, is known to aNect virtually every part of the
body; lymph nodes and the pleura are the most common sites
(Sharma 2004). Although active pulmonary TB is transmissible by
droplets spread by coughing, extrapulmonary TB is thought to
result from hematogenous spread from an initial lung infection
and is not infectious. Extrapulmonary TB can occur alone or
together with pulmonary TB. Of the 6.3 million new cases of TB
notified to WHO in 2016, 15% were cases of extrapulmonary TB
(range, 8% in the WHO Western Pacific Region to 24% in the WHO
Eastern Mediterranean Region) (WHO 2017a). Among countries in
the European Union, extrapulmonary TB was responsible for 19%
of all notified cases (range, 6% to 44%) (Sandgren 2013). However,
the number of people aNected by extrapulmonary TB is likely
to be higher, given that, according to WHO, extrapulmonary TB
is notified as pulmonary TB when the two forms exist together
(WHO 2014b), and diagnosing extrapulmonary TB is challenging, as
described below. Additionally, extrapulmonary TB accounts for an
increasing proportion of new TB cases in some countries, in part
because of host and genetic considerations, and the association of
extrapulmonary TB and HIV (Golden 2005; Pai 2016; Perkins 2007;
Webster 2014). Based on surveillance and epidemiological data,
extrapulmonary TB aNects a greater proportion of children than
adults (Nelson 2004).
WHO TB treatment guidelines recommend the same drug regimens
for extrapulmonary and pulmonary disease with notable mention
of other guidelines, which recommend longer treatment for TB
meningitis and for bone or joint TB (WHO 2010). An updated
guideline, published in 2017, provided recommendations on
the use of adjuvant steroids for treatment of TB meningitis
(strong recommendation; moderate-certainty evidence), and TB
pericarditis (conditional recommendation; very low-certainty
evidence) (WHO 2017b). Recent TB treatment guidelines include
Index-TB 2016 (India), and those issued by the American Thoracic
Society, the Centers for Disease Control and Prevention (CDC), and
the Infectious Diseases Society of America (Nahid 2016).
Diagnosis of extrapulmonary TB is challenging for several reasons.
Many forms of extrapulmonary TB require invasive diagnostic
sampling; gathering adequate specimens can pose risk of harm
to the patient and can be costly. Most forms of extrapulmonary
TB are paucibacillary (TB disease caused by a small number
of bacteria), making diagnosis by the conventional method of
smear microscopy less sensitive. This problem particularly aNects
resource-limited settings, where the more sensitive methods
of mycobacterial culture and histological examination are not
widely available. Limitations are also associated with culture and
histology: culture takes several weeks, requires a highly equipped
laboratory, and has reduced sensitivity in paucibacillary disease;
histology relies on highly trained operators, and characteristic
morphology is shared with other diseases. As a result of these
diNiculties, diagnosis of extrapulmonary TB is oQen made on the
grounds of clinical suspicion alone, and many people receive the
wrong diagnosis, leading to unnecessary TB treatment or poor
outcomes from untreated extrapulmonary TB. The need for faster,
more reliable diagnostics that are suitable for resource-limited
settings is clear and has been defined by the research community
(Denkinger 2015). In 2014, the World Health Assembly unanimously
approved the End TB Strategy, a 20-year strategy devised to end the
global TB epidemic. The END TB strategy calls for early diagnosis
of TB and universal drug susceptibility testing (DST) (WHO END TB
2014).
Xpert® MTB/RIF (Xpert) is an automated diagnostic test for the
detection of Mycobacterium tuberculosis complex (M. tuberculosis).
It is a DNA-based test that detects the M. tuberculosis rpoB gene.
Xpert also detects mutations in rpoB that may cause rifampicin
resistance. Results are available aQer two hours with minimal
hands-on technical time. A Cochrane Review found that Xpert
accurately detectsM. tuberculosis and rifampicin resistance when
used on sputum specimens (Steingart 2014). The WHO published
updated guidance on use of Xpert in 2013 (WHO 2013). This updated
policy statement expanded recommendations for use of Xpert for
pulmonary TB in adults and provided additional guidance on use
of the test for childhood TB and extrapulmonary TB.
Drawing on a systematic review (Denkinger 2014), and using
the GRADE approach, the WHO has issued the following
recommendations related to extrapulmonary TB.
• Xpert should be used in preference to conventional microscopy
and culture as the initial diagnostic test for cerebrospinal fluid
(CSF) specimens from patients presumed to have TB meningitis
(strong recommendation given the urgency for rapid diagnosis;
very low-certainty evidence).• Xpert may be used as a replacement test for usual practice
(including conventional microscopy, culture, or histopathology)
for testing specific non-respiratory specimens (lymph nodes and
other tissues) from patients presumed to have extrapulmonary
TB (conditional recommendation; very low-certainty evidence).
The use of Xpert has also been incorporated into the International
Standards for TB Care 2014 (TB Care I 2014). Clinical practice
guidelines on the diagnosis of pulmonary and extrapulmonary TB
in adults and children for clinicians in high-resource countries with
low TB incidence have recently been published (Lewinsohn 2017).
Currently, the manufacturer, Cepheid Incorporated (Sunnyvale, CA,
USA), has made no claim for the use of Xpert in non-sputum
specimens (Cepheid 2015); accordingly, Xpert is approved by the
US Food and Drug Administration (FDA) for use in raw sputum
specimens and concentrated sputum sediment only (FDA 2013).
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
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Target condition being diagnosed
Extrapulmonary TB
The various forms of extrapulmonary TB cause signs and symptoms
related to the structures aNected. Table 1 describes the forms of
extrapulmonary TB included in this Cochrane Review, as well as the
diNerent specimens that may be collected for diagnosis.
Rifampicin resistance
Rifampicin inhibits bacterial DNA-dependent RNA polymerase,
encoded by the RNA polymerase gene (rpoB) (Hartmann 1967).
Resistance to this drug has been associated mainly with mutations
in a limited region of the rpoB gene (Telenti 1993). Rifampicin
resistance may occur alone or in association with resistance to
isoniazid and other drugs. In settings with a high burden of MDR-TB,
the presence of rifampicin resistance alone may serve as a proxy for
MDR-TB (WHO 2011).
Index test(s)
Xpert is an automated diagnostic test for the detection of M.
tuberculosis complex DNA and, when M. tuberculosis complex
(hereaQer expressed to as M. tuberculosis) is detected, rifampin-
resistance associated mutations of the rpoB gene. Test results are
available for M. tuberculosis and resistance to rifampicin within
two hours aQer the test is begun, with minimal hands-on technical
time. Unlike conventional nucleic acid amplification (NAA) tests,
Xpert integrates sample processing and PCR amplification and
detection into a single self-enclosed test unit, the GeneXpert
cartridge (Blakemore 2010). Following sample loading, all steps
in the assay are completely automated and self-contained. In
addition, the assay’s sample reagent, used to liquefy sputum, has
potent tuberculocidal (the ability to kill TB bacteria) properties and
so largely eliminates biosafety concerns during the test procedure
(Banada 2010). Xpert detects both live and dead bacteria (Miotto
2012).
Xpert uses molecular beacon technology to detect rifampicin
resistance. Molecular beacons are nucleic acid probes that
recognize and report the presence or absence of the normal,
rifampicin-susceptible, ‘wild-type’ sequence of the rpoB gene of TB.
Beacons of five diNerent colours are used, each covering a separate
nucleic acid sequence within the amplified rpoB gene.
Xpert provides testing simultaneously for M. tuberculosis and
rifampicin resistance. Thus, it is really only one test. A rifampicin
resistance result is provided whether or not a patient is at risk of
resistance. One cannot deselect testing for rifampicin resistance
and run only the assay for TB detection. Xpert may be used at all
levels of the healthcare system. However, for use of the current
device, a stable and uninterrupted electrical supply is required. The
WHO has published extensive guidance and practical information
on implementing the test (WHO 2014a).
Since Xpert was released, five generations of the cartridge have
been developed: G1, G2, G3, G4, and Xpert Ultra (Ultra). Preparation
of specimens and the cartridge procedure for Xpert and Ultra
are the same (Chakravorty 2017). However, technically, Ultra
diNers from earlier Xpert generations in several ways. To improve
detection of M. tuberculosis, Ultra incorporates two diNerent multi-
copy amplification targets (IS6110 and IS1081), and to improve
detection of rifampicin resistance, Ultra uses melting temperature-
based analysis instead of real-time PCR (Chakravorty 2017).
In a multi-country diagnostic accuracy study comparing Ultra
and Xpert version G4 in sputum specimens for pulmonary TB (n
= 1439), the sensitivity of Ultra was higher than that of Xpert
(sensitivity of 63% for Ultra versus 46% for Xpert in people who were
smear-negative and culture-positive, 137 participants; sensitivity
of 95% for Ultra versus 77% for Xpert in people living with
HIV, 115 participants) (Dorman 2018). However, the specificity of
Ultra was lower than that of Xpert (specificity of 96% for Ultra
versus 98% for Xpert) (Dorman 2018). In additional retrospective
studies, Ultra showed improved sensitivity, in particular for TB
meningitis and childhood TB. In CSF, Ultra sensitivity was 95% for
TB meningitis compared with Xpert sensitivity of 45%. In children,
using respiratory specimens, Ultra sensitivity was 71% for TB
compared with Xpert sensitivity of 47% (FIND 2017; WHO 2017c).
The WHO has recently recommended Ultra as an alternative to
Xpert, stating that all recommendations concerning use of Xpert
with selected extrapulmonary specimens (CSF, lymph nodes, and
tissue specimens) also apply to Ultra (WHO 2017c).
We included in this Cochrane Review studies that used any of the
Xpert generations.
Clinical pathway
It is recommended that clinicians who evaluate patients for
extrapulmonary TB adhere to Standard 4 of the International
Standards for TB Care, which states: "For all patients, including
children, presumed to have extrapulmonary TB, appropriate
specimens from the presumed sites of involvement should be
obtained for microbiological and histological examination. An
Xpert test is recommended as the preferred initial microbiological
test for presumptive TB meningitis because of the need for a rapid
diagnosis" (TB Care I 2014).
Figure 1 shows the clinical pathway and presents the context in
which Xpert might be used. The target condition is extrapulmonary
TB, of which several forms are known (e.g. pleural TB, TB
meningitis).
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Figure 1.   The clinical pathway describes how patients might present and the point in the pathway at which they
would be considered for testing with Xpert. Before a specimen was tested with Xpert, patients presumed of having
extrapulmonary TB would have undergone a health examination (history and physical examination) and possibly a
chest radiograph. Presentation of extrapulmonary TB varies depending on the body site aIected; this condition may
imitate other diseases such as cancer and bacterial and fungal infections. Signs and symptoms of extrapulmonary
TB are oKen non-specific and may include fever, night sweats, fatigue, loss of appetite, and weight loss (as seen in
pulmonary TB) or specific complaints related to the involved site (e.g. headache for TB meningitis, back pain for TB
of the spine). The clinical presentation of extrapulmonary disease may be acute but is more oKen subacute (falling
between acute and chronic) or chronic, meaning that patients may have symptoms for days to months before they
seek care. Signs and symptoms for the forms of extrapulmonary TB included in this review are described in Table 1.
Standard practice includes obtaining specimens for microscopy, culture, and histological examination. We adapted
this algorithm for Xpert from the Global Laboratory Initiative (GLI 2018). Abbreviations: DR-TB: drug-resistant TB;
MDR-TB: multidrug-resistant TB; RIF: rifampicin; SL-LPA: line probe assay for second-line drugs; TB: tuberculosis.
 
Before a specimen is tested with Xpert, patients presumed of having
extrapulmonary TB would have undergone a health examination
(history and physical examination) and possibly a chest radiograph.
The presentation of extrapulmonary TB varies depending on the
body site aNected, and it may imitate other diseases, such as
cancer and bacterial and fungal infections. Signs and symptoms of
extrapulmonary TB are oQen non-specific and may include fever,
night sweats, fatigue, loss of appetite, and weight loss (as seen in
pulmonary TB) or specific complaints related to the involved site
(e.g. headache for TB meningitis, back pain for TB of the spine).
The clinical presentation of extrapulmonary disease may be acute
but is more oQen subacute (falling between acute and chronic) or
chronic, meaning that patients may have symptoms for days to
months before they seek care.
We have described in Table 1 signs and symptoms of the forms
of extrapulmonary TB included in this review. The clinician
should take a careful history, noting history of TB exposure,
prior TB disease, and medical conditions that increase the risk
for TB disease (e.g. HIV, diabetes mellitus, low body weight).
In comparison with HIV-negative people, HIV-positive people
have higher rates of extrapulmonary TB or mycobacteraemia
(TB bloodstream infection). HIV-positive patients with signs
or symptoms of extrapulmonary TB should have specimens
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taken from the suspected site(s) of involvement to increase the
likelihood of TB diagnosis. In general, children and adults with
extrapulmonary TB present in a similar way. However, infants and
young children are at highest risk of developing disseminated TB
disease and TB meningitis - the most severe forms of TB. In TB
meningitis, diagnosis is oQen delayed with appalling consequences
for patients. For all forms of extrapulmonary TB, patients may be
evaluated in primary or secondary care settings. However, if more
complex or invasive tests are needed, patients may be referred to
a tertiary medical centre (Iseman 2000; Reuter 2009; Sharma 2004).
In many countries, district-level and lower-level laboratories oNer a
range of basic diagnostic tests, including Xpert (GLI 2017).
Xpert is used to diagnose TB and to detect rifampicin resistance.
Xpert is performed as a replacement for standard practice,
which includes obtaining appropriate specimens from presumed
sites of involvement for microbiological (conventional microscopy
and culture) and histological examination. An Xpert test is
recommended as the preferred initial microbiological test for
presumptive TB meningitis because of the need for a rapid
diagnosis (TB Care I 2014; WHO 2013). In HIV-positive people with
a CD4 cell count of 100 cells/μL or lower, and in HIV-positive
people who are seriously ill regardless of CD4 count, the lateral
flow urine lipoarabinomannan assay (LF-LAM) (see Alternative
test(s)) may be used to facilitate diagnosis of TB (WHO 2015). The
WHO further recommends the following: "Individuals presumed
of having extrapulmonary TB but who have had a single negative
result from Xpert should undergo further diagnostic testing, and
those for whom there is a high clinical suspicion for TB (especially
children) should be treated even if an Xpert result is negative
or if the test is not available" (WHO 2013). The downstream
consequences of Xpert testing include the following.
• True-positive (TP): patients would benefit from rapid diagnosis
and appropriate treatment.• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance and pursuit of an
alternative diagnosis.• False-positive (FP): patients would likely experience anxiety and
morbidity caused by additional testing, unnecessary treatment,
and possible adverse eNects; possible stigma associated with a
TB or MDR-TB diagnosis; and the chance that a false-positive
may halt further diagnostic evaluation.• False-negative (FN): increased risk of morbidity and mortality
and delayed treatment initiation for patients.
Alternative test(s)
For a comprehensive review of new tests not yet in widespread use,
we refer the reader to Unitaid 2017.
Smear microscopy (light microscopy (Ziehl-Neelsen), fluorescence
microscopy, or light-emitting diode (LED) fluorescence microscopy)
is the examination of smears for acid-fast bacilli (TB bacteria)
under a microscope. Around 5000 to 10,000 organisms per mL
must be present in the specimen for TB bacteria to be visible by
microscopy (American Thoracic Society 2000). For extrapulmonary
TB, microscopy can be performed in fluid or tissue specimens from
sites of disease involvement, for example, in CSF in presumptive
TB meningitis or in lymph node tissue in presumptive lymph node
TB. For most extrapulmonary sites, because there are usually few
organisms, the sensitivity of smear microscopy is generally low.
Ranges from studies, some with selected cases, are quoted here: 0%
to 10% in pleural fluid; 14% to 39% in pleural tissue; 2% to 30% in
CSF; < 5% in peritoneal fluid; and 0% to 42% in pericardial fluid. In
contrast, the specificity of smear microscopy tends to be quite high,
as can be seen in pulmonary TB (≥ 90%) (Kilpatrick 1986; Lewinsohn
2017).
Mycobacterial culture is a method used to grow bacteria on
nutrient-rich media. In comparison with microscopy, a positive
culture requires only around 100 organisms per mL and
therefore can detect lower numbers of TB bacteria (American
Thoracic Society 2000). Additionally, culture is essential for
species identification and DST (Van Deun 2004). However, culture
takes several weeks and requires a highly equipped laboratory.
Culture has reduced sensitivity in paucibacillary disease (reference
standards have included culture from a diNerent specimen, such as
sputum, smear microscopy, NAA tests, presence of granulomatous
inflammation, clinical criteria, imaging studies, and response to
anti-TB therapy, done alone or in various combinations): CSF 45%
to 70%; pleural fluid 23% to 58%; urine 80% to 90%; peritoneal TB
45% to 69%; pericardial TB 50% to 65% (Lewinsohn 2017); lymph
node TB (excisional biopsy) 18% to 93%; and lymph node TB (fine-
needle aspirate) 10% to 67% (Fontanilla 2011). Culture is the main
reference standard against which the index test was measured in
this review.
Histological examination involves examination of tissue specimens
under a microscope. Diagnosis of extrapulmonary TB by
histological examination is based on finding acid-fast bacilli and
granulomatous inflammation, frequently with caseous (cheese-
like) necrosis (necrotizing granulomas). The sensitivity of histology
has been reported to vary for diNerent forms of extrapulmonary
TB (reference standards have included smear microscopy, culture,
NAA tests, clinical criteria, and imaging studies, done alone
or in various combinations): 59% to 88% for lymph node TB
(excisional biopsy) (Fontanilla 2011); 69% to 97% in pleural tissue
(closed pleural biopsy); 86% to 94% in urological tissue; 60%
to 70% in endometrial curettage; 79% to 100% in peritoneal
biopsy; and 73% to 100% in pericardial tissue (Lewinsohn
2017). Sensitivity has also been observed to vary for diNerent
diagnostic techniques. Diacon 2003 found thoracoscopy to be
more sensitive (sensitivity of 100%) than closed needle biopsy
(sensitivity of 66%) for establishing a diagnosis of pleural TB
(reference standards have included microscopy smear, culture, or
presence of granulomatous inflammation with caseous necrosis).
Specificity has been observed to be low because of the presence
of granulomas in other diseases, both infectious and non-
infectious (Lewinsohn 2017), although the presence of ‘necrotizing'
granulomatous inflammation increases specificity (Woodard 1982).
Histological examination carries the additional concern that
invasive procedures that are complex and costly may be required
to obtain the necessary specimens (Golden 2005).
Cytopathological examination of fluid specimens (such as pleural
and peritoneal fluid) may be performed, first to exclude cancer,
and then to obtain material for additional analyses, such
as measurement of levels of adenosine deaminase and free
interferon-gamma (IFN-γ) and cell counts (Lewinsohn 2017; Wright
2009a). Advantages of these tests include that they are rapid and
simple and can be performed in most clinical laboratories (Dinnes
2007). In pleural, pericardial, and peritoneal fluid, a predominance
of lymphocytes, especially in the absence of mesothelial cells,
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is highly suggestive of TB (Wright 2009a). However, in HIV-
positive people, this pattern may not be observed (Wright 2009a).
Adenosine deaminase, an enzyme involved in purine metabolism,
has been extensively studied for its potential role in the diagnosis of
pleural TB, peritoneal TB, and TB meningitis (Lewinsohn 2017). IFN-
γ is released aQer it is sensitized by T cells in response to specific M.
tuberculosis antigens. A recent review of the evidence using GRADE
provides the following recommendations.
• "...cell counts and chemistries be performed on amenable fluid
specimens (including include pleural, cerebrospinal, ascitic, and
joint fluid) collected from sites of suspected extrapulmonary TB
(conditional recommendation, very low-quality evidence).• ...adenosine deaminase levels be measured, rather than not
measured, on fluid collected from patients with suspected
pleural TB, TB meningitis, peritoneal TB, or pericardial TB
(conditional recommendation, low-quality evidence).• ...free IFN-γ levels be measured, rather than not measured,
on fluid collected from patients with suspected pleural TB
or peritoneal TB (conditional recommendation, low-quality
evidence)" (Lewinsohn 2017).
NAA test is a molecular technique that can detect small quantities
of genetic material (DNA or RNA) from micro-organisms, such as M.
tuberculosis. The key advantage of NAA tests is that they are rapid
diagnostic tests, potentially providing results in a few hours. This is
a particularly important feature of the test in life-threatening forms
of extrapulmonary TB, such as TB meningitis. A variety of molecular
amplification methods are available, of which PCR is the most
common. NAA tests are available as commercial kits and in-house
tests (based on a protocol developed in a laboratory) and are used
routinely in high-income countries for TB detection. In-house PCR
is widely used in low-income countries because these tests are less
expensive than commercial kits. An older editorial summarizing
three systematic reviews (140 studies) of commercial and in-house
NAA tests (other than Xpert) for diNerent forms of extrapulmonary
TB found relatively low sensitivity and underscored concerns about
the cost and feasibility of this technology in resource-limited areas
(Pai 2008). Similarly, another systematic review found that NAA
tests have relatively low sensitivity for extrapulmonary TB but high
specificity (e.g. for TB meningitis, for pleural TB), indicating that
these tests cannot be used reliably to rule out TB (Dinnes 2007).
A recent evidence synthesis reported sensitivities of 72% to 88%
in lymph node tissue, 28% to 81% in pleural fluid, 90% in pleural
tissue, and 31% to 56% in CSF. Specificity ranged from 90% to 100%
(Lewinsohn 2017).
GenoType MTBDRplus (Hain Lifescience, Nehren, Germany) is a
commercial NAA test that belongs to a category of molecular
tests called ‘line probe assay'. MTBDRplus detects the presence
of mutations associated with drug resistance to isoniazid and
rifampicin (Nathavitharana 2017). The WHO recommends that
MTBDRplus should be used for cultured isolates of M. tuberculosis
from both pulmonary and extrapulmonary sites (WHO 2016b).
LF-LAM (Alere Determine™ TB LAM Ag, Alere Inc, Waltham, USA) is a
commercially available point-of-care test for active TB (pulmonary
and extrapulmonary TB). The test detects lipoarabinomannan
(LAM), a component of the bacterial cell wall, which is present
in some people with active TB. LF-LAM is performed by placing
urine on one end of a test strip, with results appearing as a line
(i.e. a band) on the strip if TB is present. The test is simple,
requires no special equipment, and shows results in 25 minutes
(Shah 2016b). Of note, the presence of LAM in the urine of HIV-
positive adults undergoing treatment for TB has been found to be
associated with increased risk of mortality (Gupta-Wright 2016). In
randomized trials, use of LF-LAM in HIV-positive inpatients has been
shown to reduce mortality (Gupta-Wright 2018; Peter 2016). Based
in part on evidence from a Cochrane Review (Shah 2016b), the WHO
recommends that LF-LAM should be used to assist in the diagnosis
of TB in adult inpatients, specifically, "people living with HIV who
have signs or symptoms of TB and a CD4 cell count less than or
equal to 100 cells/μL, and people living with HIV who are ‘seriously
ill' regardless of CD4 count or if the CD4 count is unknown. This
recommendation also applies to HIV-positive children with signs
and symptoms of TB (pulmonary and/or extrapulmonary) based on
the generalisation of data from adults while acknowledging very
limited data and concern regarding low specificity of the LF-LAM
assay in children" (WHO 2015). The WHO does not recommend LF-
LAM for TB screening or diagnosis of active TB disease in most
population groups (WHO 2015).
Rationale
Existing diagnostic tests for extrapulmonary TB are not sensitive
enough or are invasive and costly. This Cochrane Review estimated
sensitivity and specificity of Xpert for detection of extrapulmonary
TB and rifampicin resistance. We are aware of six systematic reviews
previously published on this topic: Chang 2012; Denkinger 2014;
Li Y 2017; Maynard-Smith 2014; Penz 2015; Sehgal 2016 (Table
2). These reviews found diNerent pooled accuracy estimates for
diNerent forms of extrapulmonary TB and noted several limitations,
including the following: small number of samples for a given
specimen type, incomplete information on HIV status, concerns
about accuracy of the reference standards used, limited data
for assessing the accuracy of Xpert for detection of rifampicin
resistance, and considerable diNerences in the preparation of
specimens for testing. Concerning the latter, the WHO has provided
standard operating procedures for preparation of non-respiratory
specimens for use with Xpert (WHO 2014a). This Cochrane Review
updates the literature and provides an opportunity to address
some of the noted limitations.
O B J E C T I V E S
To determine the diagnostic accuracy of Xpert a) for
extrapulmonary TB by site of disease in people presumed to have
extrapulmonary TB; and b) for rifampicin resistance in people
presumed to have extrapulmonary TB.
Secondary objectives• To investigate the eNects of potential sources of heterogeneity
on test accuracy across the included studies.
For extrapulmonary TB, covariates of interest were microscopy
smear status, HIV status, anti-TB treatment, past history of TB,
reference standard used to verify pleural TB, and prevalence of
extrapulmonary TB (culture confirmed) in included studies. For
CSF, we considered the presence of a concentration step and
specimen volume. For tissue specimens, we considered whether
the WHO standard operating procedure was followed.
In addition, for TB meningitis, pleural TB, and lymph node TB,
we adjusted accuracy estimates by applying a latent class meta-
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analysis model to account for the imperfect nature of culture as the
reference standard.
For detection of rifampicin resistance, the covariate of interest in
included studies was the prevalence of rifampicin resistance.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials, cross-sectional studies,
and observational cohort studies. We included primary studies that
compared results of the index test with results of the reference
standard and reported data from which we could extract TP, FP,
FN, and TN. We excluded case-control studies and case reports.
We used abstracts to identify published studies and included these
when they met the inclusion criteria.
Participants
We included participants of all ages from all settings and countries
who were thought to have extrapulmonary TB. We included non-
respiratory specimens (such as lymph node aspirate or tissue,
pleural fluid, and CSF), except as noted. We excluded sputum and
other respiratory specimens, such as fluid obtained from bronchial
alveolar lavage and tracheal aspiration. As we anticipated finding
many studies, we set a bar to exclude smaller studies to reduce
unnecessary work. Therefore, we required studies to provide data
for at least five specimens for a form of extrapulmonary TB
included in the review. We excluded studies that evaluated Xpert
by aspiration of gastric fluid, as this specimen is used most oQen
to investigate pulmonary TB in children. We also excluded stool
specimens because TB bacteria may be swallowed and passed
into stool as a marker of pulmonary TB. We excluded studies
evaluating the use of Xpert to diagnose relapse of previously
treated extrapulmonary TB, so as to avoid the selection bias that
may arise by limiting to a group that is already at elevated risk of
extrapulmonary TB. We attempted to identify studies that included
patients who were not taking anti-TB drugs or had taken anti-TB
drugs for less than seven days. For those studies that included some
patients on TB drugs, we addressed this concern in a sensitivity
analysis.
Index tests
The index tests were the Xpert assay and the Ultra assay. Index test
results are automatically generated, and the user is provided with
a printable test result as follows.
• MTB (M. tuberculosis) DETECTED; Rif (rifampicin) resistance
DETECTED.• MTB DETECTED; Rif resistance NOT DETECTED.• MTB detected; Rif resistance INDETERMINATE.• MTB NOT DETECTED.• INVALID (the presence or absence of MTB cannot be
determined).• ERROR (the presence or absence of MTB cannot be determined).• NO RESULT (the presence or absence of MTB cannot be
determined).
Indeterminate results for detection of extrapulmonary TB refer to
‘invalid', ‘error', or ‘no result'. Indeterminate results for detection of
rifampicin resistance refer to ‘MTB detected; rifampicin resistance
indeterminate'.
Ultra incorporates a semi-quantitative classification for results:
trace, very low, low, moderate, and high. "Trace" corresponds
to the lowest bacterial burden for detection of M. tuberculosis
(Chakravorty 2017). For extrapulmonary specimens, based on
retrospective studies that enrolled selected participants, the WHO
recommends that "trace calls should be considered to be true-
positive results for use in clinical decisions and patient follow-
up" (WHO 2017c). We summarized the findings for Xpert and Ultra
separately.
Target conditions
The target condition was extrapulmonary TB. We included
eight common forms and considered subcategories of the
target condition as separate diagnostic classifications (CDC 2015;
Sandgren 2013; Sharma 2004).
• TB meningitis.• Pleural TB.• Lymph node TB.• Genitourinary TB.• Bone or joint TB.• Peritoneal TB.• Pericardial TB.• Disseminated TB.
Table 1 lists the forms of extrapulmonary TB and specimens used
for diagnosis in the review. We excluded less common forms, such
as cutaneous TB, ocular TB, female genital TB, and TB of the breast,
ear, and paranasal sinuses (Sharma 2004).
Reference standards
Detection of all forms of extrapulmonary TB
The primary reference standard was solid or liquid mycobacterial
culture.
• ‘TB' was defined as a positive M. tuberculosis culture.• ‘Not TB' was defined as a negative M. tuberculosis culture.
For pleural TB, we also included a composite reference standard
that defined a positive result as the presence of granulomatous
inflammation or a positive culture. We found evidence to
support including histopathological examination in the composite
reference standard for pleural TB. Around 60% of patients
undergoing pleural biopsy will show granulomatous inflammation
(American Thoracic Society 2000). In a prospective cohort study
of patients with clinical and radiological findings consistent with
pleural TB, Conde 2003 found that histological examination of
tissue obtained from pleural biopsy had a higher diagnostic yield
(78%; 66/84) than that of culture (62%; 52/84). For other forms
of TB, we decided against use of a composite reference standard
owing to the diNering definitions of the composite reference
standards, diNiculty involved in interpreting them, concern for bias
(Schiller 2016), and diNiculty and impracticality in obtaining biopsy
specimens in some forms of extrapulmonary TB (e.g. pericardial
TB).
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Culture is considered the best reference standard for TB, and
we calculated sensitivity and specificity by measuring the results
of Xpert against those of culture. Both culture sensitivity and
specificity are expected to be better than those of Xpert, and culture
specificity is expected to be perfect. However, culture may lead
to misclassification of some cases of extrapulmonary TB as ‘not
TB' owing to the paucibacillary nature of the disease. This means
that culture may have low sensitivity for extrapulmonary TB overall
and further that culture sensitivity may diNer for diNerent forms
of extrapulmonary TB. This misclassification by culture may lead
to biased estimates (overestimation or underestimation) of the
diagnostic accuracy of Xpert. The extent of bias will depend on the
frequency of errors by culture and the degree of correlation in errors
by culture and Xpert because both culture and Xpert are likely to
pick up cases with a higher bacterial load, and both are likely to miss
cases with a lower bacterial load. Ignoring this dependence could
lead to an overestimation of the sensitivity of Xpert.
• ENect of low sensitivity of culture on Xpert specificity: the
low sensitivity of culture means that index test TPs may be
misclassified as FPs when culture is used as the reference
standard. Therefore, when Xpert is evaluated against culture,
the number of FPs (classified as positive by the index test and
negative by the reference test) may be increased and Xpert
specificity may be underestimated.• ENect of low sensitivity of culture on Xpert sensitivity: the
low sensitivity of culture means that index test FNs may be
misclassified as TNs when culture is used as the reference
standard. Therefore, when Xpert is evaluated against culture,
the number of FNs (classified as positive by the index test and
negative by the reference test) may be decreased and Xpert
sensitivity may be overestimated.
In an attempt to improve the estimation of diagnostic accuracy,
we applied a latent class meta-analysis model to the three most
commonly studied forms of extrapulmonary TB. We discuss this
approach further in the Statistical analysis and data synthesis
section.
Detection of rifampicin resistance
The reference standard was culture-based DST using solid or liquid
media or MTBDRplus as recommended by the WHO (WHO 2012;
WHO 2016b).
Search methods for identification of studies
We attempted to identify all relevant studies regardless of
language or publication status (published, unpublished, in press,
or ongoing). We monitored abstracts to see if these studies were
published during the time we performed the review. We included
only published studies in the review.
Electronic searches
We searched the following databases up to 7 August 2017
using the search terms and strategy described in Appendix 1:
Cochrane Infectious Diseases Group Specialized Register; MEDLINE
(OVID, from 1966); Embase (OVID, from 1974); Science Citation
Index - Expanded (from 1900), Conference Proceedings Citation
Index - Science (CPCI-S, from 1990), and BIOSIS Previews (from
1926), all three from the Web of Science; Scopus (Elsevier,
from 1970); and Latin American Caribbean Health Sciences
Literature (LILACS) (BIREME, from 1982). We also searched
ClinicalTrials.gov, the WHO International Clinical Trials Registry
(ICTRP) Platform (www.who.int/trialsearch), and the International
Standard Randomized Controlled Trials Number (ISRCTN) registry
(www.isrctn.com/) for trials in progress, and ProQuest Dissertations
& Theses A&I (1990 to 7 August 2017) for dissertations.
Searching other resources
We reviewed reference lists of included articles and any
relevant review articles identified through the above methods.
We contacted the test manufacturer (Cepheid Inc.) to identify
unpublished studies. We also contacted researchers at FIND,
members of the Stop TB Partnership's New Diagnostics Working
Group, and other experts in the field of TB diagnostics for
information on ongoing and unpublished studies.
Data collection and analysis
Selection of studies
We used Covidence to manage the selection of studies (Covidence
2017). Two review authors independently scrutinized titles and
abstracts identified by electronic literature searching to identify
potentially eligible studies. We selected any citation identified by
either review author as potentially eligible for full-text review. The
same review authors independently assessed full-text papers for
study eligibility using predefined inclusion and exclusion criteria
and resolved any discrepancies by discussion. We recorded all
studies excluded aQer full-text assessment and their reasons for
exclusion in the Characteristics of excluded studies table. We
illustrated the study selection process in a PRISMA diagram.
Data extraction and management
Two review authors piloted a data extraction form with five studies
and, based on the pilot, finalized the form (Appendix 2). Next,
two review authors worked independently to extract data on the
following characteristics.
• Author; publication year; country; setting (outpatient, inpatient,
or both outpatient and inpatient); study design; manner of
participant selection; number of participants enrolled; number
of participants for whom results are available.• Characteristics of participants: gender; age; HIV status; history of
TB; receipt of anti-TB treatment.• Index test.• Target condition and subcategories.• Reference standard.• Quality Assessment of Studies of Diagnostic Accuracy - Revised
(QUADAS-2) items.• Details of specimen: type (such as CSF, pleural fluid, lymph node
aspirate or tissue); condition (fresh or frozen); smear-positive or
smear-negative.• Specimen preparation; homogenization step (for tissue
specimens); concentration step and specimen volume (for CSF);
adherence to WHO standard operating procedures.• Number of TP, FP, FN, and TN (i.e. true-positives, false-
positives, false-negatives, and true-negatives, with respect
to culture); number of indeterminate results for detection
of extrapulmonary TB; number of indeterminate results for
detection of rifampicin resistance.• Number of missing or unavailable test results.
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We classified country income status as either low- and middle-
income or high-income, according to the World Bank List of
Economies (World Bank 2017).
We extracted TP, FP, FN, and TN values for the following specimens:
CSF, pleural fluid and tissue, lymph node aspirate and tissue (the
latter specimen acquired by surgical biopsy), bone or joint fluid
and tissue, urine, peritoneal fluid and tissue, pericardial fluid
and tissue, and blood. We extracted these values for each of the
specimen types separately. For example, we used one 2 × 2 table
for lymph node aspirate, and another 2 × 2 table for lymph node
tissue. In situations in which a participant contributed more than
one specimen but of diNerent types, we extracted data for all
specimens. When a study included data for both raw specimens
and concentrated sediment involving the same participants, we
preferentially extracted data for raw specimens, except in the case
of CSF, for which we extracted data for concentrated sediment as
recommended by the WHO (WHO 2014a). We extracted accuracy
data according to the defined reference standard, which was an
inclusion criterion for the Review (see Reference standards). We did
not encounter any situations in which a subset of participants in
a study received the reference standard but others did not. Hence,
there was no need to make corrections for verification bias in the
statistical analysis (Begg 1983).
In most studies, the number of specimens was the same as the
number of participants. However, in some studies, the number of
specimens exceeded the number of participants or study authors
reported only the number of specimens. Hence the unit of analysis
in this review should be considered "specimen". We added post hoc
a sensitivity analysis limiting inclusion to studies that included one
specimen per participant.
We contacted authors of primary studies for missing data or
clarifications. We entered all data into MicrosoQ Excel 2014.
As recommended for reporting of systematic reviews of diagnostic
test accuracy, we extracted information on manufacturers'
involvement and funding (McGrath 2017). This information
included donation of the index test; financial support for non-
test-related study costs; and design, analysis, or production of the
manuscript.
Assessment of methodological quality
We used the QUADAS-2 tool, tailored to this review, to assess
the quality of the included studies (Appendix 3) (Whiting 2011).
QUADAS-2 consists of four domains: patient selection, index
test, reference standard, and flow and timing. We assessed all
domains for the potential for risk of bias and the first three
domains for concerns regarding applicability. Two review authors
independently completed QUADAS-2 and resolved disagreements
through discussion. We present the results of this quality
assessment in Review text, tables, and graphs.
We followed Cochrane policy, which states that "authors of primary
studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the
interpretation against the study report and any available study
registration details or protocol".
Statistical analysis and data synthesis
We performed descriptive analyses of the characteristics of
included studies using Stata 12 (Stata 2011), and we presented
key study characteristics in the Characteristics of included studies
table. We used data reported in the TP, FP, FN, and TN format to
calculate sensitivity and specificity estimates and 95% confidence
intervals (CIs) for individual studies and presented individual study
results graphically by plotting the estimates of sensitivity and
specificity (and their 95% CIs) in forest plots and receiver operating
characteristic (ROC) space using Review Manager 5 (RevMan 5)
(RevMan 2014).
When data were suNicient, we performed meta-analyses to
estimate pooled sensitivity and specificity and corresponding 95%
credible (CrI, defined below) and prediction intervals using an
adaptation of the bivariate random-eNects approach of Reitsma
and colleagues (Reitsma 2005), which uses the exact binomial
likelihood for the observed proportions (Chu 2006). The bivariate
random-eNects approach allowed us to calculate the pooled
estimates of sensitivity and specificity while dealing with potential
sources of variation caused by (1) imprecision of sensitivity and
specificity estimates within individual studies; (2) correlation
between sensitivity and specificity across studies; and (3) variation
in sensitivity and specificity between studies. The model has a
hierarchical structure, with the logit sensitivity in individual studies
assumed to come from a common probability distribution whose
mean is the pooled logit sensitivity, and whose standard deviation
is the between-study standard deviation, and likewise for the
specificity. This structure allows for borrowing strength across
studies. In the absence of suNicient studies, we simply presented
descriptive statistics.
We performed separate analyses grouped by type of
extrapulmonary specimen (e.g. CSF, pleural fluid, peritoneal fluid)
rather than determine summary accuracy estimates for all forms
of extrapulmonary TB combined, because we considered the
former approach to be most clinically meaningful. We performed
additional analyses for three forms of extrapulmonary TB: lymph
node and pleural TB - these being two of the most common forms
- and TB meningitis - although less common, this form has high
mortality. For analysis of Xpert accuracy for rifampicin resistance
detection, we included patients who (1) were culture-positive; (2)
had a valid phenotypic DST (or MTBDRplus) result; (3) were Xpert
TB-positive; and (4) had a valid Xpert Rif result.
• Sensitivity = Xpert Rif resistant/DST Rif resistant.• Specificity = Xpert Rif susceptible/DST Rif susceptible.
For detection of rifampicin resistance, when a study included
multiple types of specimens, we based our determination of
Xpert sensitivity and specificity on all available data in the study,
including data for specimens that we did not include in the primary
analyses for detection of extrapulmonary TB. For example, if a
study provided data for several specimen types combined (e.g.
all tissue specimens) and we could not disaggregate the data
for a specific specimen type, we included all data (for all tissue
specimens) in the analysis for rifampicin resistance detection.
We did this because we did not expect the accuracy of Xpert
for rifampicin resistance to vary by specimen type. In addition,
for detection of rifampicin resistance, we performed univariate
meta-analyses (using all available data) to determine sensitivity
and specificity estimates separately. We did this because in many
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studies, all participants were rifampicin susceptible (rifampicin
resistance-negatives), thus contributing data for specificity but
not for sensitivity. We also performed a sensitivity analysis using
the bivariate random-eNects model for the subset of studies that
provided data for both sensitivity and specificity.
Culture-negative specimens found to be Xpert-positive for
rifampicin resistance have rarely been described in the literature
(Boyles 2014; Kelly 2014). When reported in the included studies,
we extracted and included this information in the Findings and
Discussion sections of the review.
We estimated all models using a Bayesian approach with low-
information prior distributions using OpenBUGS soQware (Version
3.2.3) (Lunn 2009), along with R (Version 3.3.2) (R Core Team 2016).
Under the Bayesian approach, all unknown parameters must be
provided a prior distribution that defines the range of possible
values of the parameter and the weight of each of those values,
based on information external to the data. To allow observed data
to dominate the final results, we chose to use low-information
prior distributions. We defined prior distributions on the log-
odds scale over the pooled sensitivity and specificity parameters,
their corresponding between-study standard deviations, and the
correlation between the sensitivities and specificities across
studies. For the pooled log odds of the sensitivity or the pooled
log odds of the specificity, we used a normal prior distribution
with mean 0 and a wide variance of 4 (or a precision of 0.25).
This corresponds to a roughly uniform distribution over the pooled
sensitivity and pooled specificity on the probability scale. For the
between-study precision, we used a gamma distribution with a
shape parameter of 2 and a rate parameter of 0.5. This corresponds
to a 95% prior credible interval (Crl) for the between-study standard
deviation in the log odds of sensitivity or the log odds of specificity
ranging from roughly 0.29 to 1.44, corresponding to moderate
to high values of between-study heterogeneity. Covariance terms
followed a uniform prior distribution whose upper and lower
limits were determined by the sensitivity of the two tests. The
OpenBUGS model used appears in Appendix 4. It is known that
meta-analysis models can be sensitive to the choice of prior
distributions over between-study standard deviation parameters.
Therefore, we carried out sensitivity analyses and considered
alternative prior distributions that are less informative, allowing a
wider range of possible values. To study the sensitivity of all results
to the choice of prior distributions given above, we considered
alternative prior distributions that were less informative, allowing
a wider range of possible values. We increased the variance of
the normal distributions over the pooled log odds of sensitivity or
specificity to 100. We used a uniform prior distribution ranging from
0 to 3 over the between-study standard deviation on the log odds
scale (see programme in Appendix 4). We noted no appreciable
change in pooled accuracy parameters but found that the posterior
CrIs and prediction intervals were slightly wider, as expected.
We combined information from the prior distribution with the
likelihood of the observed data, in accordance with Bayes’
theorem, using the OpenBUGS programme, which provides a
sample from the posterior distribution of each unknown parameter.
We were particularly interested in the pooled sensitivity and
specificity of Xpert and between-study variance in the sensitivity
and specificity of Xpert on the log-odds scale. Using a sample
from the posterior distribution, we calculated various descriptive
statistics of interest. We estimated the median pooled sensitivity
and specificity and their 95% CrI. The median or the 50% quantile
is the value below which 50% of the posterior sample lies. We
report the median because the posterior distributions of some
parameters may be skewed and the median would be considered a
better point estimate of the unknown parameter than the mean in
such cases. The 95% CrI is the Bayesian equivalent of the classical
(frequentist) 95% CI (we will indicate 95% CI for individual study
estimates and 95% CrI for pooled study estimates as appropriate).
The 95% CrI may be interpreted as an interval that has a 95%
probability of capturing the true value of the unknown parameter,
given observed data and prior information. We prepared summary
receiver operating characteristic (SROC) curves for each meta-
analysis model using the methods described in Harbord 2007.
We also determined the predicted sensitivity and specificity of
Xpert and their 95% CrIs. Predicted values represent our best guess
for sensitivity and specificity in a future study and will be close
to the pooled estimates. However, their CrIs may be diNerent. If
there is no heterogeneity at all between studies, the CrI around
the predicted estimate will be the same as the CrI around the
pooled estimate. On the other hand, if considerable heterogeneity
is observed between studies, the CrI around the predicted estimate
will be much wider than the CI around the pooled estimate.
In addition, in a secondary analysis for three forms of
extrapulmonary TB - TB meningitis (CSF), pleural TB (pleural
fluid), and lymph node TB (lymph node aspirate) - we adjusted
accuracy estimates by applying a latent class meta-analysis model
to account for the imperfect nature of culture as the reference
standard (Chu 2009; Dendukuri 2012).
Latent class analysis is a statistical modelling technique that allows
estimation of test accuracy in the absence of an adequate reference
standard to define the presence or absence of disease (Van
Smeden 2014). The latent class meta-analysis model expanded
the traditional meta-analysis model in two ways: (1) we added
parameters for the sensitivity and specificity of culture; and (2)
we added covariance terms to adjust for the dependence between
Xpert and culture among disease-positive and disease-negative
participants in each study. We used hierarchical prior distributions
over the logit sensitivity and logit specificity of culture. In other
words, we assumed that the logit sensitivities in the individual
studies come from a common probability distribution whose mean
is the pooled mean logit sensitivity of culture and whose standard
deviation is the between-study standard deviation. Likewise for the
specificities. We used the same low-information prior distributions
over the pooled logit mean and between-study standard deviation
parameters as we had for the corresponding parameters for the
Xpert test. We used uniform prior distributions for covariance terms
over their ranges, which are determined by the sensitivities and
the specificities of the two tests in each study (see Appendix 4 for
the OpenBUGS model). We found that we did not need to augment
observed data with prior information from other sources for most
models. However, in a post hoc analysis of lymph node aspirate
in which we suspected a systematic bias in the performance of
culture, we used informative prior distributions over the specificity
of culture (ranging from 99% to 100%) and the specificity of Xpert
(ranging from 98% to 100%) (see Appendix 4). We added the SROC
plots of the three latent class meta-analyses to the SROC plots
resulting from the models in which culture was treated as a perfect
test, so they could be compared.
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Based on recent work evaluating Xpert for childhood TB
(Schumacher 2016), we anticipated that latent class meta-analyses
would lead to a decrease in the estimated pooled sensitivity of
Xpert and an increase in the estimated pooled specificity of Xpert
compared with the primary analyses. In other words, this method
should help to correct the biases in Xpert sensitivity and specificity
resulting from treating culture as a perfect reference standard,
which we detailed earlier in the section on the reference standard.
Approach to indeterminate index test results
Xpert reports an indeterminate test result for unexpected results
with any of the internal control measures of the assay. The
indeterminate rate for detection of extrapulmonary TB was the
number of tests classified as "invalid", "error", or "no result" divided
by the total number of Xpert tests performed. The indeterminate
rate for detection of rifampicin resistance was the number of
tests classified as "MTB detected; Rif resistance INDETERMINATE"
divided by the total number of Xpert-positive results. As we found
very few indeterminate results reported, we excluded these results
from the quantitative analysis. We used a Bayesian hierarchical
model for a single proportion to estimate the pooled proportion of
uninterpretable Xpert results.
Investigations of heterogeneity
Initially, we investigated heterogeneity through visual examination
of forest plots of sensitivities and specificities and through visual
examination of the ROC space of the raw data. We assessed
heterogeneity through meta-regression modelling. We included
the prevalence of extrapulmonary TB (confirmed by culture) as
a covariate because changes in disease prevalence have oQen
been found to be associated with other important changes, such
as changes in the disease spectrum, which may aNect diagnostic
accuracy estimates (Leeflang 2013). We planned to include the
following categorical covariates in the model, one at a time.
• Smear status.• HIV status.• Prior history of TB.• For TB meningitis, concentration step used for preparing
specimen (yes or no).• CSF specimen volume used for Xpert testing.• For pleural TB, culture reference standard versus composite
reference standard.• Prevalence of extrapulmonary TB, defined as the percentage of
TB confirmed by culture in the study.• Prevalence of rifampicin resistance, defined as the percentage of
rifampicin resistance confirmed by the reference standard in the
study.
However, we had insuNicient data to investigate smear status, prior
history of TB, and whether WHO standard procedures for preparing
tissue specimens were followed.
For analyses involving the prevalence of extrapulmonary TB and
rifampicin resistance, we compared the sensitivity or specificity
between groups of interest by calculating the diNerence between
groups together with a 95% Crl. We also calculated the probability
that the diNerence was greater than zero.
Sensitivity analyses
For Xpert testing in CSF, pleural fluid, and lymph node aspirate, we
performed sensitivity analyses to explore the contributions of risk
of bias and patient characteristics on Xpert accuracy by limiting
inclusion in the meta-analysis to the following.
• Studies that used consecutive or random selection of
participants.• Studies in which the reference standard results were interpreted
without knowledge of the index test results.• Studies that included only untreated patients.• Studies that included only one specimen per patient.• For lymph node aspirate, studies that involved only adults.
Other analyses
Non-tuberculous mycobacteria (NTM), such as M. avium complex
and M. intracellulare, constitute a multi-species group of human
pathogens that are ubiquitous in water and soil. NTM can
cause severe diseases that share clinical signs with TB but
are treated diNerently. People infected with HIV with severe
immunosuppression are particularly vulnerable to infections
caused by NTM (Gopinath 2010). Although previous studies have
shown that Xpert does not cross-react with other mycobacterial
species (Blakemore 2010; Helb 2010), we thought it important to
summarize data for NTM separately by determining the percentage
of false-positive Xpert results in specimens that grew NTMs.
Assessment of reporting bias
We did not perform a formal assessment of publication bias using
methods such as funnel plots or regression tests because such
techniques have not been helpful for diagnostic test accuracy
studies (Macaskill 2010).
Assessment of certainty of the evidence
Two review authors assessed the certainty of the evidence
(also called quality of the evidence) using the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) approach (Balshem 2011; GRADE 2013; Schünemann
2008), along with GRADEpro Guideline Development Tool (GDT)
soQware (GRADEpro GDT 2015). In the context of a systematic
review, ratings of the certainty of the evidence reflect the extent of
our confidence that the estimates of eNect (including test accuracy
and associations) are correct. As recommended, we rated the
certainty of the evidence as high (not downgraded), moderate
(downgraded by one level), low (downgraded by two levels), or very
low (downgraded by more than two levels) for five domains: risk of
bias, indirectness, inconsistency, imprecision, and publication bias.
For each outcome, we considered the certainty of the evidence
to begin as high when high-quality observational studies (cross-
sectional or cohort studies) enrolled participants with diagnostic
uncertainty. If we had a reason for downgrading, we used our
judgement to classify the reason as serious (downgraded by one
level) or very serious (downgraded by two levels). We summarized
this information in the ‘Summary of findings' tables (Schünemann
2011). As recommended, we determined the overall certainty of the
evidence by using the lowest grade for any of the outcomes deemed
critical (sensitivity and specificity) (Brozek 2009).
We applied GRADE in the following ways.
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• Risk of bias: we used QUADAS-2 to assess risk of bias.• Indirectness: we used QUADAS-2 for concerns of applicability
and looked for important diNerences between the populations
studied (e.g. patient characteristics, study setting) and the
review questions.• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity
estimates. We carried out prespecified analyses to investigate
potential sources of heterogeneity and did not downgrade when
we believed we could explain inconsistency in the accuracy
estimates.• Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered
the width of the CrI and asked ourselves, "Would we make a
diNerent decision if the lower or upper boundary of the CrI
represented the truth?" In addition, we worked out projected
ranges for TP, FN, TN, and FP for a given prevalence of TB and
made judgements on imprecision from these calculations.• Publication bias: we rated publication bias as undetected (not
serious) because of the comprehensiveness of the literature
search and following extensive outreach to TB researchers to
identify studies.
R E S U L T S
Results of the search
We identified 66 unique studies that met the inclusion criteria
(Ablanedo-Terrazas 2014; Al-Ateah 2012; Arockiaraj 2017; Bahr
2015; Bahr 2017; Bera 2015; Bholla 2016; Biadglegne 2014; Blaich
2014; Causse 2011; Che 2017; Christopher 2013; Coetzee 2014;
Dhasmana 2014; Dhooria 2016; Diallo 2016; Du 2015; Feasey 2013;
Friedrich 2011; Ghariani 2015; Gu 2015; Gursoy 2016; Hanif 2011;
Held 2014; Held 2016; Hillemann 2011; Ioannidis 2011; Iram 2015;
Jing 2017; Kim 2015a; Li 2017; Ligthelm 2011; Lusiba 2014; Malbruny
2011; Massi 2017; Mazzola 2016; Meldau 2014; Nataraj 2016; Nhu
2014; Ozkutuk 2014; Pandey 2017; Pandie 2014; Patel 2013; Penata
2016; Pink 2016; Pohl 2016; Rufai 2015; Rufai 2017a; Rufai 2017b;
Saeed 2017a; Safianowska 2012; Scott 2014; Sharma 2014; Sharma
2016; Solomons 2016; Suzana 2016; Tadesse 2015; Teo 2011; Tortoli
2012; Trajman 2014; Ullah 2017; Vadwai 2011; Van Rie 2013; Wang
2016a; Zeka 2011; Zmak 2013). Only one study evaluated Ultra; this
study compared Ultra and Xpert for TB meningitis (Bahr 2017). All
studies but four (one written in French - Diallo 2016, one in Spanish
- Penata 2016, and two in Turkish - Gursoy 2016; Ozkutuk 2014),
were written in English. Figure 2 shows the flow of studies in the
review. We recorded the excluded studies and the reasons for their
exclusion in the Characteristics of excluded studies table.
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Figure 2.   Study flow diagram. *See Table 3.
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Figure 2.   (Continued)
 
Methodological quality of included studies
Figure 3 and Figure 4 show risk of bias and applicability concerns
for each of the 66 included studies. In the patient selection domain,
we thought that 51 studies (77%) had low risk of bias, and six
studies (9%) had high risk of bias for the following reasons:
four studies selected participants by convenience (Bholla 2016;
Ioannidis 2011; Malbruny 2011; Pandey 2017), and two studies had
inappropriate exclusions (Saeed 2017a; Ullah 2017). We thought
that nine studies (14%) had unclear risk of bias for the following
reasons: the manner of patient selection was unclear - eight
studies (Diallo 2016; Gu 2015; Li 2017; Massi 2017; Rufai 2015;
Rufai 2017a; Rufai 2017b; Zmak 2013), and it was unclear whether
the study avoided inappropriate exclusions - one study (Bera
2015). Regarding applicability (patient characteristics and setting),
we thought that three studies (4%) had low concern because
participants were evaluated in local hospitals or primary health
settings (Bholla 2016; Pandie 2014; Trajman 2014); nine studies
(14%) had high concern because participants were evaluated
exclusively as inpatients at a tertiary care centre (Bahr 2015; Bahr
2017; Causse 2011; Che 2017; Du 2015; Feasey 2013; Gu 2015; Held
2014; Held 2016); and 54 studies had unclear concern because we
could not tell the clinical setting.
 
Figure 3.   Risk of bias and applicability concerns graph: review authors' judgements about each domain presented
as percentages across included studies.
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Figure 4.   Risk of bias and applicability concerns summary: review authors' judgements about each domain for each
included study.
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Figure 4.   (Continued)
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Figure 4.   (Continued)
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Figure 4.   (Continued)
 
In the index test domain, we thought that all studies had low risk
of bias because Xpert test results are automatically generated,
the user is provided with printable test results, and the test
threshold is prespecified. Regarding applicability, we thought that
42 studies (64%) had low concern because at least 75% of the
specimen types in these studies were processed according to
WHO recommendations, and 21 studies (32%) had high concern
because less than 50% of the specimen types in these studies were
processed according to WHO recommendations (Arockiaraj 2017;
Causse 2011; Che 2017; Dhasmana 2014; Feasey 2013; Friedrich
2011; Held 2014; Held 2016; Lusiba 2014; Malbruny 2011; Nhu 2014;
Pandey 2017; Pohl 2016; Rufai 2015; Rufai 2017a; Rufai 2017b;
Suzana 2016; Teo 2011; Tortoli 2012; Ullah 2017; Zeka 2011). Three
studies (5%) had unclear concern because the manner of specimen
processing was not reported (Bera 2015; Ioannidis 2011), or only
50% of the specimen types were processed according to WHO
recommendations (Christopher 2013).
In the reference standard domain, 36 studies (55%) had low risk
of bias because results of the reference standard were interpreted
without knowledge of results of the index test and only non-sterile
specimens were decontaminated (Bahr 2015; Bahr 2017; Bera 2015;
Bholla 2016; Che 2017; Christopher 2013; Coetzee 2014; Dhooria
2016; Diallo 2016; Feasey 2013; Gursoy 2016; Held 2014; Held 2016;
Iram 2015; Jing 2017; Ligthelm 2011; Malbruny 2011; Mazzola 2016;
Meldau 2014; Nhu 2014; Ozkutuk 2014; Pandie 2014; Patel 2013;
Pink 2016; Pohl 2016; Rufai 2017b; Scott 2014; Solomons 2016;
Suzana 2016; Teo 2011; Tortoli 2012; Trajman 2014; Ullah 2017; Van
Rie 2013; Wang 2016a; Zeka 2011). Five studies (8%) had high risk
of bias because results of the reference standard were interpreted
with knowledge of results of the index test (Blaich 2014; Hanif 2011;
Penata 2016; Safianowska 2012; Zmak 2013). Twenty-five studies
(38%) had unclear risk of bias for the following reasons: two studies
did not report whether there was blinding of the reference standard
(Lusiba 2014; Saeed 2017a); 21 studies decontaminated specimens
generally considered to be sterile (Al-Ateah 2012; Biadglegne 2014;
Causse 2011; Dhasmana 2014; Du 2015; Friedrich 2011; Ghariani
2015; Gu 2015; Hillemann 2011; Ioannidis 2011; Kim 2015a; Li
2017; Massi 2017; Nataraj 2016; Pandey 2017; Rufai 2015; Rufai
2017a; Safianowska 2012; Sharma 2014; Tadesse 2015; Vadwai
2011); and two studies did not report blinding and decontaminated
specimens generally considered to be sterile (Ablanedo-Terrazas
2014; Arockiaraj 2017).
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Breaking this down by type of specimen, we found that before
culture inoculation, four studies reported decontaminating CSF
specimens (Kim 2015a; Li 2017; Nataraj 2016; Vadwai 2011); 10
studies reported decontaminating pleural fluid specimens (Al-
Ateah 2012; Du 2015; Friedrich 2011; Ioannidis 2011; Kim 2015a;
Li 2017; Nataraj 2016; Rufai 2015; Safianowska 2012; Vadwai
2011); and nine studies reported decontaminating lymph node
aspirates (Al-Ateah 2012; Biadglegne 2014; Blaich 2014; Dhasmana
2014; Ghariani 2015; Nataraj 2016; Pandey 2017; Sharma 2014;
Tadesse 2015). (Some studies are mentioned more than once
because they evaluated more than one type of specimen.) We think
decontamination of sterile specimens may have led to a decrease
in viable TB bacteria and consequently false-negative cultures.
Regarding applicability of the reference standard, we thought that
54 studies (82%) had low concern because these studies performed
a test to identify M. tuberculosis species (speciation). However,
we thought that one study (2%) had high concern because this
study did not do speciation (Friedrich 2011), and 11 studies (17%)
had unclear concern because we could not tell whether the study
performed speciation (Arockiaraj 2017; Bera 2015; Christopher
2013; Dhooria 2016; Iram 2015; Lusiba 2014; Massi 2017; Penata
2016; Saeed 2017a; Trajman 2014; Ullah 2017).
In the flow and timing domain, we considered almost all studies to
have low risk of bias, noting that all participants were included in
the analysis except in one study, which included less than 50% of
eligible participants in the analysis (Trajman 2014).
We noted manufacturer involvement in five studies (8%), and this
included the following.
• Donation of the index test (four studies; Hillemann 2011;
Ioannidis 2011; Nhu 2014; Tortoli 2012).• Involvement in manuscript design, analysis, or production (one
study; Vadwai 2011).
We are also aware that studies located in low- and middle-income
countries may have received index test cartridges at a reduced
price. However, most studies did not report this information.
Findings
We included 66 unique studies that evaluated 16,213 specimens
for detection of extrapulmonary TB and rifampicin resistance.
Thirty-three studies (50%) included only one specimen type: TB
meningitis (CSF) nine studies; pleural TB (fluid) six studies; lymph
node TB (aspirate) eight studies; bone or joint TB five studies
(fluid one study, tissue four studies); genitourinary TB (urine)
zero studies; peritoneal TB (fluid) one study; pericardial TB two
studies (fluid one study, tissue one study); and disseminated TB
(blood) two studies. The remaining studies included diNerent
types of specimens in varying percentages. FiQy studies (76%)
were conducted in low- or middle-income countries. Thirty studies
(45%) included children in their study population; however, only
five studies were conducted exclusively in children (Bholla 2016;
Coetzee 2014; Held 2016; Pohl 2016; Solomons 2016). Forty-one
studies (62%) reported the HIV status of participants. Of these,
five studies exclusively or largely included HIV-positive participants
(Ablanedo-Terrazas 2014; Bahr 2015; Bahr 2017; Feasey 2013; Van
Rie 2013). In the remaining studies, the percentages of included HIV-
positive patients ranged from 1% to 87%.
FiQy-eight studies (88%) evaluated fresh specimens, six studies
(9%) evaluated only archived frozen samples (Patel 2013; Tadesse
2015; Tortoli 2012; Trajman 2014; Wang 2016a; Zeka 2011), and one
study (2%) evaluated both fresh and frozen specimens (Malbruny
2011). Bahr 2017 compared Xpert in fresh specimens versus Ultra
in frozen specimens. For the reference standard, seven studies
(11%) used only solid culture, 29 studies (44%) used only liquid
culture, and 30 studies (45%) used both solid and liquid cultures.
Most studies performed Xpert and culture on the same specimen
type, except two studies in which Xpert was performed on blood
and culture was performed on sputum (Feasey 2013; Pohl 2016).
Most studies did not report the precise number of cultures used to
confirm a diagnosis of TB; however, it is likely that many studies
used a single culture. We presented key characteristics of the
included studies in the Characteristics of included studies table.
I. Detection of extrapulmonary TB
Table 3 presents pooled (summary) and predicted sensitivity
and specificity results with respect to culture for all forms of
extrapulmonary TB and specimen types included in the review.
Xpert pooled sensitivity varied greatly by type of specimen, ranging
from 50.9% (95% CrI 39.7 to 62.8) in pleural fluid to 97.2% (95% CrI
89.5 to 99.6) in bone or joint fluid. Pooled specificity ranged from
85.3% (58.7 to 96.4) in bone or joint tissue to 99.2% (98.2 to 99.7) in
pleural fluid. In urine, pooled sensitivity and specificity were 82.7%
(69.6 to 91.1) and 98.7% (94.8 to 99.7), respectively (13 studies, 1199
specimens).
A. Xpert testing in cerebrospinal fluid for TB meningitis
1. Primary analysis, Xpert
A total of 33 studies evaluated CSF specimens (Al-Ateah 2012; Bahr
2015; Bahr 2017; Blaich 2014; Causse 2011; Gursoy 2016; Hanif 2011;
Hillemann 2011; Ioannidis 2011; Jing 2017; Kim 2015a; Li 2017;
Malbruny 2011; Mazzola 2016; Nataraj 2016; Nhu 2014; Ozkutuk
2014; Pandey 2017; Patel 2013; Penata 2016; Pink 2016; Rufai 2017b;
Safianowska 2012; Sharma 2014; Solomons 2016; Suzana 2016; Teo
2011; Tortoli 2012; Ullah 2017; Vadwai 2011; Wang 2016a; Zeka 2011;
Zmak 2013). The median sample size (interquartile range (IQR)) was
74 (19 to 155) specimens. In individual studies, Xpert sensitivity
ranged from 33% to 100% and specificity ranged from 93% to 100%
(Figure 5). Pooled sensitivity and specificity (95% Crl) were 71.1%
(60.9 to 80.4) and 98.0% (97.0 to 98.8), respectively (29 studies, 3774
specimens) (Table 3; Appendix 5).
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Figure 5.   Forest plots of Xpert® MTB/RIF sensitivity and specificity in cerebrospinal fluid. The squares represent the
sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-positive;
TN: true-negative; TP: true-positive.
 
1.a. Primary analysis, Ultra
In a study on the treatment of HIV-associated cryptococcal
meningitis in Uganda, Bahr 2017 compared the accuracy of Ultra
and Xpert in 129 CSF specimens. Measured against culture as the
reference standard, sensitivity was considerably higher with Ultra
at 90% (95% CI 55 to 100) than with Xpert at 60% (95% CI 26 to 88).
However, specificity was lower with Ultra at 90% (95% CI 83 to 95)
versus Xpert at 97% (95% CI 92 to 99).
2. Investigations of heterogeneity
a. Xpert testing in HIV-positive and HIV-negative participants
We identified three studies that included mainly HIV-positive
people (Bahr 2015; Bahr 2017; Patel 2013) and three studies that
included mainly HIV-negative people (Hanif 2011; Jing 2017; Wang
2016a). In studies involving HIV-positive people, sensitivity ranged
from 58% to 81% compared with 33% to 100% in studies involving
HIV-negative people. In all studies, specificity was ≥ 93%.
b. Specimen concentration
We found that concentrating CSF improved both sensitivity and
specificity. Pooled sensitivity in concentrated specimens was 74.8%
(95% CrI 63.1 to 84.4) (15 studies, 2758 specimens) versus 66.2%
(95% CrI 48.5 to 81.4) (12 studies, 905 specimens) in unconcentrated
specimens. Pooled specificity in concentrated specimens was
98.3% (95% CrI 97.1 to 99.1) versus 97.7% (95% CrI 95.4 to 99.0) in
unconcentrated specimens (Appendix 6).
c. Cerebrospinal fluid collection volumes
Five studies reported the volume of CSF collected for Xpert testing.
Starting from the largest collection volume, at 7 mL, Nhu 2014 found
the highest sensitivity of85%; at 6 mL, Bahr 2015 found sensitivity
of 58%; at 6 mL, Bahr 2017 found sensitivity of 60%; at 3 mL, Patel
2013 found sensitivity of 81%; and at 2 mL, Rufai 2017b found the
lowest sensitivity of 52%. Specificities in the five studies were ≥ 93%
(Figure 5).
d. TB prevalence
See Table 4. The median prevalence of TB meningitis (as measured
by culture positivity) in these studies was 10%. We found higher
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Xpert sensitivity in settings with higher TB prevalence than in those
with lower TB prevalence, with pooled sensitivity of 72.0% (95% CrI
59.7 to 82.8) versus 68.2% (95% CrI 50.9 to 82.4). We found lower
specificity in settings with higher TB prevalence than in those with
lower TB prevalence, with pooled specificity of 96.8% (95% CrI 95.0
to 98.2) versus 98.9% (95% CrI 97.9 to 99.4). In the case of specificity,
accuracy in the two groups was significantly diNerent (probability
of specificity higher in low TB prevalence group = 0.008).
3. Sensitivity analysis
See Table 5. In comparison with all studies, studies that evaluated
only one specimen per participant had lower pooled sensitivity at
63.5% (47.6 to 76.3) and lower pooled specificity at 96.1% (94.2 to
97.4). The other sensitivity analyses made little diNerence in any of
these findings.
4. Indeterminate Xpert results
Fourteen studies (42%) reported the number of indeterminate
Xpert results. Nine of these studies reported zero indeterminate
results (Al-Ateah 2012; Bahr 2015; Blaich 2014; Causse 2011; Hanif
2011; Ioannidis 2011; Sharma 2014; Teo 2011; Zeka 2011). For CSF,
of 2096 tests performed, the pooled percentage of indeterminate
Xpert results was 0.9% (95% CrI 0.3 to 1.9).
5. Latent class meta-analysis
Based on the latent class meta-analysis model, Xpert pooled
sensitivity and specificity (95% Crl) were 63.2% (53.8 to 73.6) and
99.6% (98.5 to 99.9), respectively (29 studies, 3774 specimens)
(Table 6). Xpert pooled sensitivity was lower and pooled specificity
higher than when culture was treated as having perfect accuracy.
This analysis also provided accuracy estimates of culture. The
pooled sensitivity of culture at 68.6% (59.0 to 78.0) was estimated
to be lower than 100%, although it remained greater than that of
Xpert. The pooled specificity of culture was estimated to be 99.3%
(98.1 to 99.8) (Table 6). Appendix 5 shows the summary receiver
operating characteristic (SROC) curves from the meta-analysis
treating culture as a perfect reference standard and from the latent
class meta-analysis. The latent class meta-analysis resulted in low
heterogeneity in the specificity of Xpert across studies, as would
be expected of an automated, commercial test. This was the result
of adjustments for the imperfect and heterogeneous accuracy of
culture across studies.
B. Xpert testing in pleural fluid for pleural TB
1. Primary analysis, culture reference standard
Thirty studies evaluated pleural fluid with respect to a culture
reference standard (Al-Ateah 2012; Causse 2011; Che 2017;
Christopher 2013; Du 2015; Friedrich 2011; Hanif 2011; Hillemann
2011; Ioannidis 2011; Iram 2015; Jing 2017; Kim 2015a; Li 2017;
Malbruny 2011; Mazzola 2016; Meldau 2014; Nataraj 2016; Ozkutuk
2014; Pandey 2017; Penata 2016; Rufai 2015; Saeed 2017a;
Safianowska 2012; Scott 2014; Sharma 2014; Suzana 2016; Tortoli
2012; Vadwai 2011; Zeka 2011; Zmak 2013). The median sample
size (IQR) was 77 (30 to 166) specimens. In individual studies, Xpert
sensitivity ranged from 0% to 100% and specificity ranged from
90% to 100% (Figure 6). Pooled sensitivity and specificity (95% Crl)
against culture were 50.9% (39.7 to 62.8) and 99.2% (98.2 to 99.7),
respectively (27 studies, 4006 specimens) (Table 3; Appendix 7).
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Figure 6.   Forest plots of Xpert® MTB/RIF sensitivity and specificity in pleural fluid with respect to a culture
reference standard (upper plots) and a composite reference standard (lower plots). The squares represent the
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sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-positive;
TN: true-negative; TP: true-positive.
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2. Investigations of heterogeneity
a. Composite reference standard
Five studies evaluated pleural fluid with respect to the composite
reference standard (Christopher 2013; Friedrich 2011; Lusiba 2014;
Meldau 2014; Trajman 2014) (Figure 6). With a composite reference
standard, we found lower pooled sensitivity at 18.4% (9.9 to 30.7)
compared with a culture reference standard at 50.9% (39.7 to 62.8).
We found similar specificity with a composite reference standard
at 98.2% (94.8 to 99.5) versus with a culture reference standard at
99.2% (98.2 to 99.7) (Table 3).
b. TB prevalence
See Table 4. The median prevalence of pleural TB (as measured
by culture positivity) in these studies was 15%. We found higher
sensitivity in settings with higher TB prevalence than in those with
lower TB prevalence, with pooled sensitivity of 58.0% (95% CrI 45.0
to 70.2) versus 38.0% (23.9 to 55.5) (probability of higher sensitivity
in settings with higher TB prevalence = 0.97). We found similar
specificity in settings with higher and lower TB prevalence at 99.0%
(95% CrI 97.5 to 99.8) versus 99.3% (98.1 to 99.8).
3. Sensitivity analysis
See Table 5. Overall, the sensitivity analyses made little diNerence
in any of the findings.
4. Indeterminate Xpert results
Thirteen studies (43%) reported the number of indeterminate
Xpert results. Eight of these studies reported zero indeterminate
results (Al-Ateah 2012; Causse 2011; Christopher 2013; Friedrich
2011; Hanif 2011; Ioannidis 2011; Sharma 2014; Zeka 2011). For
pleural fluid, of 1416 tests performed, the pooled percentage of
indeterminate Xpert results was 1.2% (95% CrI 0.4 to 2.6).
5. Latent class meta-analysis
Based on the latent class meta-analysis model, Xpert pooled
sensitivity and specificity (95% Crl) were 56.4% (44.7 to 68.9) and
99.7% (98.1 to 100.0), respectively (27 studies, 4006 specimens)
(Table 6). The pooled sensitivity of Xpert was slightly higher
and its pooled specificity was comparable to what was obtained
when culture was treated as having perfect accuracy. The pooled
sensitivity and specificity of culture were estimated to be 81.8%
(69.5 to 91.2) and 98.1% (95.9 to 99.5). The decrease in the
estimated specificity of culture under the latent class meta-analysis
model resulted in an increase in the estimated sensitivity of
Xpert. The apparent between-study heterogeneity in the specificity
of Xpert based on the primary meta-analysis was reduced aQer
adjustments for the imperfect and heterogeneous accuracy of
culture across studies (Appendix 7).
B.1. Xpert testing in pleural tissue for pleural TB
1. Primary analysis, culture reference standard
Four studies evaluated pleural tissue with respect to a culture
reference standard (Christopher 2013; Du 2015; Ozkutuk 2014;
Suzana 2016). The median sample size (IQR) was 41 (21 to 73)
specimens. In individual studies, Xpert sensitivity ranged from 0%
to 85% and specificity ranged from 97% to 100%. Pooled sensitivity
and specificity (95% Crl) against culture were 30.5% (3.5 to 77.8) and
97.4% (92.1 to 99.3), respectively (three studies, 207 specimens)
(Table 3).
C. Xpert testing in lymph node aspirate for lymph node TB
1. Primary analysis
Nineteen studies evaluated Xpert in lymph node aspirates (Al-
Ateah 2012; Bholla 2016; Biadglegne 2014; Blaich 2014; Coetzee
2014; Dhasmana 2014; Dhooria 2016; Ghariani 2015; Hanif 2011;
Ioannidis 2011; Kim 2015a; Ligthelm 2011; Nataraj 2016; Pandey
2017; Scott 2014; Sharma 2014; Tadesse 2015; Ullah 2017; Van Rie
2013). The median sample size (IQR) was 72 (12 to 138) specimens.
In individual studies, Xpert sensitivity ranged from 56% to 100% and
specificity from 39% to 100% (Figure 7). Xpert specificity in lymph
node aspirates was considerably more heterogeneous than in CSF
and pleural fluid (Figure 7). The variability in Xpert specificity in
lymph node aspirates was unexpected and was suspected to be the
result of a systematic, unexplained bias in some studies. Pooled
sensitivity and specificity (95% Crl) against culture were 87.6% (81.7
to 92.0) and 86.0% (78.4 to 91.5), respectively (17 studies, 1710
specimens) (Table 3; Appendix 8). We discuss potential reasons for
low pooled Xpert specificity in the Discussion section.
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Figure 7.   Forest plot of Xpert® MTB/RIF sensitivity and specificity in lymph node aspirates with respect to a culture
reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
2. Investigations of heterogeneity
a. TB prevalence
See Table 4. The median prevalence of lymph node TB (as measured
by culture positivity) in the included studies was 43%. We found
higher sensitivity in settings with higher TB prevalence than
in those with lower TB prevalence, with pooled sensitivity of
92.6% (95% CrI 88.1 to 95.7) versus 78.5% (95% CrI 69.2 to 86.4)
(probability of higher sensitivity in the higher TB prevalence group
= 0.999).
3. Sensitivity analysis
See Table 5. In comparison with all studies, studies that evaluated
only adults had lower pooled sensitivity at 83.1% (69.2 to 91.5) and
higher pooled specificity at 91.2% (85.2 to 95.0). In comparison with
all studies, studies that evaluated only participants not receiving
TB treatment had lower pooled sensitivity at 83.2% (69.2 to 90.3)
and higher pooled specificity at 88.8% (80.9 to 93.8). The other
sensitivity analyses made little diNerence in any of the findings.
4. Indeterminate Xpert results
Twelve studies (62%) reported the number of indeterminate Xpert
results. Eight of these studies reported zero indeterminate results
(Al-Ateah 2012; Bholla 2016; Blaich 2014; Hanif 2011; Ioannidis
2011; Ligthelm 2011; Scott 2014; Sharma 2014). For lymph node
aspirate, in the 1134 tests performed, the pooled percentage of
indeterminate Xpert results was 1.0% (95% CrI 0.4 to 2.0).
5. Latent class meta-analysis
Based on the latent class meta-analysis model using non-
informative priors, Xpert pooled sensitivity and specificity (95%
Crl) were 92.2% (82.9 to 98.1) and 89.2% (78.9 to 98.2). Unlike in
the meta-analyses of Xpert in CSF and pleural fluid, adjustment for
the imperfect and heterogeneous nature of culture across studies
did not bring down the heterogeneity in Xpert specificity. The
pooled sensitivity of culture at 88.5% (75.2 to 98.1) was estimated
to be lower than 100%, although it remained greater than that of
Xpert. The pooled specificity of culture was estimated to be 91.6%
(84.6 to 97.1) (Table 6). As explained in the Discussion section,
we believe this unusually low estimate of culture specificity was
possibly the result of a systematic bias. However, when informative
prior distributions were used over Xpert and culture specificity, the
pooled sensitivity of both Xpert and culture was close to 80% (Table
6; Appendix 8).
C.1. Xpert testing in lymph node tissue for lymph node TB
1. Primary analysis
Ten studies evaluated lymph node tissue with respect to a culture
reference standard (Blaich 2014; Causse 2011; Ghariani 2015; Kim
2015a; Ozkutuk 2014; Pandey 2017; Penata 2016; Sharma 2014;
Suzana 2016; Zeka 2011). The median sample size (IQR) was 43
(15 to 82) specimens. In individual studies, Xpert sensitivity ranged
from 50% to 100% and specificity ranged from 0% to 100%. Pooled
sensitivity and specificity (95% Crl) against culture were 84.4%
(74.7 to 91.0) and 78.9% (52.6 to 91.5), respectively (10 studies, 484
specimens) (Table 3).
D. Xpert testing in urine for genitourinary TB
1. Primary analysis, Xpert
Nineteen studies evaluated urine (Blaich 2014; Causse 2011; Gursoy
2016; Hanif 2011; Hillemann 2011; Ioannidis 2011; Jing 2017; Kim
2015a; Li 2017; Malbruny 2011; Mazzola 2016; Nataraj 2016; Ozkutuk
2014; Safianowska 2012; Sharma 2014; Suzana 2016; Tortoli 2012;
Zeka 2011; Zmak 2013). The median sample size (IQR) was 30 (five to
91) specimens. In individual studies, Xpert sensitivity ranged from
33% to 100% and specificity ranged from 33% to 100% (Figure 8).
Pooled sensitivity and specificity (95% Crl) were 82.7% (69.6 to 91.1)
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and 98.7% (94.8 to 99.7), respectively (13 studies, 1199 specimens)
(Table 3; Appendix 9).
 
Figure 8.   Forest plots of Xpert® MTB/RIF sensitivity and specificity in urine with respect to a culture reference
standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval.
FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
2. Investigations of heterogeneity
a. Specimen concentration
Five of the total 19 studies (26%) concentrated urine specimens. In
one study, sensitivity and specificity (95% CI) were 88% (62 to 98)
and 99% (95 to 100) (Tortoli 2012). Of the remaining four studies,
three studies had zero TB culture-positives (Malbruny 2011; Nataraj
2016; Safianowska 2012), and one study had only one TB culture-
positive (Zeka 2011).
b. TB prevalence
See Table 4. The median prevalence of genitourinary TB (as
measured by culture positivity) in these studies was 7%. We found
higher sensitivity in settings with higher TB prevalence than in
those with lower TB prevalence, with pooled sensitivity of 87.9%
(95% CrI 75.1 to 95.1) versus 69.6% (95% CrI 45.3 to 87.1). We found
lower specificity in settings with higher TB prevalence than in those
with lower TB prevalence at 98.1% (95% CrI 93.5 to 99.6) versus
99.3% (95% CrI 96.3 to 99.8). In the case of sensitivity (probability
= 0.963) and specificity (probability = 0.137), accuracy in the two
groups was not significantly diNerent.
E. Xpert testing for bone or joint TB
1. Primary analysis, Xpert in bone or joint fluid
Twelve studies evaluated bone or joint fluid (Al-Ateah 2012; Blaich
2014; Gu 2015; Ioannidis 2011; Kim 2015a; Li 2017; Malbruny
2011; Nataraj 2016; Ozkutuk 2014; Penata 2016; Safianowska 2012;
Suzana 2016). The median sample size (IQR) was five (two to 14)
specimens. The median prevalence of TB in these studies was 50%.
In individual studies, Xpert sensitivity ranged from 96% to 100%
and specificity ranged from 53% to 100% (Appendix 10). Pooled
sensitivity and specificity (95% Crl) were 97.2% (89.5 to 99.6) and
90.2% (55.6 to 98.5), respectively (five studies, 385 specimens)
(Table 3).
2. Primary analysis, Xpert in bone or joint tissue
Seven studies evaluated bone or joint tissue (Arockiaraj 2017; Held
2014; Held 2016; Malbruny 2011; Massi 2017; Ozkutuk 2014; Penata
2016). The median sample size (IQR) was 70 (13 to 90) specimens.
The median prevalence of TB in these studies was 20%. In individual
studies, Xpert sensitivity ranged from 50% to 100% and specificity
ranged from 17% to 100% (Appendix 10). Pooled sensitivity and
specificity (95% Crl) were 94.6% (84.6 to 98.5) and 85.3% (58.7 to
96.4), respectively (six studies, 280 specimens) (Table 3).
F. Xpert testing for peritoneal TB
1. Primary analysis, Xpert in peritoneal fluid
Twenty studies evaluated peritoneal fluid (Al-Ateah 2012; Causse
2011; Iram 2015; Jing 2017; Kim 2015a; Li 2017; Malbruny
2011; Mazzola 2016; Ozkutuk 2014; Penata 2016; Rufai 2017a;
Safianowska 2012; Scott 2014; Sharma 2014; Suzana 2016; Tortoli
2012; Ullah 2017; Vadwai 2011; Zeka 2011; Zmak 2013). The median
sample size (IQR) was 18 (nine to 59) specimens. The median
prevalence of TB in these studies was 16%. In individual studies,
Xpert sensitivity ranged from 33% to 100% and specificity ranged
from 90% to 100% (Appendix 11). Pooled sensitivity and specificity
(95% CrI) were 59.2% (45.2 to 73.5) and 97.9% (96.2 to 99.1),
respectively (16 studies, 712 specimens) (Table 3).
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2. Primary analysis, Xpert in peritoneal tissue
One study evaluated peritoneal tissue (Bera 2015). Xpert sensitivity
and specificity (95% CI) were 50% (7 to 93) and 92% (73 to 99)
(Appendix 11).
G. Xpert testing in fluid for pericardial TB
1. Primary analysis, Xpert
Eighteen studies evaluated pericardial fluid (Al-Ateah 2012;
Blaich 2014; Causse 2011; Ioannidis 2011; Kim 2015a; Mazzola
2016; Ozkutuk 2014; Pandie 2014; Penata 2016; Saeed 2017a;
Safianowska 2012; Sharma 2014; Suzana 2016; Tortoli 2012; Ullah
2017; Vadwai 2011; Zeka 2011; Zmak 2013). The median sample size
(IQR) was 13 (three to 19) specimens. The median prevalence of
TB in these studies was 20%. In individual studies, Xpert sensitivity
ranged from 25% to 100% and specificity ranged from 69% to 100%
(Appendix 12). Pooled sensitivity and specificity (95% Crl) were
65.7% (46.3 to 81.4) and 96.0% (85.8 to 99.3), respectively (seven
studies, 324 specimens) (Table 3).
H. Xpert testing in blood for disseminated TB
1. Primary analysis, Xpert
Three studies evaluated blood (Feasey 2013; Pohl 2016; Zmak
2013); however only two of these studies reported TB culture-
positives. In Feasey 2013, Xpert sensitivity and specificity (95%CI)
were 56% (21 to 86) and 94% (85 to 98). In Pohl 2016, Xpert
sensitivity and specificity were 7% (0 to 34) and 98% (94 to 99)
(Appendix 13).
II. Detection of rifampicin resistance
A. Primary analysis
Thirty-nine studies contributed data for rifampicin resistance. In
individual studies, sensitivity estimates varied from 50% to 100%;
specificity varied less than sensitivity (93% to 100%), (Figure
9). Three studies accounted for most of the rifampicin-resistant
specimens (65%; 96/148) (Nataraj 2016; Sharma 2014; Vadwai
2011). By univariate analysis, pooled sensitivity and specificity
(95% Crl) were 95.0% (89.7 to 97.9) and 98.7% (97.8 to 99.4) (Table
3). We also performed a sensitivity analysis using the bivariate
random-eNects model for the subset of studies that provided
data for both sensitivity and specificity and found nearly identical
results; the pooled sensitivity and specificity were 95.0% (89.9 to
97.9) and 98.8% (97.7 to 99.6), respectively (20 studies) (Al-Ateah
2012; Bera 2015; Biadglegne 2014; Coetzee 2014; Dhasmana 2014;
Du 2015; Friedrich 2011; Gu 2015; Hanif 2011; Held 2014; Li 2017;
Ligthelm 2011; Meldau 2014; Nataraj 2016; Nhu 2014; Penata 2016;
Rufai 2015; Rufai 2017b; Sharma 2014; Vadwai 2011).
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Figure 9.   Forest plot of Xpert® MTB/RIF sensitivity and specificity for rifampicin resistance. The squares represent
the sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-
positive; TN: true-negative; TP: true-positive.
 
B. Investigations of heterogeneity
1. TB prevalence
See Table 4. The median prevalence of rifampicin resistance in
these studies was 12%. We found higher sensitivity in settings with
higher prevalence of rifampicin resistance than in those with lower
prevalence, with pooled sensitivity of 96.2% (95% CrI 91.1 to 98.7)
versus 92.0% (95% CrI 80.0 to 97.4). We found similar specificity in
settings with higher and lower prevalence at 98.7% (95% CrI 96.8 to
99.6) versus 99.1% (95% CrI 97.7 to 99.7). In the case of sensitivity
(probability = 0.878) and specificity (probability = 0.310), accuracy
in the two groups was not significantly diNerent.
C. Indeterminate Xpert results for rifampicin resistance
Eighteen studies reported the number of indeterminate Xpert
results, of which six studies reported zero indeterminate results
- Al-Ateah 2012 (0/17); Blaich 2014 (0/15); Held 2016 (0/17); Li
2017 (0/76); Ligthelm 2011(0/31); Teo 2011 (0/13). For rifampicin
resistance testing, of the 1003 tests performed, the pooled
percentage of indeterminate Xpert results was 2.6% (95% CrI 1.4 to
4.3).
D. Special topics: culture-negative specimens found to be Xpert-
positive for rifampicin resistance
Culture-negative Xpert rifampicin-resistance results were
infrequently reported. Three studies each reported one culture-
negative, Xpert rifampicin-resistant result (Biadglegne 2014; Held
2014; Nhu 2014), and one study reported six cases (Scott 2014).
Other analyses
Non-tuberculous mycobacteria
Ten studies involving 6975 specimens provided data on a variety
of NTM that grew from the specimens tested to look for evidence
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of cross-reactivity: five NTM in Ablanedo-Terrazas 2014; 17 NTM in
Hillemann 2011; nine NTM in Li 2017; one NTM in Malbruny 2011; 49
NTM in Mazzola 2016; three NTM in Pandey 2017; one NTM in Pink
2016; eight NTM in Sharma 2014; one NTM in Tadesse 2015; and 47
NTM inn Tortoli 2012. Among these 10 studies comprising 141 NTM,
Xpert was negative in all specimens.
D I S C U S S I O N
Summary of main results
This systematic review summarizes the current literature and
includes 66 unique studies on the accuracy of Xpert for
extrapulmonary tuberculosis (TB) and rifampicin resistance.
Seventy-six per cent of these studies were conducted in low- and
middle-income countries. Major findings from our review include
the following.
• Xpert sensitivity for TB in extrapulmonary specimens varied
across diNerent types of specimens (from 31% in pleural tissue
to 97% in bone or joint fluid) (Table 3).• Xpert specificity varied less than sensitivity and in cerebrospinal
fluid, pleural fluid, urine, and peritoneal fluid was ≥ 98%, with
all results measured against culture as the reference standard
(Table 3).• In cerebrospinal fluid, Xpert sensitivity and specificity were 71%
and 98% against culture (Summary of findings 1).• In pleural fluid, Xpert sensitivity and specificity were 51% and
99% against culture (Summary of findings 2).• In urine, Xpert sensitivity and specificity were 83% and 99%
against culture (Summary of findings 3).• For rifampicin resistance, Xpert sensitivity and specificity were
95% and 99% (Summary of findings 4).• The percentage of indeterminate Xpert results was 2% for TB
detection.• The percentage of indeterminate Xpert results was 3% for
rifampicin resistance detection.
For most forms of extrapulmonary TB investigated, pooled
sensitivity was higher in settings with higher TB prevalence and
specificity was similar or lower in settings with lower TB prevalence
(Table 4).
Xpert testing in cerebrospinal fluid
(Summary of findings 1)
Results of these studies indicate that in theory, for a population of
1000 people where 100 have TB meningitis on culture, 89 would
be Xpert-positive: of these, 18 (20%) would not have TB (false-
positives); and 911 would be Xpert-negative: of these, 29 (3%)
would have TB (false-negatives).
Rapid diagnosis of TB meningitis is critical so that lifesaving
treatment can be started promptly. Around 50% of those aNected
die or experience disabling consequences (Thwaites 2013). In
this review, we found Xpert to have a pooled sensitivity of 71%
and a pooled specificity of 98% for TB meningitis. In a meta-
regression analysis, we found improved Xpert accuracy in studies
that concentrated the cerebrospinal fluid (CSF): pooled sensitivity
concentrated 75% versus unconcentrated 66%, and identical
pooled specificity of 98% in both concentrated and unconcentrated
specimens. The Tuberculous Meningitis International Research
Consortium has recommended increasing the volume of CSF
collected for diagnosis followed by centrifugation as a way of
improving Xpert sensitivity (Bahr 2016); however, we did not have
suNicient data to investigate CSF collection volume. Increased
Xpert sensitivity in HIV-positive people compared with HIV-negative
people has been reported, with the increased bacterial burden
in TB and HIV co-infection proposed as the reason (Patel 2013).
We had limited data to investigate this as we identified only
three studies in HIV-positive people, with Xpert sensitivities of
58% (Bahr 2015), 60% (Bahr 2017), and 81% (Patel 2013). In
a sensitivity analysis in which we limited the studies to those
using one specimen per participant, accuracy estimates decreased
(sensitivity 64% and specificity 96%).
Xpert Ultra testing in CSF
Ultra was designed to improve TB detection, in particular in people
with paucibacillary disease. The limit of detection is lower with
Ultra (16 bacterial colony-forming units (cfu) per mL) than with
Xpert (131 cfu per mL) (Chakravorty 2017). We identified one study
that evaluated Ultra for TB meningitis in HIV-positive patients.
This study found considerably higher sensitivity with Ultra (90%)
compared with Xpert (60%) based on a culture reference standard
(Bahr 2017). Notwithstanding Ultra's high sensitivity, given the
disastrous consequences of missing a diagnosis of TB meningitis,
providers should use clinical judgement and should not rely solely
on an Ultra result when deciding to withhold treatment.
Bahr 2017 found the specificity of Ultra (90%) for TB meningitis
to be considerably lower than that of Xpert (97%). We considered
several reasons in trying to explain this finding. One reason that
has been proposed is the lingering presence of dead TB bacteria
(or bacterial components) from previous TB (WHO 2017c). In a
study of pulmonary TB, Ultra had lower specificity than Xpert,
and of interest, the diNerence was more pronounced in previously
treated patients (Chakravorty 2017). However, Bahr and colleagues
considered that this reason may not apply to Ultra for TB meningitis
because it is unlikely that TB bacilli in CSF are derived from prior
TB (either TB bacteria are no longer present or the patient has
died). A second reason for the lower specificity with Ultra is linked
to ‘trace-calls' (Chakravorty 2017). For extrapulmonary specimens,
the World Health Organization (WHO) recommends that ‘trace calls'
should be considered to be true-positive results for use in clinical
decisions and patient follow-up" (WHO 2017c).
Xpert testing in pleural fluid
(Summary of findings 2)
Results of these studies indicate that in theory, for a population
of 1000 people where 150 have pleural TB on culture, 83 would
be Xpert-positive: of these, seven (8%) would not have TB (false-
positives); and 917 would be Xpert-negative: of these, 74 (8%)
would have TB (false-negatives).
We found Xpert to have low sensitivity (51%) in pleural fluid when
measured against a culture reference standard and even lower
sensitivity (18%) when measured against a composite reference
standard. By design, we expected to find higher pooled sensitivity
with the culture reference standard than with the composite
reference standard. One reason for the low sensitivity of Xpert
could be the paucibacillary nature of pleural TB. Other possible
reasons are contamination of blood or the presence of certain
polymerase chain reaction (PCR) inhibitors in the pleural fluid (Pai
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2004; Woods 2001). However, in a study by Theron and colleagues,
extrapulmonary specimens showed less evidence of PCR inhibition
than pulmonary specimens, with the bacterial load more important
for a positive Xpert result (Theron 2014).
Xpert specificity in pleural fluid was 99%. However, given that false-
negative results were common (low sensitivity), a negative Xpert
result may not be relied on to exclude TB. The WHO recommends
that pleural biopsy tissue is the preferred specimen type for
diagnosing pleural TB using Xpert (WHO 2013). However, we had
insuNicient data to determine summary accuracy of Xpert in pleural
tissue (three studies, 207 specimens).
Xpert testing in lymph node aspirates
In 76% of the included studies (13 of 17 studies contributing both
sensitivity and specificity data), Xpert achieved a sensitivity of
80% or higher, suggesting that Xpert could improve the diagnosis
of lymph node TB. It is important to point out that although
tissue biopsy provides material for histological examination, which
may be of substantial diagnostic value, a fluid specimen may be
collected more easily. In addition, fine-needle aspiration of lymph
nodes is well suited for use in resource-limited settings because
the procedure is simple, easy to learn, minimally invasive, and
inexpensive (Wright 2009b). Thus clinicians may want to consider
fine-needle aspiration of lymph nodes before surgical biopsy.
In our review, using a standard bivariate meta-analysis model,
Xpert specificity (defined by culture) in lymph node aspirate
was 86%, whereas with a latent class meta-analysis model with
informative priors, Xpert specificity increased to 99%. In previous
meta-analyses, Xpert specificity for lymph node TB (aspirate and
tissue) against culture as a reference standard was 94% (Denkinger
2014), 93% (Maynard-Smith 2014), and 92% (Penz 2015). See Table
2. Using a composite reference standard (defined by the primary
study authors), Denkinger and colleagues found increased Xpert
specificity of 99% for lymph node TB (five studies, 728 specimens)
(Denkinger 2014). Thus, it appears that accuracy results depend
in part on the choice of reference standard. In our review, we
used culture as the reference standard and adjusted accuracy
estimates with a latent class meta-analysis model rather than using
a composite reference standard owing to diNering definitions of
the composite reference standards, diNiculty in interpreting them,
and concern for bias (Schiller 2016) (see section Strengths and
weaknesses of the review).
We considered several reasons why Xpert specificity would be lower
for lymph node TB than for other forms of extrapulmonary TB.
Lymph node aspirates may be of lesser quality when collected
from children (Coetzee 2014), and we included participants of
all ages in the review. In a post hoc sensitivity analysis limiting
inclusion to studies that involved only adults, specificity increased
from 86% to 91% (Table 5). Although not always reported, studies
may have included patients receiving TB treatment. In a sensitivity
analysis limiting inclusion to studies that involved participants not
receiving TB treatment, specificity increased from 86% to 89%
(Table 5). Theron and colleagues found Xpert-positive, culture-
negative results to be more common in people with a history of
TB (Theron 2016); however, we had insuNicient data to evaluate
this factor. We considered the type of culture used in the included
studies because liquid culture is more sensitive than solid culture
(American Thoracic Society 2000). Most studies did use liquid
culture or a combination of solid and liquid culture; only two of the
17 studies (12%) exclusively used solid culture. Culture results may
also be negative owing to ineNicient specimen collection or errors
in sampling, diNering bacterial load, and contamination (Wright
2009b). Negative culture results in lymph node TB have previously
been reported (Fontanilla 2011).
Another reason for negative culture results is that there may have
been a decrease in live TB bacteria during processing with N-
acetyl-L-cysteine-sodium hydroxide, which is routinely used to
homogenize, decontaminate, and liquefy non-sterile specimens,
such as sputum, for TB culture (American Thoracic Society 2000).
Harsh decontamination practices have been noted to contribute
to false-negative culture results, especially in paucibacillary
specimens (FIND 2017). Standards specify, "specimens collected
from normally sterile sites may be placed directly into the culture
medium” (American Thoracic Society 2000). CSF, pleural fluid,
and lymph node aspirates are usually considered to be sterile
specimens. It is our understanding that some laboratories do
decontaminate sterile site specimens as a precaution against non-
sterile collection procedures. In this review, 47% of the studies
reported decontaminating lymph node aspirates before culture
inoculation. We did not have suNicient data to further investigate
laboratory practices.
In sum, several factors probably contributed to low Xpert specificity
in lymph node aspirate. The "true" specificity of Xpert in lymph
node aspirate is likely to be higher, similar to that found in
CSF, pleural fluid, and other specimens (Table 3). For all of the
aforementioned reasons, we recommend caution in interpreting
the results of Xpert accuracy for lymph node TB.
Xpert testing in urine
(Summary of findings 3)
Results of these studies indicate that in theory, for a population
of 1000 people where 70 have genitourinary TB on culture, 70
would be Xpert-positive: of these, 12 (17%) would not have TB
(false-positives); and 930 would be Xpert-negative: of these, 12 (1%)
would have TB (false-negatives).
Xpert was sensitive and specific for genitourinary TB. Urine is an
attractive specimen for TB diagnosis because of its availability,
accessibility (it is easily collected from adults and children), few
processing requirements, and low risk of infection risk to healthcare
workers during specimen collection (Peter 2010). It has been
proposed that concentrated urine increases the sensitivity of Xpert
(Peter 2012). However, we had insuNicient data to investigate this
proposition.
Xpert specificity in patients with a prior history of TB or TB
treatment
For detection of extrapulmonary TB, we intended to determine
Xpert specificity in patients with a prior history of TB. However, this
information was infrequently reported: lymph node, five studies
(24%); pleural fluid, four studies (13%); and CSF, seven studies
(21%).
Xpert testing for rifampicin resistance
(Summary of findings 4)
For detection of rifampicin resistance, we found a sensitivity of 95%
and a specificity of 99%, similar to the estimates in the review for
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pulmonary TB: sensitivity (95%) and specificity (98%) (Steingart
2014). These findings suggest that use of Xpert could assist in
rapid diagnosis of rifampicin-resistant TB and early initiation of
treatment for multidrug-resistant TB (MDR-TB).
Results of these studies indicate that in theory, for a population
of 1000 people where 120 have rifampicin-resistant TB, 125 would
be positive for rifampicin-resistant TB: of these, 11 (9%) would
not have rifampicin resistance (false-positives); and 875 would be
negative for rifampicin-resistant TB: of these, six (1%) would have
rifampicin resistance (false-negatives).
Culture-negative specimens found to be Xpert-positive for
rifampicin resistance have been described in the literature for
pulmonary TB (Boyles 2014; Kelly 2014). In the included studies, we
looked for information on this topic but found only a few cases.
Of note, concerns have been raised about rapid drug susceptibility
testing (DST) methods, in particular automated mycobacteria
growth indicator tube (MGIT) 960 for TB drug resistance using the
recommended critical concentrations. As a priority, the WHO is
planning to re-evaluate the critical concentrations for rifampicin
(WHO 2018).
Strengths and weaknesses of the review
Completeness of evidence
This is a reasonably complete data set. We included any non-
English studies that we found from which we could obtain accuracy
data. However, we acknowledge that we may have missed some
studies despite the comprehensive search and our outreach to
investigators. We included eight common forms of extrapulmonary
TB in the review. However, for some of these forms, such as
disseminated TB, data were insuNicient to allow us to determine
summary accuracy estimates. We did not include less common
forms, such as cutaneous TB, ocular TB, female genital TB, and TB
of the breast.
Accuracy of the reference standards used
In a systematic review of diagnostic test accuracy studies, the
reference standard is the best available test to determine the
presence or absence of the target condition. In this review, we used
culture as the reference standard for all forms of extrapulmonary
TB. Although culture is the best available reference standard, it is
not a perfect reference standard for extrapulmonary TB owing to
the paucibacillary nature of the disease. Therefore, we applied a
latent class model to correct the biases in Xpert sensitivity and
specificity resulting from treating culture as a perfect reference
standard. We added parameters for the sensitivity and specificity
of culture and terms for conditional dependence to adjust for the
dependence between Xpert and culture among disease-positive
and disease-negative patients. In this way, we were able to improve
estimation of both the pooled sensitivity and specificity of Xpert, as
well as between-study variability.
In terms of accuracy of the reference standard for lymph node
aspirate in particular, several factors may have contributed to false-
negative culture results, including ineNicient specimen collection
and overly harsh decontamination. For this particular analysis, we
were able to take advantage of the Bayesian estimation approach to
incorporate prior information on Xpert and culture specificity. This
allowed us to make the best use of data from the included studies
and our knowledge of the performance of Xpert.
Establishing a diagnosis of extrapulmonary TB would ideally
include pursuing the diagnosis of pulmonary TB as well because
patients with TB may have both pulmonary and extrapulmonary
TB and the lung may be the only site where the presence of
TB may be established. For example, for lymph node TB in
children, specimens would include lymph node aspirate or tissue,
sputum, gastric washings, and possibly stool. It is necessary to
pursue every avenue of diagnosis because of the paucibacillary
nature of extrapulmonary TB and the varying sensitivity of culture
among diNerent specimen types. As another example, because
of the diNiculties involved in diagnosing HIV-associated TB, it is
recommended that multiple cultures from sputum and other types
of specimens be evaluated in HIV-positive people (Shah 2016b).
Given these limitations in the reference standard, we recommend
that future studies consider utilizing liquid culture because liquid
culture is more sensitive than solid culture and that researchers
obtain multiple specimens for culture to confirm the diagnosis of
extrapulmonary TB.
In terms of detection of rifampicin resistance, most studies included
in this review used culture-based DST (either Löwenstein-Jensen
(LJ) or mycobacteria growth indicator tube (MGIT) 960) as the
reference standard. Of note, concerns have been raised about
rapid DST methods, in particular automated MGIT 960, for TB
drug resistance using the recommended critical concentrations.
As a priority, the WHO is planning to re-evaluate the critical
concentrations for rifampicin (WHO 2018).
Quality and quality of reporting of the included studies
Risk of bias was low for the patient selection, index test, and flow
and timing domains and was high or unclear for the reference
standard domain (most of these studies performed specimen
decontamination before culture inoculation). A limitation was
that several studies included more than one specimen per
participant, which artificially inflated the sample size of the study
and may have led to overestimation or underestimation of the
accuracy estimates. In general, studies were fairly well reported,
although we corresponded with almost all primary study authors
to ask for additional data and missing information. In several
studies, accuracy data by site of extrapulmonary disease were
not reported, and in a minority of studies, blinding was not
reported. We strongly encourage the authors of future studies to
follow the recommendations provided in the updated Standards
for Reporting Diagnostic Accuracy (STARD) statement to improve
the quality of reporting (Bossuyt 2015).
Interpretability of subgroup analyses
We investigated potential sources of heterogeneity in the diNerent
extrapulmonary specimens. Generally, we found increased
sensitivity in settings with higher TB prevalence (culture-confirmed
TB cases in the study) and similar or slightly lower specificity.
In pleural fluid, with use of a composite reference standard, as
expected, Xpert sensitivity was lower in comparison with culture
(composite 18% vs culture 51%). Specificity was similar (composite
98% versus culture 99%).
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Comparison with other systematic reviews
We are aware of six systematic reviews previously published on this
topic that estimated summary accuracy with respect to a culture
reference standard, as we did in our review (Table 2). Chang 2012
(seven studies) and Li Y 2017 (26 studies) determined the diagnostic
accuracy of Xpert for multiple forms of extrapulmonary TB
combined, and Denkinger 2014 (18 studies), Maynard-Smith 2014
(27 studies), Penz 2015 (37 studies), and Sehgal 2016 (24 studies)
determined Xpert accuracy for specific forms of extrapulmonary
TB. In these reviews, sensitivities ranged from 69% to 85% for CSF
(our review: 71%). In pleural fluid, sensitivities ranged from 34% to
51% (our review: 51%). Specificities ranged from 97% to 100% (our
review: CSF 98%, pleural fluid 99%).
Wen 2017 (12 studies) determined Xpert accuracy for bone or joint
TB measured against culture, histology, or a composite reference
standard and found pooled sensitivity and specificity of 81% and
83%, respectively (our review, against a culture reference standard:
sensitivity 97%, specificity 92%).
Compared with previous systematic reviews, our review extended
the date of the search for potential studies for inclusion. Our
strict inclusion criteria - for example, including only studies that
used culture as the reference standard and excluding case-control
studies - meant that some of the studies included in other reviews
were excluded from our review.
Applicability of findings to the review question
For the patient selection domain, most studies had high or
unclear risk because either patients were evaluated exclusively as
inpatients in tertiary care or we were not sure about the clinical
settings. Therefore, we cannot be sure of the applicability of
our findings to primary care. Studies that take place in referral
settings may include patients whose condition is more diNicult
to diagnose than are seen at lower levels of the health system.
However, we recognize that classifying studies with respect to
primary, secondary, or tertiary care may not adequately account
for diNerences in disease spectrum (Leeflang 2013). For the index
and reference test domains, most studies had low concern for
applicability.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In people presumed to have extrapulmonary TB, Xpert may be
helpful in confirming the diagnosis. Xpert sensitivity varies across
diNerent extrapulmonary specimens, while for most specimens,
specificity is high, the test rarely yielding a positive result for people
without TB (defined by culture). Xpert is accurate for detection of
rifampicin resistance. For people thought to have TB meningitis,
treatment should be based on clinical judgement, and not withheld
solely on an Xpert result, as is common practice when culture
results are negative.
Implications for research
Future studies should perform comparisons of diNerent tests,
including Xpert Ultra, as this approach will reveal which tests (or
strategies) yield superior diagnostic accuracy. For these studies, the
preferred study design is one in which all participants receive all
available diagnostic tests or are randomly assigned to receive one
or another of the tests. Studies should include children and HIV-
positive people. Future research should acknowledge the concern
associated with culture as a reference standard in paucibacillary
specimens and should consider ways to address this limitation.
Rapid point-of-care diagnostic tests for extrapulmonary TB are
critically needed. Research groups should focus on developing
diagnostic tests and strategies that use readily available clinical
specimens such as urine, rather than specimens that require
invasive procedures for collection.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: HIV-positive patients with palpable cer-
vical lymph nodes
Age: median 29 years [interquartile range (IQR) 24 to 36]
Sex, female: 12%
Children: no
HIV infection: 100%
Clinical setting: tertiary care centre (inpatient and outpatient)
Ablanedo-Terrazas 2014 
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Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 15
Laboratory level: central
Country: Mexico
World Bank Income Classification: middle income
TB incidence rate: 22 per 100,000
Per cent MDR-TB among new TB cases: 2.6%; among retreatment cases:
11% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO standard operating procedure (SOP) or manufacturer's protocol
followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node (LN) TB
Reference standard for TB detection: Löwenstein–Jensen (LJ) and My-
cobacterium growth indicator tube (MGIT)
Reference standard for rifampicin resistance: not reported
Speciation: yes
Decontamination: yes, N-acetyl-L-cysteine-sodium hydroxide (NALC-
NaOH)
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Ablanedo-Terrazas 2014  (Continued)
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Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Unclear    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Ablanedo-Terrazas 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients suspected of having extrapul-
monary TB
Age: median 35 years
Sex, female: 45%
Children: 3%
HIV infection: 0%
Clinical setting: tertiary care centre (laboratory-based evaluation)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 67
Laboratory level: central
Al-Ateah 2012 
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Country: Saudi Arabia
World Bank Income Classification: high income
TB incidence rate: 10 per 100,000
Per cent MDR-TB among new TB cases: 2.6%; among retreatment cases:
20% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB
Reference standards for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-drug susceptibility
testing (DST)
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Site of extrapulmonary disease was not reported for 16 tissue speci-
mens and 10 abscesses
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Al-Ateah 2012  (Continued)
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Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Al-Ateah 2012  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: people with back pain for longer than 3
months and radiological features suggestive of spondylodiscitis (refers to
infection of the intervertebral disc and neighbouring vertebral bodies)
Age: mean 42 years, range 5 to 82 years
Sex, female: 40%
Children: not reported
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 338
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB report, 2017)
Arockiaraj 2017 
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Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: bone and joint TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: not reported
Speciation: not reported
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Unclear    
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    Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Arockiaraj 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients presenting with
symptoms of meningitis being evaluated for cryptococcal meningitis. All
persons who were CSF cryptococcal antigen-negative had a TB workup
Age: median 40 years (IQR 30 to 45)
Sex, female: 34%
Children: no
HIV infection: 98%
Clinical setting: tertiary care centre (Inpatient)
Past history of TB: 22%
Participants on anti-TB treatment: yes, 11%
Number of specimens evaluated: 80
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
TB incidence rate: 201 per 100,000
Per cent MDR-TB among new TB cases: 1.6%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard for TB detection: LJ and MGIT
Bahr 2015 
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Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes Reference standards were culture and a TB meningitis uniform case defi-
nition
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Bahr 2015  (Continued)
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Were all patients included in the analysis? Yes    
    Low  
Bahr 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients presenting with
symptoms of meningitis being evaluated for cryptococcal meningitis. All
persons who were CSF cryptococcal antigen-negative had a TB workup
Age: TB meningitis: median 32 years (IQR 30 to 34); other meningitis: 34
years (IQR 29 to 43)
Sex, female: 45%
Children: no
HIV infection: 100%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: 6%
Participants on anti-TB treatment: yes, 2%
Number of specimens evaluated: 129
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
TB incidence rate: 201 per 100,000
Per cent MDR-TB among new TB cases: 1.6%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF and Xpert® MTB/RIF Ultra
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Bahr 2017 
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Comparative  
Notes This study evaluated Xpert® MTB/RIF and Xpert® MTB/RIF Ultra
Reference standards were culture and a TB meningitis uniform case defini-
tion
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Bahr 2017  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with exudative ascites (lympho-
cytic ascites and ascitic fluid protein content > 2.5 g/dL)
Age: mean 43 years (standard deviation (SD) 15 years)
Sex, female: 29%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre (outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 28
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: not reported
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: peritoneal TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: LJ and MGIT-DST
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes "The study included only smear-negative specimens, however, the study
excluded specimens that were negative for malignant cells on prior testing
(i.e. cytology)"
Methodological quality
Bera 2015 
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Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Bera 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, manner of participant selection by conve-
nience
Bholla 2016 
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Patient characteristics and setting Presenting signs and symptoms: 1 or more palpable lymph nodes of 1 cm or
larger persisting for longer than 4 weeks in spite of oral antibiotic therapy
and a strong clinical suspicion or microbiological confirmation of mycobac-
terial infection
Age: 6 weeks to 16 years
Sex, female: 39%
Children: 100%
HIV infection: 20%
Clinical setting: local hospital (outpatient)
Past history of TB: 3%
Patients on anti-TB treatment: yes, 11%
Number of specimens evaluated: 36
Laboratory level: central
Country: Tanzania
World Bank Income Classification: low income
TB incidence rate: 287 per 100,000
Per cent MDR-TB among new TB cases: 1.3%; among retreatment cases:
6.2% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes Exclusions: children who had received TB treatment in the preceding 12
months
Culture contamination rate was high
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Bholla 2016  (Continued)
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Was a consecutive or random sample of patients en-
rolled?
No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Bholla 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with enlarged lymph nodes not
responding to a 2-week course of antibiotics and clinically suspected for TB
lymphadenitis
Age: ≤ 14 years: 15%; > 14 years: 85%
Sex, female: 57%
Biadglegne 2014 
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Children: 15%
HIV infection: not reported
Clinical setting: tertiary care centres (multi-centre study)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 213
Laboratory level: intermediate
Country: Ethiopia
World Bank Income Classification: low income
TB incidence rate: 177 per 100,000
Per cent MDR-TB among new TB cases: 2.7%; among retreatment cases:
14% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: LJ and Gottsascker and BacT/ALERT
3D
Reference standard for rifampicin resistance: MTBDRplus and BacT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Total number of patients: 231; included: 213 (excluded: contaminated = 11;
invalid/error = 7)
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
Biadglegne 2014  (Continued)
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DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Unclear    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Biadglegne 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion of extrapulmonary
TB
Age: median 34 (IQR 30 to 52)
Sex, female: 46%
Children: no
HIV infection: yes, 8%
Clinical setting: university hospital (inpatient and outpatient)
Past history of TB: yes, 11%
Patients on anti-TB treatment: no
Blaich 2014 
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Number of specimens evaluated: 20
Laboratory level: central
Country: Switzerland
World Bank Income Classification: high income
TB incidence rate: 7.8 per 100,000
Per cent MDR-TB among new TB cases: 3.2%; among retreatment cases: 26%
(source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for lymph node aspirate,
bone and joint fluid, urine, peritoneal fluid, and lymph node tissue; no for
CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, lymph node TB, pericardial TB,
genitourinary TB, bone and joint TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH for all specimens except pleural fluid and
CSF
Flow and timing  
Comparative  
Notes Study included 1 bone marrow specimen that consisted of both aspirate and
tissue
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference standard?
Yes    
Blaich 2014  (Continued)
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If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Unclear    
Were the reference standard results interpreted
without knowledge of the results of the index tests?
No    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Blaich 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 45 years, range 5 to 83 years
Sex, female: 31%
Children: yes, 15%
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 261
Laboratory level: central
Country: Spain
Causse 2011 
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World Bank Income Classification: high income
TB incidence rate: 10 per 100,000
Per cent MDR-TB among new TB cases: 4.2%; among retreatment cases:
18% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, peritoneal
TB, pericardial TB, genitourinary TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: not reported
Speciation: yes
Decontamination: yes, NALC-NaOH for all specimens except pleural flu-
id and CSF
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Causse 2011  (Continued)
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Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Unclear    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Causse 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with evidence of pleur-
al effusion demonstrated by X-ray, suspected to have tuberculosis
pleurisy
Age: median 44 years, range 18 to 83 years
Sex, female: 31%
Children: no
HIV infection: 1%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 78
Laboratory level: central
Country: China
World Bank Income Classification: middle income
TB incidence rate: 64 per 100,000
Per cent MDR-TB among new TB cases: 7.1%; among retreatment
cases: 24% (source: WHO Global TB Report, 2017)
Che 2017 
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Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: not reported
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results of
the index test?
Unclear    
Che 2017  (Continued)
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    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Che 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: clinical symptoms and radiographic evi-
dence of a pleural effusion
Age: median 46 years (IQR 33 to 57)
Sex, female: 20%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre (Inpatient and outpatient)
Past history of TB: yes, 18%
Patients on anti-TB treatment: not reported
Number of specimens evaluated against culture: 142
Number of specimens evaluated against composite reference standard:
146
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for pleural tissue, no
for pleural fluid
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Christopher 2013 
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Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: not reported
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Unclear    
    Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Christopher 2013  (Continued)
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Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Christopher 2013  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: children with persistent superficial
lymphadenopathy and clinical suspicion of mycobacterial infection
Age: < 1 year 33%, 1 to 4 years 42%, 5 to 9 years 18%, ≥ 10 years 7%
Sex, female: 40%
Children: 100%
HIV infection: 8%
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 72
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases:
7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT and Middlebrook 7H9
Reference standard for rifampicin resistance: MTBDRplus
Speciation: yes
Decontamination: no
Flow and timing  
Coetzee 2014 
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Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Coetzee 2014  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: all participants undergoing endo-
bronchial ultrasound (EBUS) for mediastinal lymphadenopathy
Age: median 46 years, range 14 to 85 years
Sex, female: 37%
Children: no
HIV infection: 7%
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 116
Laboratory level: central
Country: United Kingdom
World Bank Income Classification: high income
TB incidence rate: 9.9 per 100,000
Per cent MDR-TB among new TB cases: 1.4%; among retreatment cas-
es: 3.4% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Dhasmana 2014 
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Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Dhasmana 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with enlarged mediastinal or
hilar lymph nodes (≥ 1 cm in short axis) on computed tomography of
the chest who underwent EBUS-guided transbronchial needle aspira-
tion
Age: median 40 years, range 30 to 53 years
Sex, female: 43%
Dhooria 2016 
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Children: no
HIV infection: 0%
Clinical setting: tertiary care centre (outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 147
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: not reported
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Dhooria 2016  (Continued)
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Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Unclear    
    Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Dhooria 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and manner of participant selection
not reported
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of
EPTB
Age: < 18 years 30%, ≥ 18 years 70%
Sex, female: 45%
Children: 30%
HIV infection: not reported
Clinical setting: university hospital (laboratory-based evaluation)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 43
Diallo 2016 
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
81
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Laboratory level: central
Country: Senegal
World Bank Income Classification: low income
TB incidence rate: 140 per 100,000
Per cent MDR-TB among new TB cases: 0.9%; among retreatment cas-
es: 19% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, pericardial TB, genitourinary TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Diallo 2016  (Continued)
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Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Diallo 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients found to be smear-negative on prior
testing with radiographic evidence of pleural effusion and those subsequently
undergoing thoracocentesis and pleural biopsy
Age: mean 39 years, SD 13
Sex, female: 44%
Children: 0%
HIV infection: 4%
Clinical setting: 4 tertiary care centres (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 126
Laboratory level: central
Country: China
World Bank Income Classification: middle income
TB incidence rate: 64 per 100,000
Per cent MDR-TB among new TB cases: 7.1%; among retreatment cases: 24%
(source: WHO Global TB report, 2017)
Du 2015 
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Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Study included specimens found to be smear-negative on prior testing. In the
present study, 4 specimens were smear-positive specimens for pleural fluid and
15 were smear-positive for pleural tissue
The reference standard for both pleural fluid and pleural tissue was pleural
biopsy culture
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
Unclear    
Du 2015  (Continued)
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Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
For rifampicin resistance testing, were the refer-
ence standard results interpreted without knowl-
edge of the results of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Du 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients with clinical
suspicion of TB
Age: mean 37 years, SD 11 years
Sex, female: 33%
Children: no
HIV infection: 100%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: no
Patients on anti-TB treatment: no
Number of specimens evaluated: 74
Laboratory level: central
Country: Malawi
World Bank Income Classification: low income
TB incidence rate: 159 per 100,000
Per cent MDR-TB among new TB cases: 0.75%; among retreatment
cases: 6.4% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
Feasey 2013 
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WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: disseminated TB (blood)
Reference standard for TB detection: Bactec Myco/F Lytic culture
Reference standard for rifampicin resistance: not reported
Speciation: yes
Decontamination: yes, NALC-NaOH for sputum specimens
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results of
the index test?
Unclear    
    Low Low
Feasey 2013  (Continued)
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DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Feasey 2013  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with undiagnosed pleural ef-
fusion and high clinical suspicion of pleural TB
Age: not reported
Sex, female: 36%
Children: 0%
HIV infection: 28%
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated against culture: 24
Number of specimens evaluated against composite reference standard:
25
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases:
7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: MGIT
Friedrich 2011 
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Reference standard for rifampicin resistance: not reported
Speciation: no
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Unclear    
    Unclear High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Friedrich 2011  (Continued)
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Were all patients included in the analysis? Yes    
    Low  
Friedrich 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of
TB
Age: mean 32 years, range 3 to 79 years
Sex, female: 68%
Children: 13%
HIV infection: no
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: 18%
Patients on anti-TB treatment: yes, 3%
Number of specimens evaluated: 174
Laboratory level: central
Country: Tunisia
World Bank Income Classification: middle income
TB incidence rate: 38 per 100,000
Per cent MDR-TB among new TB cases: 0.93%; among retreatment
cases: 4.2% (source: WHO global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Ghariani 2015 
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Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Ghariani 2015  (Continued)
 
 
Study characteristics
Gu 2015 
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Patient sampling Cross-sectional, prospective; manner of participant selection not re-
ported
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion of bone and
joint TB
Age: median 42 years for TB patients, range 18 to 82 years
Sex, female: 54%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: yes, 100%
Number of specimens evaluated: 60
Laboratory level: central
Country: China
World Bank Income Classification: middle income
TB incidence rate: 64 per 100,000
Per cent MDR-TB among new TB cases: 7.1%; among retreatment
cases: 24% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: bone and joint TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Gu 2015  (Continued)
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Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Unclear High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results of
the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Gu 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: not reported
Children: not reported
Gursoy 2016 
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HIV infection: not reported
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 303
Laboratory level: central
Country: Turkey
World Bank Income Classification: middle income
TB incidence rate: 18 per 100,000
Per cent MDR-TB among new TB cases: 2.9%; among retreatment
cases: 16% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis, genitourinary TB
Reference standard for TB detection: LJ and VersaTrek
Reference standard for rifampicin resistance: VersaTrek
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Gursoy 2016  (Continued)
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Were the index test results interpreted without knowledge of
the results of the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Gursoy 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion of TB due to
symptoms such as fever, cough, and/or weight loss, or because they were
not responding to initial therapy for other diseases
Age: range 20 to 57 years
Sex, female: 39%
Children: no
HIV infection: no
Clinical setting: national reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 29
Hanif 2011 
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Laboratory level: central
Country: Kuwait
World Bank Income Classification: middle income
TB incidence rate: 24 per 100,000
Per cent MDR-TB among new TB cases: 2.7%; among retreatment cases:
0% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol: yes for lymph node aspirate,
pleural fluid, and urine; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis, lymph node TB, pleural TB, genitouri-
nary TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: LJ-DST and MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
Hanif 2011  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
No    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Yes    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Hanif 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: history of chronic pain for longer than
3 months and presence of constitutional symptoms: low-grade fever,
night sweats, loss of appetite, weight loss; loss of anterior vertebral
height
Age: median 40 years, IQR 27 to 60 years
Sex, female: 55%
Children: no
HIV infection: 32%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 71
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Held 2014 
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Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases:
7.1% (source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: bone and joint TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
Held 2014  (Continued)
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For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Held 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients under 13 years of age who presented
with suspected musculoskeletal TB were included. Symptoms and signs suspi-
cious for musculoskeletal TB included joint or back pain of insidious onset as-
sociated with elevated inflammatory markers, TB contact, constitutional symp-
toms, chronic cough, and HIV. Suspicious radiological signs were a chest radi-
ograph suggestive of TB, or a radiograph of an affected joint showing erosions
and osteopenia involving both sides of the joint
Age: median 6 years, IQR 2 to 9 years
Sex, female: 41%
Children: 100%
HIV infection: 10%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: no
Patients on anti-TB treatment: no
Number of specimens evaluated: 109
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases: 7.1%
(source: WHO Global TB report, 2017)
Index tests Xpert® MTB/RIF
Held 2016 
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WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: bone and joint TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
Yes    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
For rifampicin resistance testing, were the refer-
ence standard results interpreted without knowl-
edge of the results of the index test?
Yes    
    Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Held 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with suspected M tuberculosis
or non-tuberculous mycobacterial infection on the basis of clinical cri-
teria
Age: not reported
Sex, female: not reported
Children: 5%
HIV infection: not reported
Clinical setting: national reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 200
Laboratory level: central
Country: Germany
World Bank Income Classification: high income
TB incidence rate: 8.1 per 100,000
Per cent MDR-TB among new TB cases: 2.2%; among retreatment cases:
23% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: yes, donation of index test
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, genitourinary TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Hillemann 2011 
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Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Hillemann 2011  (Continued)
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    Low  
Hillemann 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, manner of participant selection by conve-
nience
Patient characteristics and setting Presenting signs and symptoms: patients with high clinical suspicion of TB
Age: not reported
Sex, female: not reported
Children: not reported
HIV infection: not reported
Clinical setting: national reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 26
Laboratory level: central
Country: Greece
World Bank Income Classification: high income
TB incidence rate: 4.4 per 100,000
Per cent MDR-TB among new TB cases: 1.5%; among retreatment cases:
9.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: not reported
Manufacturer's involvement: yes, donation of index test
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, pericardial
TB, bone and joint TB, genitourinary TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: LJ-DST, MGIT-DST, MTBDR-
plus
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
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Notes Specimens were primarily smear-negative
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    High Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Ioannidis 2011  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinical presentation,
radiological findings, and histopathological evidence of extrapul-
monary TB
Age: mean 37 years, range 10 to 80 years
Sex, female: 41%
Children: 3%
HIV infection: 2%
Clinical setting: teaching hospital
Past history of TB: 53%
Patients on anti-TB treatment: yes, 3%
Number of specimens evaluated: 18
Laboratory level: intermediate
Country: Pakistan
World Bank Income Classification: middle income
TB incidence rate: 268 per 100,000
Per cent MDR-TB among new TB cases: 4.2%; among retreatment
cases: 16% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, peritoneal TB
Reference standard for TB detection: LJ
Reference standard for rifampicin resistance: LJ-DST
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
Iram 2015 
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results of
the index test?
Yes    
    Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Iram 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion of EPTB
Age: not reported
Sex, female: not reported
Jing 2017 
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Children: not reported
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 277
Laboratory level: central
Country: China
World Bank Income Classification: middle income
TB incidence rate: 64 per 100,000
Per cent MDR-TB among new TB cases: 7.1%; among retreatment
cases: 24% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, genitourinary TB, peri-
toneal TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Jing 2017  (Continued)
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Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Jing 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 59 years (IQR 44 to 71 years)
Sex, female: 47%
Children: 7%
HIV infection: 1%
Clinical setting: tertiary care centre
Past history of TB: 9%
Patients on anti-TB treatment: no
Number of specimens evaluated: 1209
Laboratory level: central
Kim 2015a 
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Country: Korea
World Bank Income Classification: high income
TB incidence rate: 77 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment
cases: 11% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB, TB meningitis, peri-
toneal TB, pericardial TB, bone and joint TB, genitourinary TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Kim 2015a  (Continued)
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Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Kim 2015a  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective; manner of participant selection not re-
ported
Patient characteristics and setting Presenting signs and symptoms: patients with suspected EPTB
Age: mean 48 years, SD 10 years
Sex, female: 39%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 414
Laboratory level: central
Country: China
World Bank Income Classification: middle income
TB incidence rate: 64 per 100,000
Per cent MDR-TB among new TB cases: 7.1%; among retreatment cases:
24% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
Li 2017 
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WHO SOP or manufacturer's protocol followed: yes for pleural fluid,
bone and joint TB fluid, urine, and peritoneal fluid; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal TB, bone and
joint TB, genitourinary TB
Reference standard for TB detection: LJ
Reference standard for rifampicin resistance: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
Li 2017  (Continued)
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    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Li 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion of lymph node TB
Age: < 5 years 4%; 5 to 20 years 13%; > 20 years 83%
Sex, female: 58%
Children: 4%
HIV infection: 19%
Clinical setting: university hospital (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 48
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases:
7.1% (source: WHO Global TB Report, 2017
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MTBDRplus
Ligthelm 2011 
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Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes "It is unlikely that our patient cohort had exacerbated disease compared to
patients presenting at primary health care clinics, as these patients are rou-
tinely referred from the primary health care clinic to the referral centre for
FNAB (fine needle aspiration biopsy)"
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Ligthelm 2011  (Continued)
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Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Ligthelm 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with suspected pleural TB
based on clinical signs and symptoms and radiological evidence of a
pleural effusion that was considered large enough for a pleural biopsy
Age: mean 34 years, SD 13 years
Sex, female: 43%
Children: no
HIV infection: 45%
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 116
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
TB incidence rate: 201 per 100,000
Per cent MDR-TB among new TB cases: 1.6%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: not reported
Decontamination: no
Flow and timing  
Lusiba 2014 
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Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Lusiba 2014  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, manner of participant selection by con-
venience
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of TB
Age: median 52 years
Sex, female: 40%
Children: 7%
HIV infection: not reported
Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 67
Laboratory level: central
Country: France
World Bank Income Classification: high income
TB incidence rate: 7.7 per 100,000
Per cent MDR-TB among new TB cases: 1%; among retreatment cases:
10% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, bone and joint TB, peri-
toneal TB, genitourinary TB
Reference standard for TB detection: MGIT and Coletsos slants
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
Malbruny 2011 
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    High Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Malbruny 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective; manner of participant selection not reported
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: not reported
Massi 2017 
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Children: not reported
HIV infection: not reported
Clinical setting: university hospital
Past history of TB: not reported
Patients not on anti-TB treatment: not reported
Number of specimens evaluated: 70
Laboratory level: central
Country: Indonesia
World Bank Income Classification: middle income
TB incidence rate: 391 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
16% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: bone and joint TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: not reported
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Study observed low specificity, which was probably due to inclusion of
many participants on anti-TB treatment, considered standard procedure
in this setting before surgery for spondylitis TB
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Unclear    
    Unclear Unclear
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DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Yes    
    Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Massi 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: 40%
Children: not reported
HIV infection: not reported
Clinical setting: reference laboratories
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 1201
Mazzola 2016 
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Laboratory level: central
Country: Italy
World Bank Income Classification: high income
TB incidence rate: 6.1 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment
cases: 13% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal TB, pericar-
dial TB, genitourinary TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: LJ-DST and MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
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Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Unclear    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Mazzola 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients presumed to have pleural TB
with any symptoms, including cough, fever, night sweats, loss of weight,
haemoptysis, and chest pain, along with features consistent with a pleural
effusion on chest X-ray
Age: definitive TB: median 39 years (IQR 29 to 55 years); non-TB: median 61
years (IQR 54 to 69 years)
Sex, female: 40%
Children: no
HIV infection: 15%
Clinical setting: tertiary care hospital
Past history of TB: 13%
Patients on anti-TB treatment: no
Number of specimens evaluated against culture: 76
Number of specimens evaluated against a composite reference standard: 88
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
Meldau 2014 
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TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases:
7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
Meldau 2014  (Continued)
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
121
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Meldau 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of extrapul-
monary TB
Age: < 14 years 13%; 15 to 45 years 52%; > 45 years 34%; range 2 months to 78
years
Sex, female: 44%
Children: 13%
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 494
Laboratory level: intermediate
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases: 12%
(source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Nataraj 2016 
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Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, bone and joint TB,
genitourinary TB
Reference standard TB detection: LJ
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Patients on treatment may have been included, although the number was not re-
ported: "Of the two specimens that were smear-positive and smear-negative on
both culture and Xpert, one was pleural fluid from a patient who had been receiv-
ing Category II anti-tuberculosis treatment for 2 months and the other was pus
aspirated from an axillary lymph node"
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
Unclear    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
For rifampicin resistance testing, were the ref-
erence standard results interpreted without
knowledge of the results of the index test?
Yes    
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    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Nataraj 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients suspected of having TB
meningitis with at least 5 days of meningitis symptoms, nuchal rigidity,
and CSF abnormalities
Age: > 18 years
Sex, female: not reported
Children: no
HIV infection: 21%
Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 379
Laboratory level: central
Country: Vietnam
World Bank Income Classification: middle income
TB incidence rate: 133 per 100,000
Per cent MDR-TB among new TB cases: 4.1%; among retreatment cases:
26% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: yes, donation of index test
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT
Nhu 2014 
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Reference standard rifampicin resistance detection: MGIT-DST and
MTBDRplus
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes Analysis by uniform case definition also included
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
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Were all patients included in the analysis? Yes    
    Low  
Nhu 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 54 years, range 1 to 99 years
Sex, female: 47%
Children: 3%
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 1022
Laboratory level: central
Country: Turkey
World Bank Income Classification: middle
TB incidence rate: 18 per 100,000
Per cent MDR-TB among new TB cases: 2.9%; among retreatment cas-
es: 16% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, genitouri-
nary TB, bone and joint TB, pericardial TB, peritoneal TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
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Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Ozkutuk 2014  (Continued)
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Patient sampling Cross-sectional, prospective, manner of participant selection by conve-
nience
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: not reported
Children: not reported
HIV infection: not reported
Clinical setting: reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 57
Laboratory level: central
Country: Australia
World Bank Income Classification: high income
TB incidence rate: 6.1 per 100,000
Per cent MDR-TB among new TB cases: 3.6%; among retreatment cases:
24% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol: no for lymph node aspirate,
pleural fluid, and CSF; yes for lymph node tissue
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB, TB meningitis
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: yes for lymph node aspirate
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Pandey 2017  (Continued)
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Was a consecutive or random sample of patients en-
rolled?
No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    High Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Pandey 2017  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with presence of a large peri-
cardial effusion amenable to safe pericardiocentesis (> 10 mm echo-
free space around the heart in diastole)
Age: median 34 years (IQR 29 to 42)
Sex, female: 38%
Pandie 2014 
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Children: no
HIV infection: 74%
Clinical setting: 4 district hospitals and 1 tertiary centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 134
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases:
7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pericardial TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MTBDRplus
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Low
DOMAIN 2: Index Test All tests
Pandie 2014  (Continued)
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
130
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Pandie 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of
meningitis
Age: mean 33 years (SD 9)
Sex, female: 61%
Children: 2%
HIV infection: 87%
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: 31%
Patients on anti-TB treatment: no
Number of specimens evaluated: 59
Laboratory level: central
Patel 2013 
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Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment
cases: 7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes Study used frozen specimens
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Patel 2013  (Continued)
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Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Patel 2013  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of ex-
trapulmonary tuberculosis
Age: mean 42 years (SD 19), range 1 to 91 years
Sex, female: 39%
Children: 7%
HIV infection: 40%
Clinical setting: university hospital (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 236
Laboratory level: intermediate
Country: Colombia
World Bank Income Classification: middle income
TB incidence rate: 32 per 100,000
Per cent MDR-TB among new TB cases: 2.4%; among retreatment cases:
14% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Penata 2016 
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Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB, TB meningitis, peritoneal
TB, pericardial TB, bone and joint TB
Reference standard TB detection: Ogawa medium
Reference standard rifampicin resistance detection: Ogawa-DST
Speciation: not reported
Decontamination: unclear
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
No    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
No    
    High Unclear
DOMAIN 4: Flow and Timing
Penata 2016  (Continued)
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
134
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Penata 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 46 years; range 0 to 93 years
Sex, female: 41%
Children: not reported
HIV infection: not reported
Clinical setting: national reference laboratory
Past history of TB: mot reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 735
Laboratory level: central
Country: United Kingdom
World Bank Income Classification: high income
TB incidence rate: 9.9 per 100,000
Per cent MDR-TB among new TB cases: 1.4%; among retreatment
cases: 3.4% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT and Kirchner media
Reference standard rifampicin resistance detection: not reported
Speciation: yes
Decontamination: no
Flow and timing  
Pink 2016 
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Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Unclear    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with presumptive TB meeting 1 or more of the
following criteria: persistent, non-remitting cough longer than 14 days not responding to
course of antibiotics; repeated episodes of fever within the previous 14 days not respond-
ing to course of antibiotics and after malaria has been excluded; weight loss or failure to
thrive within the previous 3 months; signs and symptoms suggestive of extrapulmonary
tuberculosis: non-painful enlarged lymph nodes; gibbus (form of structural kyphosis),
especially of recent onset; lethargy; convulsions; meningism (symptoms and signs of
meningitis, but without actual inflammation of the meninges); pleural effusion; pericar-
dial effusion; distended abdomen with ascites; non-painful enlarged joint; signs of tuber-
culin hypersensitivity
Age: median 5 years (IQR 3 to 10 years)
Sex, female: 56%
Children: 100%
HIV infection: 36%
Clinical setting: multi-centre tertiary care centres (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 192
Laboratory level: central
Country: Tanzania and Uganda
World Bank Income Classification: low income
TB incidence rate: 287 per 100,000 (Tanzania); 201 per 100,000 (Uganda)
Per cent MDR-TB among new TB cases: 1.3% (Tanzania), 1.6% (Uganda); among retreat-
ment cases: 6.2% (Tanzania); 12% (Uganda) (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference stan-
dard(s)
Target condition: disseminated TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: not reported
Speciation: yes
Decontamination: yes, NALC-NaOH for sputum specimens
Flow and timing  
Comparative  
Notes This study performed Xpert on blood and culture on sputum specimens
Pohl 2016 
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Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted
without knowledge of the results of the
reference standard?
Yes    
If a threshold was used, was it pre-spec-
ified?
Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to cor-
rectly classify the target condition?
Yes    
Were the reference standard results in-
terpreted without knowledge of the re-
sults of the index tests?
Yes    
For rifampicin resistance testing, were
the reference standard results interpret-
ed without knowledge of the results of
the index test?
Unclear    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
tween index test and reference stan-
dard?
Yes    
Did all patients receive the same refer-
ence standard?
Yes    
Were all patients included in the analy-
sis?
Yes    
    Low  
Pohl 2016  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, manner of participant selection not reported
Patient characteristics and setting Presenting signs and symptoms: patients with high suspicion of pleural TB.
Enrolment was based on standard clinical and radiological criteria, includ-
ing a persistent cough of 2 weeks or longer, unexplained fever for 2 weeks
or longer, unexplained weight loss with or without night sweats, chest pain,
and radiological evidence of pleural effusion
Age: males: mean 42 years (SD 19 years); females: mean 39 years (SD 19
years)
Sex, female: 28%
Children: 6%
HIV infection: no
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 161
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Rufai 2015 
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
139
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify
the target condition?
Unclear    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Rufai 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, manner of participant selection not re-
ported
Rufai 2017a 
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Patient characteristics and setting Presenting signs and symptoms: patients with clinical or radiological
suspicion of abdominal TB
Age: males: mean 41 years (SD 19 years); females: mean 46 years (SD
20 years)
Sex, female: 36%
Children: no
HIV infection: no
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 67
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cas-
es: 12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: peritoneal TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Rufai 2017a  (Continued)
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Did the study avoid inappropriate exclusions? Yes    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Rufai 2017a  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, manner of participant selection not re-
ported
Patient characteristics and setting Presenting signs and symptoms: fatigue, malaise, low-grade fever, con-
fusion, nausea and vomiting, lethargy, irritability, and unconsciousness
Age: males: mean 38 years (SD 10 years); females: mean 34 years (SD 22
years)
Sex, female: 41%
Children: 6%
HIV infection: not reported
Rufai 2017b 
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Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: yes, 4%
Number of specimens evaluated: 267
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
Rufai 2017b  (Continued)
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If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Rufai 2017b  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective; manner of participant selection not reported
Patient characteristics and setting Presenting signs and symptoms: patients with strong suspicion of TB on the ba-
sis of (a) clinical presentation, (b) relative laboratory investigation, (c) echocar-
diography, and (d) radiological finding
Age: not reported
Sex, female: not reported
Children: not reported
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 286
Laboratory level: intermediate
Country: Pakistan
Saeed 2017a 
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World Bank Income Classification: middle income
TB incidence rate: 268 per 100,000
Per cent MDR-TB among new TB cases: 4.2%; among retreatment cases: 16%
(source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, pericardial TB
Reference standard TB detection: LJ
Reference standard rifampicin resistance detection: LJ-DST
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes Study authors report, "In this study, strict patient selection criteria in which
strong suspicion of TB patients were included on the basis of clinical and radio-
logical evidence could have [been] attributed to high sensitivity"
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
    High Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
Yes    
Saeed 2017a  (Continued)
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Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Unclear    
For rifampicin resistance testing, were the refer-
ence standard results interpreted without knowl-
edge of the results of the index test?
Unclear    
    Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Saeed 2017a  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: 46%
Children: no
HIV infection: no
Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 51
Laboratory level: intermediate
Country: Poland
World Bank Income Classification: high income
TB incidence rate: 18 per 100,000
Per cent MDR-TB among new TB cases: 0.83%; among retreatment
cases: 4.4% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
Safianowska 2012 
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WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, peri-
toneal TB, pericardial TB, genitourinary TB, bone and joint TB
Reference standard TB detection: LJ
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
No    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
No    
    High Low
Safianowska 2012  (Continued)
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DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Safianowska 2012  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 39 years, range < 1 year to 96 years
Sex, female: 45%
Children: 4%
HIV infection: not reported
Clinical setting: reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 696
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cas-
es: 7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for lymph node as-
pirate, pleural fluid, and peritoneal fluid; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, peri-
toneal TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST and
MTBDRplus
Scott 2014 
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Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Scott 2014  (Continued)
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    Low  
Scott 2014  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion of
EPTB
Age: mean 35 years (SD 15 years)
Sex, female: 50%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 1139
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol: yes for body fluids and LN tissue;
no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, peritoneal
TB, pericardial TB, genitourinary TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH (for all specimens except CSF, pleur-
al fluid, and urine)
Flow and timing  
Comparative  
Sharma 2014 
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Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Sharma 2014  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: women being evaluated for infer-
tility and suspected to have TB
Age: mean 29 years, range 19 to 41 years
Sex, female: 100%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 240
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment
cases: 12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: genitourinary TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Sharma 2016 
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Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Sharma 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with clinically suspected meningitis in-
cluding fever, irritability, lethargy, bulging fontanelle, nuchal rigidity, fever with or
without headache, or photophobia, confirmed by CSF analysis
Age: TBM median 31 months (IQR 21 to 54 months); bacterial meningitis median
29 months (IQR 20 to 81 months); viral meningitis median 62 months (IQR 22 to 92
months)
Solomons 2016 
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Sex, female: TBM 48%; bacterial meningitis 50%; viral meningitis 24%
Children: 100%
HIV infection: 11%
Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 139
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment cases: 7.1%
(source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST and MTBDRplus
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes This study was performed at a single hospital, which may limit generalization of
study findings to other settings; however, Tygerberg Children’s Hospital serves a
population that shares a similar disease burden and health challenges experienced
in other TB-endemic areas.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Solomons 2016  (Continued)
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    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
Yes    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Yes    
For rifampicin resistance testing, were the ref-
erence standard results interpreted without
knowledge of the results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Solomons 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with signs and symptoms sug-
gestive of extrapulmonary TB
Age: median 34 years
Sex, female: 39%
Children: 0.06%
HIV infection: 7%
Clinical setting: tertiary care centre
Suzana 2016 
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Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 215
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
12% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for lymph node tis-
sue and pleural tissue; no for pleural fluid, bone and joint fluid, urine, peri-
toneal fluid, pericardial fluid, and CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis, peritoneal TB,
pericardial TB, genitourinary TB, bone and joint TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: LJ-DST and MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
Suzana 2016  (Continued)
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If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Suzana 2016  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: people with presumptive lymph
node TB
Age: ≤ 15 years 15%; > 15 years 85%
Sex, female: 53%
Children: 15%
HIV infection: not reported
Clinical setting: university hospital (outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 136
Laboratory level: central
Country: Ethiopia
Tadesse 2015 
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World Bank Income Classification: low income
TB incidence rate: 177 per 100,000
Per cent MDR-TB among new TB cases: 2.7%; among retreatment
cases: 14% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard TB detection: LJ
Reference standard rifampicin resistance detection: not reported
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Study used frozen specimens
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Unclear    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
Tadesse 2015  (Continued)
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For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results of
the index test?
Unclear    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Tadesse 2015  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: not reported
Children: not reported
HIV infection: not reported
Clinical setting: university hospital (laboratory-based evaluation)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 7
Laboratory level: central
Country: Singapore
World Bank Income Classification: high income
TB incidence rate: 51 per 100,000
Per cent MDR-TB among new TB cases: 1.4%; among retreatment
cases: 2.3% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Teo 2011 
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Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Teo 2011  (Continued)
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Were all patients included in the analysis? Yes    
    Low  
Teo 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: not reported
Sex, female: not reported
Children: 34%
HIV infection: 10%
Clinical setting: 8 Italian laboratories
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 668
Laboratory level: central
Country: Italy
World Bank Income Classification: high income
TB incidence rate: 6.1 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases:
13% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for CSF; no for
pleural fluid, urine, peritoneal fluid, and pericardial fluid
Manufacturer's involvement: yes, donation of the index test
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal TB, pericardial
TB, genitourinary TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Tortoli 2012 
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Notes Study used frozen specimens
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Tortoli 2012  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patientsParticipants with a pleural effusion need-
ing thoracentesis
Age: median 50 years (IQR 40 to 57)
Sex, female: 20%
Children: no
HIV infection: 5%
Clinical setting: secondary health facility (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 85
Laboratory level: central
Country: Brazil
World Bank Income Classification: middle income
TB incidence rate: 42 per 100,000
Per cent MDR-TB among new TB cases: 1.5%; among retreatment cases: 8% (source:
WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes Patients were excluded if they had bleeding disorders contraindicating thoracente-
sis, if the fluid volume was insufficient for storage, or if a final diagnosis could not
be ascertained. One of the main limitations of the study was the high number of pre-
sumptive (non-confirmed) cases. The number of exclusions was also high - out of
203 eligible patients, 110 were excluded: 21 did not have a final diagnosis and 89 did
not have sufficient fluid to store. "Cultures of pleural tissue, which could significant-
ly improve accuracy of diagnosis, were not performed"
Study used frozen specimens
Trajman 2014 
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Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
Yes    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Yes    
For rifampicin resistance testing, were the ref-
erence standard results interpreted without
knowledge of the results of the index test?
Yes    
    Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Unclear    
Were all patients included in the analysis? No    
    High  
Trajman 2014  (Continued)
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients meeting the following criteria: previous-
ly TB-treated cases with both positive and negative smears; failure of Cat-I and Cat-
II TB drugs; all smear-positive cases that remained positive by the end of the second
month of TB treatment; TB/HIV co-infection cases; seriously ill patients; contacts of
MDR-TB patients
Age: mean 34 years (SD 19 years), range 3 to 80 years
Sex, female: 51%
Children: 14%
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: 60%
Patients on anti-TB treatment: yes, percentage not reported
Number of specimens evaluated: 168
Laboratory level: central
Country: Pakistan
World Bank Income Classification: middle income
TB incidence rate: 268 per 100,000
Per cent MDR-TB among new TB cases: 4.2%; among retreatment cases: 16% (source:
WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, TB meningitis, peritoneal TB, pericardial TB
Reference standard TB detection: Middlebrook 7H10
Reference standard rifampicin resistance detection: Middlebrook 7H10
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes Study included a highly selective population that met specified criteria: previously
TB-treated cases with both positive and negative smears; failure of Cat-I and Cat-II
TB drugs; all smear-positive cases that remained positive by the end of the second
month of TB treatment; TB/HIV co-infection cases; seriously ill patients; contacts of
MDR-TB patients
Ullah 2017 
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Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
No    
    High Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted with-
out knowledge of the results of the refer-
ence standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
Yes    
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Yes    
For rifampicin resistance testing, were the
reference standard results interpreted with-
out knowledge of the results of the index
test?
Yes    
    Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
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Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: suspected extrapulmonary TB based on symptoms:
brain: irritability, restlessness, neck stiffness, headache persistent for 2 to 3 weeks, vom-
iting, seizures, changes in mental condition or behaviour; intestinal tract, abdomen: ab-
dominal pain, diarrhoea; lymph nodes: enlargement of lymph nodes, mass formation in
the neck; cardiorespiratory: shortness of breath, hypertension, chest pain, dyspnoea; en-
dometrium: pelvic pain, pelvic mass, irregular periods, infertility; skin (cutaneous): visible
presence of ulcers or lesions, tender nodules
Age: median 37 years
Sex, female: 15%
Children: 3%
HIV infection: 3%
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 60
Laboratory level: central
Country: India
World Bank Income Classification: middle income
TB incidence rate: 211 per 100,000
Per cent MDR-TB among new TB cases: 2.8%; among retreatment cases: 12% (source:
WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for pleural fluid, peritoneal fluid, peri-
cardial fluid; no for CSF
Manufacturer's involvement: yes, in design, analysis, or manuscript production (David Al-
land is among a group of co-investigators who invented molecular beacons and receive
income from licensees, including to Cepheid, for M tuberculosis detection)
Target condition and reference stan-
dard(s)
Target condition: pleural TB, TB meningitis, peritoneal TB, pericardial TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Vadwai 2011 
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Notes "Patients were enrolled only if they could provide detailed clinical history and radiologi-
cal and histology/cytology reports, along with an adequate amount of specimen materi-
al"
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted
without knowledge of the results of the
reference standard?
Yes    
If a threshold was used, was it pre-spec-
ified?
Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to cor-
rectly classify the target condition?
Unclear    
Were the reference standard results in-
terpreted without knowledge of the re-
sults of the index tests?
Yes    
For rifampicin resistance testing, were
the reference standard results interpret-
ed without knowledge of the results of
the index test?
Yes    
    Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
tween index test and reference stan-
dard?
Yes    
Did all patients receive the same refer-
ence standard?
Yes    
Vadwai 2011  (Continued)
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Were all patients included in the analy-
sis?
Yes    
    Low  
Vadwai 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients with suspi-
cion of LNTB
Age: mean 36 years, range 18 to 73 years
Sex, female: 49%
Children: no
HIV infection: 100%
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 344
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
TB incidence rate: 781 per 100,000
Per cent MDR-TB among new TB cases: 3.4%; among retreatment
cases: 7.1% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Van Rie 2013 
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Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and ref-
erence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Van Rie 2013  (Continued)
 
 
Study characteristics
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Patient sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients presenting with symptoms of
meningitis (fever, headache, seizure, vomiting, nuchal rigidity, or abnor-
mal CSF parameters)
Age: mean 31 years, range 1 to 80 years
Sex, female: 38%
Children: not reported
HIV infection: no
Clinical setting: 11 tertiary care centres
Past history of TB: 2%
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 316
Laboratory level: central
Country: China
World Bank Income Classification: middle income
TB incidence rate: 64 per 100,000
Per cent MDR-TB among new TB cases: 7.1%; among retreatment cases:
24% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: not reported
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes Includes analysis by uniform case definition also. Study used frozen
specimens
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Wang 2016a  (Continued)
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Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Unclear    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Wang 2016a  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, retrospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: clinical findings of possible TB
Age: median 48 years
Sex, female: 42%
Children: 13%
Zeka 2011 
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HIV infection: 1%
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 149
Laboratory level: central
Country: Turkey
World Bank Income Classification: middle income
TB incidence rate: 18 per 100,000
Per cent MDR-TB among new TB cases: 2.9%; among retreatment
cases: 16% (source: WHO Global TB Report, 2017)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, genitourinary TB, peri-
toneal TB, pericardial TB
Reference standard TB detection: LJ and BacT liquid medium
Reference standard rifampicin resistance detection: 7H10 agar media
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes Study used frozen specimens
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Low Unclear
DOMAIN 2: Index Test All tests
Zeka 2011  (Continued)
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Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results of
the index test?
No    
    Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Zeka 2011  (Continued)
 
 
Study characteristics
Patient sampling Cross-sectional, prospective; manner of participant selection not reported
Patient characteristics and setting Presenting signs and symptoms: patients suspected of EPTB
Age: not reported
Sex, female: not reported
Children: not reported
HIV infection: not reported
Clinical setting: reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 176
Laboratory level: central
Zmak 2013 
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Country: Croatia
World Bank Income Classification: high income
TB incidence rate: 12 per 100,000
Per cent MDR-TB among new TB cases: 0%; among retreatment cases: 0%
(source: WHO Global TB Report, 2016)
Index tests Xpert® MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for pleural fluid, urine,
peritoneal fluid, pericardial fluid, and blood; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal TB, pericardial TB,
genitourinary TB, disseminated TB
Reference standard TB detection: LJ, Stonebrink, and MGIT
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes "Although the NRL performs a third-level laboratory service for the whole
country, it is actually also involved in first and
second-level laboratory work for several counties"
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results interpreted without
knowledge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Zmak 2013  (Continued)
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Is the reference standards likely to correctly classify
the target condition?
Yes    
Were the reference standard results interpreted
without knowledge of the results of the index tests?
No    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of
the results of the index test?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Yes    
    Low  
Zmak 2013  (Continued)
CSF: cerebrospinal fluid; DST: drug susceptibility testing; EBUS: endobronchial ultrasound; EPTB: extrapulmonary tuberculosis: IQR:
interquartile ratio; LJ: Löwenstein-Jensen; LN: lymph node; MDR-TB: multi-drug-resistant tuberculosis; MGIT: mycobacteria growth
indicator tube; NALC-NaOH: N-acetyl-L-cysteine-sodium hydroxide; SD: standard deviation; SOP: standard operating procedure; TB:
tuberculosis; TBM: tuberculous meningitis; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alvarez Uria 2012 Inappropriate reference standard
Andrey 2015 Case report
Armand 2011 Case-control study
Arockiaraj 2015 Abstract; we included the published study, Arockiaraj 2017, in the review
Bablishvili 2015 Did not contain specimen for extrapulmonary TB
Bajrami 2016 Could not extract 2 × 2 values
Balcha 2014 Did not contain specimen for extrapulmonary TB
Bemba 2017 Inappropriate reference standard
Bhatia 2016 Could not extract 2 × 2 values
Biadglegne 2013 Could not extract 2 × 2 values
Bilgin 2016 Could not extract 2 × 2 values
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Study Reason for exclusion
Bunsow 2014 Could not extract 2 × 2 values
Celik 2015 Could not extract 2 × 2 values
Chen 2016 Could not extract 2 × 2 values
Coleman 2015 Case-control study
Deggim 2013 Fewer than 5 specimens for a given type of specimen (only 1 pleural fluid specimen)
Dharan 2016 Did not contain specimen for extrapulmonary TB
Diop 2016 Inappropriate reference standard
Edwards 2016 Case report
Erdem 2014 Index test other than Xpert MTB/RIF
Fanosie 2016 Did not contain specimen for extrapulmonary TB
Gascoyne-Binzi 2012 Abstract; we could not extract data by form of extrapulmonary TB
Habeenzu 2017 Did not contain specimen for extrapulmonary TB
Ioannidis 2010 Duplicate data
Jain 2017 Inappropriate reference standard
Kilfoil 2015 Could not extract 2 × 2 values
Kim 2014 Could not extract 2 × 2 values; unclear if culture-positive; pleural fluid (3), CSF (2); peritoneal fluid
(1)
Kim 2015b Case-control study
Kim 2015c Could not extract 2 × 2 values
Kumar 2017 Case-control study
Kurbaniyazova 2017 Did not contain specimen for extrapulmonary TB
Kwak 2015 Duplicate data
Lawn 2012 Screening study
Lawn 2013 Could not extract 2 × 2 values
Lawn 2015 Screening study
Lawn 2017 Could not extract 2 × 2 values
Lee 2017 Duplicate data
Liu 2015 Duplicate data
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Study Reason for exclusion
Lombardi 2017 Could not extract data by site of extrapulmonary TB
Marouane 2014 Abstract; we excluded the publication, Marouane 2016, because we could not extract 2 × 2 values
Marouane 2016 Could not extract 2 × 2 values
Miller 2011 Fewer than 5 specimens for a given type of specimen; lymph node biopsy (3 specimens, of which 1
was culture-positive) and endometrial biopsy (1 specimen that was culture-positive)
Mishra 2017 Abstract; we did not identify a published study
Moure 2011 Fewer than 5 specimens for a given type of specimen: CSF (3 specimens, all culture-negative);
pleural fluid (4 specimens, 2 culture-positive); lymph node aspirate (1 specimen, culture-negative);
urine (2 specimens, both culture-positive); peritoneal fluid (2, both culture-negative)
Moure 2012 Case-control study
Nhu 2013 Inappropriate reference standard
Patel 2014 Duplicate data
Peter 2012 Case-control study
Porcel 2013 Case-control study
Rachow 2012 Did not contain specimen for extrapulmonary TB
Raizada 2015 Inappropriate reference standard
Ramamurthy 2016 Could not extract data by site of extrapulmonary TB
Razack 2014 Index test other than Xpert MTB/RIF
Saeed 2017b Could not extract 2 × 2 values
Salvador 2015 Case-control study
Sanjuan Jimenez 2015 Case-control study
Shah 2016a Case-control study
Singanayagam 2014 Could not extract 2 × 2 values
Singh 2016 Could not extract 2 × 2 values
Smith 2014 Did not contain specimen for extrapulmonary TB
Solomons 2015 Duplicate data
Theron 2014 Duplicate data
Toure 2017 Could not extract 2 × 2 values
Vallejo 2015 Could not extract 2 × 2 values
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Study Reason for exclusion
Verghese 2016 Abstract; we did not identify a published study
Wang 2016 Could not extract 2 × 2 values
Wei 2016 Inappropriate reference standard
Yuan 2016 Inappropriate reference standard
Zhang 2016 Could not extract 2 × 2 values
TB: tuberculosis.
 
 
D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of partici-
pants
1 Cerebrospinal fluid 33 3820
2 Cerebrospinal fluid, Ultra 1 129
3 Pleural fluid, culture 30 4209
4 Pleural fluid, composite reference standard 5 405
5 Pleural tissue, culture 4 214
6 Pleural tissue, composite reference standard 1 55
7 Lymph node aspirate 19 1721
8 Lymph node tissue 10 484
9 Urine 19 1324
10 Bone or joint fluid 12 407
11 Bone or joint tissue 7 618
12 Peritoneal fluid 20 751
13 Peritoneal tissue 1 28
14 Pericardial fluid 18 435
15 Blood 3 277
16 Rifampicin resistance testing 39 1336
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Test 1.   Cerebrospinal fluid.
 
 
Test 2.   Cerebrospinal fluid, Ultra.
 
 
Test 3.   Pleural fluid, culture.
 
 
Test 4.   Pleural fluid, composite reference standard.
 
 
Test 5.   Pleural tissue, culture.
 
 
Test 6.   Pleural tissue, composite reference standard.
 
 
Test 7.   Lymph node aspirate.
 
 
Test 8.   Lymph node tissue.
 
 
Test 9.   Urine.
 
 
Test 10.   Bone or joint fluid.
 
 
Test 11.   Bone or joint tissue.
 
 
Test 12.   Peritoneal fluid.
 
 
Test 13.   Peritoneal tissue.
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Test 14.   Pericardial fluid.
 
 
Test 15.   Blood.
 
 
Test 16.   Rifampicin resistance testing.
 
 
A D D I T I O N A L   T A B L E S
 
Form of extrapul-
monary TB
Characteristics Diagnostic speci-
mens and means of
collection
TB meningitis, al-
so called tubercu-
lous meningitis
TB infection of the meninges affects people of all ages but is most common among
children and people with untreated HIV infection. In adults, TB meningitis presents
with gradual onset of headache, neck stiffness, malaise, and fever, and, if untreated,
can progress to altered sensorium, focal neurological deficits, coma, and death. Young
children may present with poor weight gain, low-grade fever, and listlessness. Infants
may present with fever, cough (related to the primary pulmonary infection that occurs
before TB meningitis develops), change of consciousness at presentation, bulging an-
terior fontanel, and seizures (Thwaites 2013). TB meningitis is sometimes associated
with a concurrent cerebral tuberculoma, or, more rarely, a tuberculous abscess
Cerebrospinal flu-
id, acquired by lum-
bar puncture with
or without radiologi-
cal guidance; biopsy
of tuberculoma, ac-
quired surgically
Pleural TB, also
called TB pleurisy
TB infection of the pleura presents with gradual onset of pleuritic chest pain, shortness
of breath, fever, night sweats, and weight loss. Chest X-ray may demonstrate unilat-
eral or occasionally bilateral pleural effusion. The severity of symptoms is highly vari-
able, with many patients experiencing spontaneous resolution of symptoms, while
others may develop severe pleural effusions requiring drainage. Pleuro-pulmonary TB,
in which parenchymal lung involvement is visible on a chest X-ray, is associated with
higher mortality than isolated pleural infection, which appears to be rarely fatal (Shu
2011)
Pleural fluid; pleur-
al biopsy, which may
be performed via
thoracoscopy or per-
cutaneously with
Abram's needle, with
or without ultra-
sound guidance
Lymph node TB,
also called TB
lymphadenitis
TB infection of lymph nodes may affect 1 node or a group of nodes, or multiple groups
within a chain. Lymph node TB is relatively more common among children than adults.
The most common presentation is of a single, firm, non-tender enlarged node in the
neck, although any lymph node group can be affected. This may be accompanied by
fever, weight loss, and night sweats, particularly in people with HIV. Patients with TB in
deep lymph nodes, such as the mediastinal or mesenteric lymph nodes, may present
with fever, night sweats, and weight loss, or, more rarely, with symptoms related to
compression of adjacent structures. Over time lymph nodes become fluctuant and
may discharge via a sinus to the skin or an adjacent viscus. It should be noted that lym-
phadenopathy may also be seen in other forms of TB as part of the immune response,
but this is not usually caused by direct infection of the lymph nodes
Fine-needle aspira-
tion of fluid from af-
fected lymph node,
with or without ra-
diological guidance;
surgical biopsy of
superficial lymph
nodes; endoscop-
ic biopsy of deep
lymph nodes with ul-
trasound guidance
Bone or joint TB TB infection of bones or joints or both causes chronic pain, deformity, and disabili-
ty, and TB of the cervical spine can be life-threatening. The usual presenting symp-
tom is pain. Fever and weight loss, with or without signs of spinal cord compression,
may be present. Patients with advanced disease may have severe pain, spinal deformi-
ty, paraspinal muscle wasting, and neurological deficit. Children may have failure to
thrive and difficulty walking
Aspiration of joint
fluid or periarticular
abscesses; percuta-
neous computed to-
mography-guided
biopsy of lesions is
preferred, but some
Table 1.   Forms of extrapulmonary TB 
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patients may require
open biopsy
Genitourinary TB TB infection of the genitourinary tract includes renal TB and TB of the reproductive
system. Renal TB presents with flank pain, haematuria, and dysuria. Female genital TB
presents with infertility (and may be otherwise asymptomatic), pelvic pain, and vaginal
bleeding. Testicular TB presents with a scrotal mass and infertility
Urine; biopsy of af-
fected organs, ac-
quired under radio-
logical guidance or
surgically
Pericardial TB, al-
so called TB peri-
carditis
TB infection of the pericardium presents with fever, malaise, night sweats, and weight
loss. Chest pain and shortness of breath are also commonly experienced symptoms.
Pericardial TB may be associated with pericardial effusion, which can be severe and
lead to life-threatening tamponade. Some patients go on to develop pericardial con-
striction, which can lead to heart failure and death and may require surgical interven-
tion even after mycobacterial cure
Pericardial fluid ac-
quired by pericardio-
centesis; pericardial
biopsy, acquired un-
der radiological guid-
ance or surgically
Peritoneal TB TB infection of the peritoneum usually presents with pain and abdominal swelling,
which may be accompanied by fever, weight loss, and anorexia
Ascitic fluid acquired
by paracentesis;
peritoneal biopsy
(Chow 2002)
Disseminated
TB, also called
miliary TB. It has
been proposed
that the designa-
tion ‘miliary TB'
be restricted to
disseminated TB
with miliary shad-
ows on chest ra-
diograph (Reuter
2009)
Disseminated TB refers to TB that involves 2 or more distinctly separate sties. Mani-
festations may be varied, ranging from acute fulminant disease to non-specific symp-
toms of fever, weight loss, and weakness. HIV-positive people are more likely to have
disseminated TB than HIV-negative people. In a systematic review of the prevalence of
TB in postmortem evaluations of HIV-positive people, among adults disseminated TB
was found in 88% of TB cases and was considered the cause of death in 91% of TB cas-
es (Gupta 2015)
Blood; specimens ac-
quired from affected
extrapulmonary sites
Table 1.   Forms of extrapulmonary TB  (Continued)
Abbreviations: HIV: human immunodeficiency virus; TB: tuberculosis.
We adapted the table from Index-TB 2016.
 
 
Accuracy against culture reference standardSystem-
atic re-
view
Search peri-
od
Number
of stud-
ies (total
number of
extrapul-
monary
speci-
mens)
Forms of extra-
pulmonary TB or
types of speci-
mens
TB meningitis Pleural TB (pleural
fluid)
Lymph node
TB
Chang
2012a
Up to 1 Octo-
ber 2011
7 (1058) Multiple forms com-
bined
Not reported Not reported Not reported
Denkinger
2014b
Up to 15
October
2013
18 (4461) Lymph node, pleur-
al fluid, CSF
Sensitivity 81%; speci-
ficity 98%
Sensitivity 46%;
specificity 99%
Sensitivity 83%;
specificity 94%
Table 2.   Systematic reviews of Xpert® MTB/RIF for extrapulmonary TB  (Continued)
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May-
nard-Smith
2014
Up to 6 No-
vember 2013
27 (6026) Lymph node, pleur-
al fluid, CSF, other
forms
Median sensitivi-
ty 85% (IQR 75% to
100%); median speci-
ficity 100% (IQR 98%
to 100%)
Sensitivity 34%;
specificity 98%
Sensitivity 96%;
specificity 93%
Penz 2015 Up to 15 Au-
gust 2014
36 (9523) Lymph node, pleur-
al fluid, CSF, other
forms
Sensitivity 69%; speci-
ficity 97%
Sensitivity 37%;
specificity 98%
Sensitivity 87%;
specificity 92%
Sehgal
2016
Up to 31 Au-
gust 2015
24 (2486) Pleural fluid Not applicable Sensitivity 51%;
specificity 99%
Not applicable
Li Y 2017c Up to 20
June 2015
26 (not re-
ported)
Multiple forms com-
bined
Not reported Not reported Not reported
Table 2.   Systematic reviews of Xpert® MTB/RIF for extrapulmonary TB  (Continued)
Abbreviations: CI: confidence interval; CSF: cerebrospinal fluid: IQR: interquartile range; TB: tuberculosis.
aFor all forms of extrapulmonary TB combined, Chang 2012 reported pooled sensitivity and specificity of 80.4% (95% confidence interval
(CI) 75.0 to 85.1) and 86.1% (95% CI 83.5 to 88.4), respectively.
bUsing a composite reference standard, Denkinger 2014 found the following pooled sensitivity and specificity estimates: lymph node TB
(aspirate or tissue) 81.2% (95% CI 72.4 to 87.7) and 99.1% (95% CI 94.5 to 99.9); pleural TB 21.4% (95% CI 8.8 to 33.9) and 100% (95% CI 99.4
to 100); and meningeal TB 62.8% (95% CI 47.7 to 75.8) and 98.8% (95% CI 95.7 to 100), respectively.
cFor both pulmonary and extrapulmonary TB, review authors included 106 studies involving 52,410 samples. For all forms of
extrapulmonary TB combined, Li Y 2017 reported pooled sensitivity and specificity of 80% (95% CI 69 to 88) and 97% (95% CI 94 to 98),
respectively.
 
 
Form of extrapul-
monary TB, type
of specimen
Number
of stud-
ies (speci-
mens)
Number
of spec-
imens
with cul-
ture-con-
firmed TB
(%)
Pooled sensitivi-
ty (95% credible
interval)
Pooled specificity
(95% credible in-
terval)
Predicted sensi-
tivity (95% credi-
ble interval)
Predicted speci-
ficity (95% credi-
ble interval)
TB meningitis,
cerebrospinal flu-
id
29 (3774) 433 (11.5) 71.1% (60.9 to
80.4)
98.0% (97.0 to
98.8)
71.1% (27.8 to
94.8)
98.0% (88.1 to
99.7)
Pleural TB, fluida 27 (4006) 607 (15.2) 50.9% (39.7 to
62.8)
99.2% (98.2 to
99.7)
50.9% (12.3 to
88.8)
99.2% (81.6 to
100)
Pleural TB, tissue 3 (207) 71 (34.3) 30.5% (3.5 to 77.8) 97.4% (92.1 to
99.3)
30.9% (0.2 to 98.2) 97.4% (87.3 to
99.6)
Lymph node, aspi-
rate
17 (1710) 671 (39.2) 87.6% (81.7 to
92.0)
86.0% (78.4 to
91.5)
87.7% (58.1 to
97.4)
86.0% (46.5 to
97.9)
Lymph node, tis-
sue
10 (484) 147 (30.4) 84.4% (74.7 to
91.0)
78.9% (52.6 to
91.5)
78.9% (52.6 to
91.5)
78.9% (9.1 to 99.2)
Genitourinary TB,
urine
13 (1199) 73 (6.1) 82.7% (69.6 to
91.1)
98.7% (94.8 to
99.7)
82.7% (54.3 to
95.1)
98.8% (45.2 to
100)
Table 3.   Accuracy of Xpert® MTB/RIF for detection of extrapulmonary TB and rifampicin resistance 
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Bone or joint TB,
fluid
5 (385) 58 (15.1) 97.2% (89.5 to
99.6)
90.2% (55.6 to
98.5)
97.3% (83.9 to
99.7)
90.5% (6.1 to 99.9)
Bone or joint TB,
tissue
7 (618) 179 (29.0) 91.8% (82.5 to
96.8)
82.0% (56.6 to
94.9)
91.8% (70.1 to
98.4)
82.0% (10.4 to
99.5)
Peritoneal TB, flu-
id
16 (712) 115 (16.2) 59.2% (45.2 to
73.5)
97.9% (96.2 to
99.1)
59.1% (23.3 to
88.8)
97.9% (93.4 to
99.6)
Pericardial TB, flu-
id
7 (324) 76 (23.5) 65.7% (46.3 to
81.4)
96.0% (85.8 to
99.3)
65.7% (30.7 to
89.3)
95.9% (41.8 to
99.9)
Disseminated TB,
blood
2 (266) 23 (8.6) - - - -
Rifampicin resis-
tance
b b 95.0% (89.7 to
97.9)
98.7% (97.8 to
99.4)
95.0% (82.3 to
98.8)
98.7% (95.3 to
99.7)
Table 3.   Accuracy of Xpert® MTB/RIF for detection of extrapulmonary TB and rifampicin resistance  (Continued)
Abbreviations: Crl: credible interval; TB: tuberculosis.
Studies included in the table are limited to those that report data for both sensitivity and specificity; thus the number of studies (specimens)
may diNer slightly from those reported in the main text of the review. For TB detection, the reference standard was culture. For rifampicin
resistance detection, the reference standard was culture-based drug susceptibility testing or MTBDRplus. Pooled sensitivity and pooled
specificity are posterior median estimates.
aFor pleural fluid measured against the composite reference standard, pooled sensitivity and specificity (95% CrI) were 18.4% (9.9 to 30.7)
and 98.2% (94.8 to 99.5).
bUnivariate analyses: pooled sensitivity included 20 studies (148 specimens); pooled specificity included 39 studies (1088 specimens).
Bivariate analysis: pooled sensitivity and specificity (95% CrI) were 95.0% (89.9 to 97.9) and 98.8% (97.7 to 99.6) (20 studies, 990 specimens).
We did not perform a meta-analysis for blood owing to sparse data.
 
 
Analysis (number of studies, specimens) Pooled sensitivity (95%
credible interval)
Pooled specificity (95%
credible interval)
Cerebrospinal fluid
Among studies with prevalence ≥ 10% (17, 1704) 72.0% (59.7 to 82.8) 96.8% (95.0 to 98.2)
Among studies with prevalence < 10% (12, 2070) 68.2% (50.9 to 82.4) 98.9% (97.9 to 99.4)
Difference (≥ 10% group minus < 10% group) 3.8% (-13.8 to 23.5) -2.0% (-3.8 to -0.4)
Probability (difference > 0) 0.658 0.008
Pleural fluid
Among studies with prevalence ≥ 15% (15, 1847) 58.0% (45.0 to 70.2) 99.0% (97.5 to 99.8)
Among studies with prevalence < 15% (12, 2159) 38.0% (23.9 to 55.5) 99.3% (98.1 to 99.8)
Difference (≥ 15% group minus < 15% group) 19.8% (-0.9 to 37.9) -0.3% (-1.8 to 0.9)
Probability (difference > 0) 0.970 0.296
Lymph node aspirate
Table 4.   Impact of TB prevalence on sensitivity and specificity 
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Among studies with prevalence ≥ 43% (10, 925) 92.6% (88.1 to 95.7) 84.0% (72.0 to 92.1)
Among studies with prevalence < 43% (7, 785) 78.5% (69.2 to 86.4) 89.3% (80.6 to 94.5)
Difference (≥ 43% group minus < 43% group) 14.0% (5.3 to 23.6) -5.1% (-17.7 to 6.0)
Probability (difference > 0) 0.999 0.248
Urine
Among studies with prevalence ≥ 7% (8, 504) 87.9% (75.1 to 95.1) 98.1% (93.5 to 99.6)
Among studies with prevalence < 7% (5, 695) 69.6% (45.3 to 87.1) 99.3 % (96.3 to 99.8)
Difference (≥ 7% group minus < 7% group) 18.0% (-1.5 to 41.5) -1.1% (-5.0 to 1.4)
Probability (difference > 0) 0.963 0.137
Rifampicin resistance
Among studies with prevalence ≥ 12% (10, 536) 96.2% (91.1 to 98.7) 98.7% (96.8 to 99.6)
Among studies with prevalence < 12% (11, 479) 92.0% (80.0 to 97.4) 99.1% (97.7 to 99.7)
Difference (≥ 12% group minus < 12% group) 4.0% (-2.6 to 15.9) -0.3% (-2.2 to 1.1)
Probability (difference > 0) 0.878 0.310
Table 4.   Impact of TB prevalence on sensitivity and specificity  (Continued)
Abbreviations: TB: tuberculosis.
Prevalence refers to the percentage of culture-confirmed TB specimens or confirmed rifampicin-resistant specimens in the study. We used
median prevalence in the studies.
 
 
Type of specimen Number
of stud-
ies (speci-
mens)
Pooled sensitivity
(95% credible inter-
val)
Pooled specificity
(95% credible inter-
val)
Predicted sensitivi-
ty (95% credible in-
terval)
Predicted specifici-
ty (95% credible in-
terval)
Cerebrospinal fluid
All participants 29 (3774) 71.1% (60.9 to 80.4) 98.0% (97.0 to 98.8) 71.1% (27.8 to 94.8) 98.0% (88.1 to 99.7)
Consecutive partici-
pant selection
25 (3408) 71.2% (59.8 to 80.9) 98.2% (97.0 to 99.0) 71.1% (24.9 to 95.1) 98.2% (87.6 to 99.8)
Reference standard
blinding
27 (3723) 70.5% (59.8 to 79.8) 98.0% (96.9 to 98.8) 70.4% (26.7 to 94.2) 98.0% (87.6 to 99.7)
Participants not on
anti-TB treatment
12 (2257) 72.8% (60.5 to 83.4) 98.6% (97.4 to 99.3) 72.7% (36.0 to 93.2) 98.6% (92.2 to 99.8)
Single specimen per
patient
15 (1835) 63.5% (47.6 to 76.3) 96.1% (94.2 to 97.4) 63.7% (17.9 to 93.1) 96.1% (87.6 to 98.9)
Table 5.   Sensitivity analyses 
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Pleural fluid
All participants 27 (4006) 50.9% (39.7 to 62.8) 99.2% (98.2 to 99.7) 50.9% (12.3 to 88.8) 99.2% (81.6 to 100.0)
Consecutive partici-
pant selection
20 (3381) 48.2% (36.6 to 61.5) 98.8% (97.7 to 99.6) 48.2% (12.9 to 86.2) 98.9% (81.7 to 100.0)
Reference standard
blinding
19 (3301) 48.8% (37.9 to 60.8) 98.5% (96.8 to 99.5) 48.8% (15.0 to 84.0) 98.5% (75.4 to 100.0)
Participants not on
anti-TB treatment
9 (1822) 43.1% (25.0 to 64.1) 97.9% (94.3 to 99.4) 43.2% (6.3 to 90.0) 97.9% (65.9 to 99.9)
Single specimen per
patient
13 (1160) 51.0% (39.2 to 63.0) 97.4% (95.2 to 98.9) 50.9% (20.0 to 81.3) 97.4% (84.9 to 99.7)
Lymph node aspirate
All participants 17 (1710) 87.6% (81.7 to 92.0) 86.0% (78.4 to 91.5) 87.7% (58.1 to 97.4) 86.0% (46.5 to 97.9)
Consecutive partici-
pant selection
15 (1660) 88.4% (82.7 to 92.8) 85.1% (76.9 to 91.2) 88.4% (61.0 to 97.6) 85.1% (44.6 to 97.7)
Reference standard
blinding
15 (1694) 87.5% (81.0 to 92.2) 85.6% (77.6 to 91.5) 87.5% (56.4 to 97.5) 85.5% (44.3 to 97.9)
Participants not on
anti-TB treatment
6 (852) 82.3% (69.2 to 90.3) 88.8% (80.9 to 93.8) 82.3% (46.1 to 96.1) 88.8% (65.5 to 97.2)
Single specimen per
patient
11 (1183) 90.5% (84.7 to 94.4) 84.4% (72.9 to 92.3) 90.5% (68.3 to 97.7) 84.3% (36.9 to 98.3)
Adults only 6 (789) 83.1% (69.2 to 91.5) 91.2% (85.2 to 95.0) 83.0% (44.5 to 96.9) 91.2% (75.7 to 97.3)
Table 5.   Sensitivity analyses  (Continued)
Abbreviations: TB: tuberculosis.
Pooled sensitivity and pooled specificity are posterior median estimates.
 
 
Form of extrapul-
monary TB, type
of specimen
Number
of stud-
ies (speci-
mens)
Cul-
ture-con-
firmed TB
(%)
Pooled sensitivi-
ty (95% credible
interval)
Pooled specificity
(95% credible in-
terval)
Predicted sensi-
tivity (95% credi-
ble interval)
Predicted speci-
ficity (95% credi-
ble interval)
Accuracy estimates of Xpert® MTB/RIF
TB meningitis,
cerebrospinal flu-
id
29 (3774) 433 (11.5) 63.2% (53.8 to
73.6)
99.6% (98.5 to
99.9)
63.1% (39.9 to
83.0)
99.6% (98.3 to
99.9)
Pleural TB, fluid 27 (4006) 607 (15.2) 56.4% (44.7 to
68.9)
99.7% (98.1 to
100.0)
56.5% (25.6 to
83.5)
99.7% (99.0 to
99.9)
Lymph node TB,
aspiratea
17 (1710) 671 (39.2) 92.2% (82.9 to
98.1)
89.2% (78.9 to
98.2)
92.3% (72.6 to
98.8)
90.1% (57.9 to
98.6)
Table 6.   Latent class meta-analysis 
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Lymph node TB,
aspirateb
17 (1710) 671 (39.2) 81.5% (73.4 to
88.3)
99.0% (98.1 to
99.5)
81.4% (54.4 to
94.9)
99.0% (78.4 to
100)
Accuracy estimates of culture
TB meningitis,
cerebrospinal flu-
id
29 (3774) 433 (11.5) 68.6% (59.0 to
78.0)
99.3% (98.1 to
99.8)
68.5% (44.9 to
86.5)
99.3% (97.7 to
99.8)
Pleural TB, fluid 27 (4006) 607 (15.2) 81.8% (69.5 to
91.2)
98.1% (95.9 to
99.5)
81.5% (43.7 to
97.1)
98.1% (95.0 to
99.5)
Lymph node TB,
aspiratea
17 (1710) 671 (39.2) 88.5% (75.2 to
98.1)
91.6% (84.6 to
97.1)
89.6% (51.5 to
98.8)
91.7% (81.3 to
97.5)
Lymph node TB,
aspirateb
17 (1710) 671 (39.2) 78.8% (68.9 to
89.8)
99.6% (99.4 to
99.8)
79.3% (45.5 to
94.8)
99.6% (98.5 to
97.9)
Accuracy estimates of Xpert® MTB/RIF against culture as a reference standardc
TB meningitis,
cerebrospinal flu-
id
29 (3774) 433 (11.5) 71.1% (60.9 to
80.4)
98.0% (97.0 to
98.8)
71.1% (27.8 to
94.8)
98.0% (88.1 to
99.7)
Pleural TB, fluid 27 (4006) 607 (15.2) 50.9% (39.7 to
62.8)
99.2% (98.2 to
99.7)
50.9% (12.3 to
88.8)
99.2% (81.6 to
100)
Lymph node TB,
aspirate
17 (1710) 671 (39.2) 87.6% (81.7 to
92.0)
86.0% (78.4 to
91.5)
87.7% (58.1 to
97.4)
86.0% (46.5 to
97.9)
Table 6.   Latent class meta-analysis  (Continued)
Abbreviations: TB: tuberculosis.
We generally used non-informative priors in the latent class model.
aThe model used non-informative priors.
bThe model used informative priors.
cAccuracy estimates were determined via a bivariate random-eNects approach for comparison.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
MEDLINE (OVID)
1 Mycobacterium tuberculosis/
2 Tuberculosis/ or "Tuberculosis, Multidrug-Resistant"/ or Extensively Drug-Resistant Tuberculosis/
3 (Tuberculosis or MDR-TB or XDR-TB or "Multidrug Resistant Tuberculosis" or "Extensively Drug Resistant Tuberculosis" or tuberculous).ti.
ab .
4 (extrapulmonary or extra-pulmonary or EPTB).ti. ab .
5 (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal
or splenic or genitourinary or pericardial).ti. ab .
6 "Tuberculosis, Central Nervous System"/ or "Tuberculosis, Urogenital"/ or "Tuberculosis, Splenic"/ or "Tuberculosis, Spinal"/ or
"Tuberculosis, Renal"/ or "Tuberculosis, Pleural"/ or "Tuberculosis, Osteoarticular"/ or "Tuberculosis, Oral"/ or "Tuberculosis, Ocular"/ or
"Tuberculosis, Meningeal"/ or "Tuberculosis, Lymph Node"/ or "Tuberculosis, Laryngeal"/ or "Tuberculosis, Hepatic"/ or "Tuberculosis,
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Gastrointestinal"/ or "Tuberculosis, Female Genital"/ or "Tuberculosis, Endocrine"/ or "Tuberculosis, Cutaneous"/ or "Tuberculosis,
Cardiovascular"/ or Tuberculosis, Miliary/ or Tuberculosis, Male Genital/
7 1 or 2 or 3
8 4 or 5
9 7 and 8
10 9 or 6
11 Xpert*.ti. ab .
12 (GeneXpert or cepheid).ti.ab .
13 (near* patient or near-patient).ti.ab
14 11 or 12 or 13
15 10 and 14
Embase (OVID)
1 Tuberculosis, Multidrug-Resistant/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Mycobacterium
tuberculosis/
2 (MDR-TB or XDR-TB).mp.
3 1 or 2
4 (extrapulmonary or extra-pulmonary or EPTB).ti. or (extrapulmonary or extra-pulmonary or EPTB).ab.
5 (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal
or genitourinary or pericardial).ti. or (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or
intra-ocular or ocular or abdominal or genitourinary or pericardial).ab.
6 tuberculous.ti. or tuberculous.ab.
7 3 or 6
8 Tuberculosis, Central Nervous System/ or Tuberculosis, Hepatic/ or Tuberculosis, Male Genital/ or Tuberculosis, Spinal/ or Tuberculosis,
Cutaneous/ or Tuberculosis, Urogenital/ or Tuberculosis, Osteoarticular/ or Tuberculosis, Endocrine/ or Tuberculosis, Renal/ or
Tuberculosis, Splenic/ or Tuberculosis, Ocular/ or Tuberculosis, Laryngeal/ or Tuberculosis, Gastrointestinal/ or Tuberculosis/ or
Tuberculosis, Meningeal/ or Tuberculosis, Oral/ or Tuberculosis, Pleural/ or Tuberculosis, Lymph Node/ or Tuberculosis, Female Genital/
or Tuberculosis, Miliary/ or Tuberculosis, Cardiovascular/
9 4 or 5 or 8
10 7 and 9
11 xpert*TB.mp.
12 Xpert* MTB RIF.ti. or Xpert* MTB RIF.ab.
13 (GeneXpert or cepheid).ti. or (GeneXpert or cepheid).ab.
14 (near* patient or near-patient).ti. or (near* patient or near-patient).ab.
15 12 or 13 or 14
16 10 and 15
Indexes=SCI-EXPANDED, CPCI-S, Biosis previews
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TOPIC
(tuberculosis or tuberculous) AND TOPIC: (extrapulmonary or extra-pulmonary or EPTB or lymphadenitis or disseminated or miliary or
pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal or genitourinary or pericardial) AND TOPIC:
(Xpert* or Genexpert or cepheid)
LILACS
tuberculosis or tuberculous [Words] and Xpert$ or Genexpert or cepheid [Words]
SCOPUS
( TITLE-ABS-KEY ( tuberculosis OR tuberculous ) AND TITLE-ABS-KEY ( extrapulmonary OR extra-pulmonary OR eptb OR lymphadenitis
OR disseminated OR miliary OR pleur* OR skeletal OR spine OR mening* OR intracranial OR intra-ocular OR ocular OR abdominal OR
genitourinary OR pericardial ) AND TITLE-ABS-KEY ( xpert* OR genexpert OR cepheid ) )
Cochrane Infectious Diseases Group Specialist Register; ClinicalTrials.gov, WHO ICTRP, ISRCTN registry, ProQuest Dissertations &
Theses A&I
tuberculosis and Xpert$; tuberculosis and Genexpert; tuberculosis and Cepheid.
Appendix 2. Data extraction form
 
Data extractor MK KRS
First study author  
Corresponding study author and email  
Title of paper  
Journal  
Language if other than English  
Year  
 
 
I. Study details
Type of study: randomized controlled trial; cross-sectional cohort (with follow-up); case-control (exclude); unclear/not reported
Study data collection: prospective; retrospective; unclear/not reported
Participant selection: convenience; consecutive; random; other; unclear/not reported
Country:
Country income status: low; middle; high
II. Presenting signs and symptoms, setting
Presenting signs and symptoms?
Clinical setting: inpatient; outpatient; both; unclear/not reported
Level of laboratory running Xpert? peripheral; intermediate; central (reference)
Comments, describe exclusions
(Tests at laboratory levels)
Peripheral: AFB (Ziehl-Neelsen, Auramine-rhodamine, Auramine-O staining) and Xpert MTB/RIF
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Intermediate: peripheral laboratory tests and culture on solid media and line probe assay (LPA) from smear-positive sputum
Central: intermediate laboratory tests and culture on liquid media and DST (first- and second-line anti-TB drugs) on solid or in liquid media
and LPA on positive cultures and rapid speciation tests
III. Other demographics
HIV patients included? yes; no; unclear/not reported; if yes ## and percentage? (denominator is number tested, when possible)
Age? Median age in years (IQR); mean (SD); range; unclear/not reported
Children (< 15 years old) included: yes; no; unclear/not reported; if yes, percentage?
Percentage female included? Unclear/not reported
Past history of TB? yes; no; unclear/not reported; if yes, percentage?
Only patients who received TB treatment for ≤ 7 days were included? yes; no; unclear/not reported; if no, percentage on treatment included?
IV. Reference standard
A. Reference standard for TB detection
Solid culture (specify): LJ 7H10 7H11; other
Liquid culture (specify): MGIT Bactec 460; other
Solid and liquid culture (indicate which kind above)
Were reference standard results interpreted without knowledge of index test results? yes; no; unclear/not reported
B. Composite reference standard for pleural TB
Solid culture (specify): LJ 7H10 7H11; other
Liquid culture (specify): MGIT Bactec 460; other
Solid and liquid culture (indicate which kind above)
Histopathology (specify): granulomas; caseating granulomas
Were reference standard results interpreted without knowledge of index test results? yes; no; unclear/not reported
Did all patients receive the same reference standard? yes; no; unclear/not reported; if no, describe
C. Reference standard for rifampicin resistance
LJ DST MGIT DST MTBDRplus
Were reference standard results interpreted without knowledge of index test results? yes; no; unclear/not reported
V. Sites with more than five specimens (check all that apply)
A. Lymph node TB fluid; tissue; both fluid and tissue
B. Pleural TB fluid; tissue; both fluid and tissue
C. TB meningitis CSF
D. Bone or joint TB fluid; tissue; both fluid and tissue
E. Genitourinary TB urine; other, specify
F. Peritoneal TB fluid; tissue; both fluid and tissue
G. Pericardial TB fluid; tissue; both fluid and tissue
H. Disseminated TB blood
I. Other, specify
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VI. Specimen processing for Xpert
Condition of specimens: fresh frozen
If frozen for > 7 days, indicate WHO not followed
For a given site, how many specimens were collected per patient? one; multiple; unclear/not reported
A. Lymph node tissue, other tissue
Was the WHO standard operating procedure (SOP) followed for each specimen type?
1a. Lymph node tissue WHO followed: yes; no; unclear
1b. Lymph node tissue homogenization step for tissue specimens: yes; no; unclear/not reported
2a. Other tissue, specify WHO followed: yes; no; unclear
2b. Other tissue homogenization step for tissue specimens: yes; no; unclear/not reported
(For tissue, if WHO SOP not followed, briefly describe specimen processing in comments.)
WHO SOPs for specimen processing; lymph node and other tissue; sterile specimen
1. Cut the tissue specimen into small pieces in a sterile mortar.
2. Add approximately 2 mL of sterile phosphate bu.ered saline (PBS).
3. Grind solution of tissue and PBS until homogeneous suspension has been obtained.
4. Place approximately 0.7 mL of the homogenized tissue in a sterile, conical screw-capped tube.
5. Double volume of specimen with Xpert® Sample Reagent (1.4 mL Sample Reagent to 0.7 mL of homogenized tissue).
6. Shake tube vigorously 10 to 20 times or vortex for at least 10 seconds.
7. Incubate specimen for 10 minutes at room temperature, and again shake specimen 10 to 20 times or vortex for at least 10 seconds.
8. Incubate specimen at room temperature for an additional 5 minutes.
9. Transfer 2mL to Xpert® MTB/RIF cartridge.
10.Load into GeneXpert and per manufacturer’s instructions.
(Note: For specimens not collected in a sterile manner, WHO SOP suggests an NaOH decontamination/concentration protocol similar to
that used for sputum.)
B. CSF
3a. CSF WHO followed: yes; no; unclear
3b. CSF concentration step: yes; no; unclear/not reported
3c. CSF sample input volume: specify; unclear/not reported
(For CSF, if WHO SOP not followed, briefly describe specimen processing in comments.)
WHO SOPs for CSF
If more than 5 mL of CSF is available for testing.
1. Transfer all of the CSF specimen to a conical centrifuge tube and concentrate the specimen at 3000 × g for 15 minutes.
2. Resuspend the pellet to a final volume of 2 mL by adding Xpert® MTB/RIF Sample Reagent.
3. Transfer 2 mL of the resuspended CSF sample to the Xpert® MTB/RIF cartridge.
4. Load the cartridge into the GeneXpert instrument according to the manufacturer’s instructions.
If 1 mL to 5 mL of CSF is available.
1. Add an equal volume of Sample Reagent to the CSF.
2. Mix the specimen and the Sample Reagent by vortexing as described above. ALer seven to eight minutes at room temperature, vortex the
sample as above a second time.
3. Incubate for an additional seven to eight minutes (15 minutes total incubation) at room temperature.
4. Add 2 mL of the sample mixture directly to the Xpert® MTB/RIF cartridge.
5. Load the cartridge into the GeneXpert instrument according to the manufacturer’s instructions.
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
191
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
C. Body fluids, other than CSF
4a. Body fluid: specify; processed as per manufacturer for sputum
Yes/No/Unclear
4b. Body fluid: specify; sample input volume: specify; unclear/not reported
5a. Body fluid: specify; processed as per manufacturer for sputum (WHO followed)
Yes/No/Unclear
5b. Body fluid: specify; sample input volume: specify; unclear/not reported
(Add additional specimens as needed.)
(For body fluids other than CSF, if manufacturer’s instructions not followed, briefly describe specimen processing in comments.)
Manufacturer’s instructions for sputum
Raw specimen
1. Pour or pipette (pipette not provided) approximately 2 times the volume of Sample Reagent into the specimen (2:1 dilution, Sample
Reagent: specimen).
2. Shake vigorously 10 to 20 times or vortex for at least 10 seconds.
3. Incubate sample for a total of 15 minutes at 20°C to 30°C.
4. Between 5 and 10 minutes into the incubation period, shake vigorously 10 to 20 times or vortex for at least 10 seconds.
Specimen sediment
Assay requires at least 0.5 mL of resuspended specimen sediment aLer digestion, decontamination, and concentration.
1. Use the method of Kent and Kubica and resuspend the sediment in a 67 mM phosphate/H2O bu.er.
2. ALer resuspension, keep at least 0.5 mL of the resuspended sediment for the Xpert® MTB/RIF assay.
3. Add 1.5 mL of Sample Reagent to 0.5 mL of the resuspended sediment (3:1 dilution, Sample Reagent: specimen)
4. Follow steps 2 to 4 above.
Comments on specimen processing.
VII. Specimen processing for culture
Specimen collected from sterile site: Yes/No/Unclear
Specimen processed for culture as per American Thoracic Society Diagnostic Standards? Yes/No/Unclear
(ATS guidelines: specimens collected from normally sterile sites may be placed directly into the culture medium.)
Note: All specimens such as CSF, pleura, lymph node aspirates and tissues, peritoneal fluid, pericardial fluid, bone or joint fluid and tissue,
and urine are considered sterile.
VIII. Results
TB detection: number error or invalid or both Xpert® MTB/RIF results over total number of cultures performed. The denominator includes
contaminated cultures and cultures that were uninterpretable.
Unclear/not reported.
RIF resistance: number indeterminate Xpert results (over total number of cultures performed).
Unclear/not reported.
Non-tuberculous mycobacteria (NTM): number of cultures with NTM (over total number of cultures performed).
Unclear/not reported.
IX. Tables
(Non-tuberculous mycobacteria (NTM) should be included as not TB.)
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TB detection against culture reference standard (example; provide additional tables for other extrapulmonary specimens).
 
Definite TBXpert in lymph node fluid
Yes No Total
Positive      
Negative      
Total      
Xpert result
Error/invalid      
  (Continued)
 
By smear status (extrapulmonary specimens)
 
Definite TBXpert in smear-positives
Yes No Total
Positive      
Negative      
Total      
Xpert result
Error/invalid      
  (Continued)
 
 
Definite TBXpert in smear-negatives
Yes No Total
Positive      
Negative      
Total      
Xpert result
Error/invalid      
  (Continued)
 
Rifampicin resistance detection (for all culture-positive, extrapulmonary specimens)
 
Rifampicin resistance detection Rifampicin resistance
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Yes No Total
Positive      
Negative      
Total      
Xpert result
Indeterminate      
  (Continued)
 
Appendix 3. Rules for QUADAS-2
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: was a consecutive or random sample of patients enrolled?
We scored "yes" if the study enrolled a consecutive or random sample of eligible patients, "no" if the study selected patients by
convenience, and "unclear" if the study did not report the manner of patient selection or we could not tell.
Signalling question 2: was a case-control design avoided?
We did not include in the review studies using a case-control design because this study design, especially when used to compare results in
severely ill patients versus those in relatively healthy individuals, may lead to overestimation of accuracy in diagnostic studies. We scored
"yes" for all studies.
Signalling question 3: did the study avoid inappropriate exclusions?
We scored "yes" if the study included both smear-positive and smear-negative specimens or included only smear-negative specimens. We
judged "no" if the study included only smear-positive specimens or excluded specimens based on physical appearance (such as purulence)
or a biochemical analysis (e.g. adenosine deaminase (ADA), cytology (cell analysis)). We scored "unclear" if we could not tell.
Applicability: are there concerns that the included patients and setting do not match the review question?
We were interested in how Xpert performed in patients presumed to have extrapulmonary TB who were evaluated as they would be in
routine practice. We scored "low concern" if patients were evaluated at local hospitals or primary care centres. We scored "high concern"
if patients were evaluated exclusively as inpatients at tertiary care centres. We scored "unclear concern" if the clinical setting was not
reported or if information was insuNicient to allow a decision. We also scored "unclear concern” if Xpert testing was done at a reference
laboratory and the clinical setting was not reported for the following reason. It was diNicult to tell if a given reference laboratory provided
services mainly to very sick patients (inpatients in tertiary care) or to all patients, including very sick patients and those with less severe
disease (primary, secondary, and tertiary care).
Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of results of the reference standard?
We answered this question "yes" for all studies because Xpert test results are automatically generated and the user is provided with
printable test results. Thus, there is no room for subjective interpretation of test results.
Signalling question 2: If a threshold was used, was it pre-specified?
As the threshold is pre-specified in all versions of Xpert, we answered this question "yes" for all studies.
Applicability: are there concerns that the index test, its conduct, or its interpretation diNer from the review question?
We note that variations in execution of the test might aNect accuracy estimates. We judged "low concern" if the test was performed
according to WHO standard operating procedures (WHO 2014a), or if the index test was performed as recommended by the manufacturer
for sputum. We scored "high concern" if the test was performed in a way that deviated from these recommendations. We scored "unclear
concern" if we could not tell. In studies that evaluated several diNerent types of specimens, we used the following rule: if ≥ 75% of the
specimen types were processed per WHO standard operating procedure (SOP) or as per the manufacturer's instructions, we judged "low
concern"; if < 50% of the specimen types were processed per WHO SOP or as per the manufacturer's instructions, we scored "high concern";
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and if at least 50% to 74% of the specimen types were processed per WHO SOP or as per the manufacturer's instructions, or if we could
not tell, we scored "unclear concern".
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
We considered this domain separately for the reference standard for detection of extrapulmonary TB and the reference standard for
detection of rifampicin resistance.
Signalling question 1: is the reference standard likely to correctly classify the target condition?
For detection of extrapulmonary TB, culture is generally considered the best reference standard. For the diagnosis of all forms of
extrapulmonary TB (except as noted for pleural TB below), culture is a criterion for inclusion in the review. However, limitations are
associated with culture; bacterial load is usually low in extrapulmonary TB, leading to a reduction in the sensitivity of culture. Concerning
the conduct of the reference standard (preparation of the specimen for culture), N-acetyl-L-cysteine-sodium hydroxide is routinely used
to homogenize, decontaminate, and liquefy non-sterile specimens for TB culture (American Thoracic Society 2000). However, CSF, pleural
fluid, and lymph node aspirates are usually considered sterile, and standards specify, "specimens collected from normally sterile sites
may be placed directly into the culture medium” (American Thoracic Society 2000). Overly processing (sterile) specimens with N-acetyl-
L-cysteine-sodium hydroxide may lead to a decrease in viable TB bacteria and consequently false-negative cultures. We scored "yes"
if studies did not use N-acetyl-L-cysteine-sodium hydroxide for processing specimens and "unclear" if studies used N-acetyl-L-cysteine-
sodium hydroxide. We discussed this further under Discussion and Strengths and weaknesses of the review.
For detection of pleural TB, use of culture or a composite reference standard was a criterion for inclusion in the review. We answered this
question "yes" for all studies of pleural TB.
For detection of rifampicin resistance, culture-based drug susceptibility testing (DST, also called conventional phenotypic method) is
considered to be the best reference standard. MTBDRplus is also a WHO-recommended test for rifampicin resistance. As we extracted data
only for studies that used culture-based DST or MTBDRplus, we answered this question "yes" for all studies.
Signalling question 2: were the reference standard results interpreted without knowledge of results of the index test?
We scored "yes" if the reference test provided an automated result (e.g. MGIT 960), if blinding was explicitly stated, or if it was clear that the
reference standard was performed at a separate laboratory and/or was performed by diNerent people. We scored "no" if the study stated
that the reference standard result was interpreted with knowledge of the Xpert® MTB/RIF test result. We scored "unclear" if we could not tell.
Signalling question 3: (rifampicin resistance) were the reference standard results interpreted without knowledge of results of the index test?
We added a signalling question for rifampicin resistance detection. We scored "yes" if the reference test provided an automated result
(e.g. MGIT 960), if solid culture was performed followed by speciation, if blinding was explicitly stated, or if it was clear that the reference
standard was performed at a separate laboratory or was performed by diNerent people, or both. We scored "no" if the study stated that the
reference standard result was interpreted with knowledge of the Xpert test result. We scored "unclear" if we could not tell. Not all studies
evaluated detection of rifampicin resistance; therefore this question was not applicable to all studies.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
We judged "high concern" if included studies did not speciate mycobacteria isolated in culture, "low concern" if speciation was performed,
and "unclear concern" if we could not tell.
Domain 4: flow and timing
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and the reference standard?
In most included studies, we expected that specimens for Xpert and culture would be obtained at the same time, when patients were
evaluated for presumptive extrapulmonary TB. However, even if there were a delay of several days between index test and reference
standard, TB is a chronic disease, and we considered misclassification of disease status to be unlikely, as long as treatment was not initiated
in the interim. We judged "yes" if the index test and the reference standard were performed at the same time or if the time interval was
less than or equal to seven days, "no" if the time interval was greater than seven days, and "unclear" if we could not tell.
Signalling question 2: did all patients receive the same reference standard?
For the diagnosis of any form of extrapulmonary TB, except pleural TB, we answered this question "yes" if all participants in the study or a
subset of participants in the study (for whom we extracted data) received the acceptable reference standard (solid culture, liquid culture, or
both), which we specified as a criterion for inclusion in the review. However, we acknowledge that it is possible that some specimens could
undergo solid culture and others liquid culture as the reference standard. This could potentially result in variations in accuracy, but we think
the variation would be minimal. For the diagnosis of pleural TB as measured against a composite reference standard, we answered this
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question "yes" if all participants received the same reference standard, "no" if not all participants received the same reference standard,
and "unclear" if we could not tell.
For rifampicin resistance detection, we answered "yes" if all participants received the same reference standard (either culture-based DST
or MTBDRplus), "no" if not all participants received the same reference standard, and "unclear" if we could not tell.
Signalling question 3: were all patients included in the analysis?
We will determine the answer to this question by comparing the number of patients enrolled with the number of patients included in the
2 × 2 tables. We will answer "yes" if the numbers matched and "no" if there were patients enrolled in the study who were not included in
the analysis. We will answer "unclear" if we cannot tell.
Judgements for overall ʽRisk of bias' assessments.
• If we answered all signalling questions for a domain "yes", then we scored risk of bias as "low".• If we answered all or most signalling questions for a domain "no", then we scored risk of bias as "high".• If we answered only one signalling question for a domain "no", we discussed further the "risk of bias" judgement.• If we answered all or most signalling questions for a domain "unclear", then we scored risk of bias as "unclear".• If we answered only one signalling question for a domain "unclear", we discussed further the "risk of bias" judgement for the domain.• In the Reference Standard Domain, if we answered "yes" for both signalling questions concerning detection of extrapulmonary TB, we
scored risk of bias as "low", regardless of our judgement for blinding of the reference standard for detection of rifampicin resistance.
Appendix 4. OpenBugs
In this section we provide OpenBUGS models for the bivariate meta-analysis as well as the latent class meta-analysis. Any alternative prior
distributions used are provided in the comments within each model.
BIVARIATE MODEL ASSUMING PERFECT CULTURE REFERENCE TEST
model {
for(i in 1:N) { # N is the number of studies
############################# LIKELIHOOD
logit(TPR[i]) <- l[i,1]
logit(FPR[i]) <- -l[i,2]
pos[i]<-TP[i]+FN[i]
neg[i]<-TN[i]+FP[i]
TP[i] ˜ dbin(TPR[i],pos[i])
FP[i] ˜ dbin(FPR[i],neg[i])
se[i] <- TPR[i]
sp[i] <- 1-FPR[i]
l[i,1:2] ˜ dmnorm(mu[1:2], T[1:2,1:2])
}
############################# HYPER PRIOR DISTRIBUTIONS
mu[1] ˜ dnorm(0,0.25) # replaced by mu[1] ˜ dnorm(0, 0.01) in sensitivity analysis to check impact of less informative prior
mu[2] ˜ dnorm(0,0.25) # replaced by mu[2] ˜ dnorm(0, 0.01) in sensitivity analysis to check impact of less informative prior
T[1:2,1:2]<-inverse(TAU[1:2,1:2])
#### BETWEEN-STUDY VARIANCE-COVARIANCE MATRIX
TAU[1,1] <- tau[1]*tau[1]
TAU[2,2] <- tau[2]*tau[2]
TAU[1,2] <- rho*tau[1]*tau[2]
TAU[2,1] <- rho*tau[1]*tau[2]
tau[1]<-pow(prec[1],-0.5) # replaced by tau[1] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior
tau[2]<-pow(prec[2],-0.5) # replaced by tau[2] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior
sigma.sq[1] <- pow(tau[1], 2)
sigma.sq[2] <- pow(tau[2], 2)
#### prec = between-study precision in the logit(sensitivity) and logit(specificity)
prec[1] ˜ dgamma(2,0.5) # replaced by prec[1] <- 1/pow(tau[1],-2) in sensitivity analysis to check impact of less informative prior
prec[2] ˜ dgamma(2,0.5) # replaced by prec[2] <- 1/pow(tau[2],-2) in sensitivity analysis to check impact of less informative prior
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rho ˜ dunif(-1,1)
############################# OTHER PARAMETERS OF INTEREST
#### POOLED SENSITIVITY AND SPECIFICITY
Pooled_S<-1/(1+exp(-mu[1]))
Pooled_C<-1/(1+exp(-mu[2]))
#### POOLED POSITIVE AND NEGATIVE LIKELIHOOD RATIOS
PLR <- Pooled_S/(1-Pooled_C)
NLR <- (1-Pooled_S)/Pooled_C
#### PREDICTED SENSITIVITY AND SPECIFICITY IN A FUTURE STUDY
l.new[1:2] ˜ dmnorm(mu[],T[,])
sens.new <- 1/(1+exp(-l.new[1]))
spec.new <- 1/(1+exp(-l.new[2]))
} #### END OF PROGRAM
LATENT CLASS META-ANALYSIS MODEL
# WinBUGS PROGRAM FOR ESTIMATING A BIVARIATE HIERARCHICAL META-ANALYSIS MODEL
# FOR SENSITIVITY AND SPECIFICITY ALLOWING FOR HETEROGENEITY BETWEEN STUDIES
model {
############################# #############################
for(i in 1:N) {# N is the number of studies
############################# LIKELIHOOD
logit(p[1, i]) <- l[i,1]
logit(p[2, i]) <- -l[i,2]
prob[i,1] <- pi[i]*(p[1,i]* s2[i] + covp[i]) + (1-pi[i])*(p[2,i]*(1-c2[i]) + covn[i])
prob[i,2] <- pi[i]*(p[1,i]* (1-s2[i]) - covp[i]) + (1-pi[i])*(p[2,i]*c2[i] - covn[i])
prob[i,3] <- pi[i]*((1-p[1,i])*s2[i] - covp[i]) + (1-pi[i])*((1-p[2,i])*(1-c2[i]) - covn[i])
prob[i,4] <- pi[i]*((1-p[1,i])*(1-s2[i]) + covp[i]) + (1-pi[i])*((1-p[2,i])*c2[i] + covn[i])
n[i] <- sum(cell[i,1:4])
cell[i,1:4] ˜ dmulti(prob[i,1:4],n[i])
pi[i] ˜ dbeta(1,1)
se[i] <- p[1,i]
sp[i] <- 1-p[2,i]
l[i,1:2] ˜ dmnorm(mu[1:2], T[1:2,1:2])
#=================================================================
# CONDITIONAL DEPENDENCE
#=================================================================
#=======================================
# upper limits of covariance parameters
#=======================================
us[i]<-min(se[i],s2[i])-(se[i]*s2[i]);
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uc[i]<-min(sp[i],c2[i])-(sp[i]*c2[i]);
ls[i]<- -(1-se[i])*(1-s2[i])
lc[i]<- -(1-sp[i])*(1-c2[i])
#==============================================================
# prior distribution of transformed covariances on (0,1) range
#==============================================================
covp[i]˜dunif(ls[i],us[i]);
covn[i]˜dunif(lc[i],uc[i]);
#covn[i]<-0
}
# ==================================
# NON-INFORMATIVE HIERARCHICAL PRIOR DISTRIBUTION OVER REF STD PROPERTIES
# ==================================
for(j in 1:29) {
logit(s2[j]) <- l2[j,1]
logit(c2[j]) <- l2[j,2]
l2[j,1:2] ˜ dmnorm(mu2[1:2], T2[1:2,1:2])
}
############################# HYPER PRIOR DISTRIBUTIONS #############################
##########################################################
##########################################################
###
### XPERT TEST
###
##########################################################
##########################################################
mu[1] ˜ dnorm(0,0.25)
mu[2] ˜ dnorm(0,0.25) #dnorm(4.59512,10)
T[1:2,1:2]<-inverse(TAU[1:2,1:2])
#### BETWEEN-STUDY VARIANCE-COVARIANCE MATRIX
TAU[1,1] <- tau[1]*tau[1]
TAU[2,2] <- tau[2]*tau[2]
TAU[1,2] <- rho*tau[1]*tau[2]
TAU[2,1] <- rho*tau[1]*tau[2]
tau[1]<-pow(prec[1],-0.5)
tau[2]<-pow(prec[2],-0.5)
sigma.sq[1] <- pow(tau[1], 2)
sigma.sq[2] <- pow(tau[2], 2)
#### prec = between-study precision in the logit(sensitivity) and logit(specificity)
prec[1] ˜ dgamma(2,0.5)
prec[2] ˜ dgamma(2,0.5)
rho ˜ dunif(-1,1)
############################# OTHER PARAMETERS OF INTEREST
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#### POOLED SENSITIVITY AND SPECIFICITY OF XPERT
Pooled_S<-1/(1+exp(-mu[1]))
Pooled_C<-1/(1+exp(-mu[2]))
#### POOLED POSITIVE AND NEGATIVE LIKELIHOOD RATIOS
PLR <- Pooled_S/(1-Pooled_C)
NLR <- (1-Pooled_S)/Pooled_C
#### PREDICTED SENSITIVITY AND SPECIFICITY OF XPERT IN A FUTURE STUDY
l.new[1:2] ˜ dmnorm(mu[],T[,])
sens.new <- 1/(1+exp(-l.new[1]))
spec.new <- 1/(1+exp(-l.new[2]))
##########################################################
##########################################################
###
### CULTURE TEST
###
##########################################################
##########################################################
mu2[1] ˜ dnorm(0,0.25)
mu2[2] ˜ dnorm(0,0.25)
T2[1:2,1:2]<-inverse(TAU2[1:2,1:2])
#### BETWEEN-STUDY VARIANCE-COVARIANCE MATRIX
TAU2[1,1] <- tau2[1]*tau2[1]
TAU2[2,2] <- tau2[2]*tau2[2]
TAU2[1,2] <- rho2*tau2[1]*tau2[2]
TAU2[2,1] <- rho2*tau2[1]*tau2[2]
tau2[1] <-pow(prec2[1],-0.5)
tau2[2] <-pow(prec2[2],-0.5)
sigma.sq2[1] <- pow(tau2[1], 2)
sigma.sq2[2] <- pow(tau2[2], 2)
#### prec = between-study precision in the logit(sensitivity) and logit(specificity)
prec2[1] ˜ dgamma(2,0.5)
prec2[2] ˜ dgamma(2,0.5)
rho2 ˜ dunif(-1,1)
#### POOLED SENSITIVITY AND SPECIFICITY OF CULTURE
S2<-1/(1+exp(-mu2[1]))
C2<-1/(1+exp(-mu2[2]))
s2.new <- 1/(1+exp(-ls2.new))
c2.new <- 1/(1+exp(-lc2.new))
ls2.new ˜ dnorm(mu2[1],prec2[1])
lc2.new ˜ dnorm(mu2[2],prec2[2])
}
Appendix 5. Receiver operating characteristic plot for TB meningitis
Figure 10 displays the receiver operating characteristic plot for TB meningitis.
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Figure 10.   Receiver operating characteristic plot for TB meningitis. The black curve corresponds to the model that
assumes culture is a perfect reference standard. The black emptied circles are plotted at co-ordinates corresponding
to study sensitivity and specificity estimates obtained from the data. The filled black circle is the pooled estimate
of sensitivity and specificity obtained from the bivariate model under the assumption that culture is a perfect
reference standard. The red dashed line corresponds to the latent class meta-analysis. The red emptied squares
are plotted at sensitivity and specificity co-ordinates corresponding to sensitivity and specificity estimates
obtained from the latent class model. The filled red square has co-ordinates corresponding to pooled sensitivity and
specificity estimates from the latent class model. The size of the emptied circles and squares is proportionate to the
size of the studies.
 
Appendix 6. Impact of concentrating cerebrospinal fluid on Xpert® MTB/RIF accuracy
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Covariate (number of studies, participants) Pooled sensitivity (95% credi-
ble interval)
Pooled specificity (95% credi-
ble interval)
Concentration step
Concentrated specimen (15, 2758) 74.8% (63.1 to 84.4) 98.3% (97.1 to 99.1)
Unconcentrated specimen (12, 905) 66.2% (48.5 to 81.4) 97.7% (95.4 to 99.0)
Difference (concentrated minus unconcentrated) 8.5% (-9.9 to 27.7) 0.6% (-1.1 to 2.9)
Probability (concentrated minus unconcentrated) 0.825 0.754
 
 
Appendix 7. Receiver operating characteristic plot for pleural fluid
Figure 11 displays the receiver operating characteristic plot for pleural fluid.
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Figure 11.   Receiver operating characteristic plot for pleural fluid. The black curve corresponds to the model that
assumes culture is a perfect reference standard. The black emptied circles are plotted at co-ordinates corresponding
to study sensitivity and specificity estimates obtained from the data. The filled black circle is the pooled estimate
of sensitivity and specificity obtained from the bivariate model under the assumption that culture is a perfect
reference standard. The red dashed line corresponds to the latent class meta-analysis. The red emptied squares
are plotted at sensitivity and specificity co-ordinates corresponding to sensitivity and specificity estimates
obtained from the latent class model. The filled red square has co-ordinates corresponding to pooled sensitivity and
specificity estimates from the latent class model. The size of the emptied circles and squares is proportionate to the
size of the studies.
 
Appendix 8. Receiver operating characteristic plot for lymph node aspirate
Figure 12 displays the receiver operating characteristic plot for lymph node aspirate.
 
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
202
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 12.   Receiver operating characteristic plot for lymph node aspirate. The black curve corresponds to the
model that assumes culture is a perfect reference standard. The red curve corresponds to the latent class meta-
analysis model with non-informative priors. The green curve corresponds to the latent class meta-analysis model
with informative priors. The filled circles of each colour correspond to the pooled sensitivity and specificity of
the respective model. The empty circles for each colour are plotted at sensitivity and specificity co-ordinates
corresponding to sensitivity and specificity estimates obtained from the respective models. The size of the emptied
circles is proportionate to the size of the studies.
 
Appendix 9. Receiver operating characteristic plot for urine
Figure 13 displays the receiver operating characteristic plot for urine.
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Figure 13.   Receiver operating characteristic plot for urine. The black curve corresponds to the model that assumes
culture is a perfect reference standard. The black emptied circles are plotted at co-ordinates corresponding to
study sensitivity and specificity estimates obtained from the data. The filled black circle is the pooled estimate
of sensitivity and specificity obtained from the bivariate model under the assumption that culture is a perfect
reference standard. The size of the emptied circles and squares is proportionate to the size of the studies.
 
Appendix 10. Bone or joint TB
Figure 14 displays forest plots of Xpert sensitivity and specificity in bone or joint fluid and tissue.
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Figure 14.   Forest plots of Xpert® MTB/RIF sensitivity and specificity for bone or joint TB (fluid and tissue) with
respect to a culture reference standard. The squares represent the sensitivity and specificity of one study, the black
line its confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Appendix 11. Peritoneal TB
Figure 15 displays forest plots of Xpert sensitivity and specificity in peritoneal fluid and tissue.
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Figure 15.   Forest plots of Xpert® MTB/RIF sensitivity and specificity for peritoneal TB (fluid and tissue) with respect
to a culture reference standard. The squares represent the sensitivity and specificity of one study, the black line its
confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Appendix 12. Pericardial TB
Figure 16 displays forest plots of Xpert sensitivity and specificity in pericardial fluid.
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Figure 16.   Forest plots of Xpert® MTB/RIF sensitivity and specificity in pericardial fluid with respect to a culture
reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Appendix 13. Disseminated TB
Figure 17 displays forest plots of Xpert sensitivity and specificity in blood.
 
Figure 17.   Forest plots of Xpert® MTB/RIF sensitivity and specificity in blood with respect to a culture reference
standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval.
FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
C O N T R I B U T I O N S   O F   A U T H O R S
MK and KRS wrote early draQs of the protocol. CMD and SGS contributed methodological advice. KD contributed clinical expertise. CMD
and SGS tailored QUADAS-2 to the review. MK and KRS reviewed the studies and extracted accuracy data. MK and KRS assessed the
methodological quality of included studies. IS and ND performed the statistical analyses. All review authors interpreted the findings. MK,
ND, and KRS wrote the first draQ of the review. MK and KRS prepared the ‘Summary of findings' tables. All review authors contributed to
the final manuscript.
D E C L A R A T I O N S   O F   I N T E R E S T
We have no financial involvement with any organization or entity that has a financial interest in, or financial conflict with, the subject
matter or materials discussed in the review apart from those disclosed.
CMD and SGS work for FIND. FIND is a non-for-profit foundation whose mission is to find diagnostic solutions to overcome diseases of
poverty in low- and middle-income countries. FIND works closely with the private and public sectors and receives funding from donors and
some of its industry partners. FIND has an independent Scientific Advisory Committee and organizational firewalls that protect it against
any undue influences in its work or in publication of its findings. More information on FIND’s policy and guidelines for working with private
sector partners can be found at www.finddx.org/business-model.
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
207
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
KRS received financial support for the submitted work from the CIDG, and has received financial support for the preparation of systematic
reviews and educational materials, consultancy fees from FIND (for the preparation of a systematic review), honoraria, and travel support
to attend WHO guideline meetings.
ND received funding from the CIDG.
S O U R C E S   O F   S U P P O R T
Internal sources• Liverpool School of Tropical Medicine, UK.
External sources• Department for International Development, UK.
Project number 300342-104
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
QUADAS-2: we modified QUADAS-2 as follows. Reference standard domain: we clarified that CSF, pleural fluid, and lymph node aspirates
are usually considered to be sterile, and standards specify that these specimens may be placed directly into the culture medium. Overly
processing specimens may lead to false-negative cultures. We scored ‘yes' if studies did not use N-acetyl-L-cysteine-sodium hydroxide for
processing sterile specimens and "unclear" if studies used N-acetyl-L-cysteine-sodium hydroxide.
Investigations of heterogeneity: for specimen volume, we restricted this analysis to CSF because it was most clinically meaningful. For
other fluid specimen types, the manufacturer's instructions for sputum were usually followed requiring 2 mL of input fluid for the Xpert
cartridge. In terms of the WHO standard operating procedure for lymph node tissue, we did not investigate this further because 80% (8/10)
of the included studies followed WHO recommendations. In performing the review, it became clear that because a homogenization step
is part of the WHO standard operating procedure for preparing tissue specimens, there was no need to perform an additional separate
analysis to confirm the presence of a homogenization step. We removed condition of specimen (fresh or frozen) from the analysis because
we identified only six studies in the current review that used frozen specimens, and we had already performed an analysis of this possible
source of heterogeneity for the Cochrane Review on Xpert for pulmonary TB (Steingart 2014).
In the case of lymph node TB, for which we suspected a systematic bias in the performance of culture, we used informative prior
distributions over the specificity of culture (ranging from 99% to 100%) and the specificity of Xpert (ranging from 98% to 100%).
We performed sensitivity analyses that limited inclusion to studies that reported one specimen per patient, and for lymph node aspirate
limited inclusion to studies that involved only adults.
We have tried to eliminate stigmatizing language, for example, by changing ‘suspected TB' to ‘presumptive TB'.
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